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Abstract 
The majority of cancer research projects mainly focus on the epithelial cancer cell, 
while the role of the tumour stroma has been largely neglected. Conventional 2D 
techniques, such as well plates and other kinds of tissue culture plastic, and 
animal models are mainly used to broaden our understanding of how tumours 
arise, develop, and induce metastasis. However, there is accumulating evidence 
suggesting a tremendous impact of the non-cancerous tumour stroma on 
carcinogenesis, while other publications illustrate the great importance of 
advanced 3D in vitro models for cancer research. 
The overall goal of this work was to investigate how cancer associated fibroblasts 
(CAFs; the most abundant component in the tumour stroma) and normal prostate 
fibroblasts (NPFs), isolated from patients diagnosed with aggressive forms of 
prostate cancer, contribute to angiogenesis, an important hallmark of cancer 
progression. For this purpose, a 3D in vitro angiogenesis co-culture model was 
established. At first, two (semi-) synthetic hydrogel platforms, gelatine 
methacrylate (GelMA) and star-shaped (star)PEG-heparin hydrogels were 
characterised and their physicochemical properties were compared with each 
other. Interestingly, GelMA gels shrank while starPEG-heparin gels swelled in cell 
culture medium over the course of 24 hours. The cell concentration, in addition to 
the stiffness, was critical for the formation of endothelial networks, and the 
knowledge of swelling behaviour enabled the adjustment of initial cell density to 
ensure the density between both gel types was comparable. Moreover, 
preliminary tests with mesenchymal stem cells demonstrated that the hydrogel 
can be actively remodelled, as evaluated by stiffness parameters at day one and 
seven of incubation. 
Growth factors (GFs) affect cellular fate and behaviour, and storage, presentation 
and administration of such chemokines can be critical for certain cellular 
applications. Due to the high anionic charge density of heparin, starPEG-heparin 
hydrogels are known to reversibly immobilise several GFs and thereby might 
mimic the GF reservoir of the extra cellular matrix. Thus, transport processes of 
GFs with low and high heparin affinity inside these hydrogels were analysed by 
fluorescence correlation spectroscopy and a bulk diffusion approach. Results 
indicated that diffusion constants were synergistically decreased with increasing 
size and heparin affinity of the diffusant. 
Next, the capability of endothelial cells (ECs) to self-assemble and organise into 3D 
capillary networks was tested in GelMA, starPEG-heparin and Matrigel hydrogels. 
Abstract 
VI 
Only starPEG-heparin hydrogels allowed the formation of interconnected 
capillaries in macroscopic hydrogel samples. However, as it is widely used to test 
for pro- and anti-angiogenic agents, the 2D Matrigel angiogenesis assay was 
included for subsequent co-culture experiments of ECs and fibroblasts in order to 
investigate how the stromal cells influence the formation of endothelial networks. 
For a detailed characterisation of 3D structures, a conventionally applied 2D 
method (Maximum Intensity Projection for 3D reconstructed images, MIP) was 
compared to an optimised 3D analysing tool. As a result, it was discovered that 
MIP analysis did not allow for an accurate determination of 3D endothelial 
network parameters, and can result in misleading interpretations of the data set.  
Indirect co-cultures of hydrogel-embedded ECs with a 2D layer of fibroblasts 
showed that fibroblast-derived soluble factors, including stromal cell-derived 
factor 1 and interleukin 8, affected endothelial network properties. However, only 
co-encapsulation of ECs and fibroblasts in starPEG-heparin hydrogel discs 
revealed remarkable changes in endothelial network parameters between CAF 
and NPF samples. In detail, the total length and branching of the capillaries was 
increased. For two donor pairs, the diameter of capillaries was decreased in CAF 
samples compared to NPF samples, underlining the high physiological relevance 
of this model. In contrast, significant differences in 2D Matrigel assays were not 
detected between, CAF, NPF and control (ECs only) samples. 
In summary, a 3D angiogenesis co-culture system was successfully developed and 
used to characterise stromal-endothelial interactions in detail. The combination of 
advanced biomaterials (starPEG-heparin) and 3D analysing techniques goes 
beyond conventional 2D in vitro cancer research, and opens new avenues for the 
development of more complex models to further improve the acquisition of more 
biologically relevant data. 
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1. Introduction 
1.1 Background 
Prostate cancer is the second most common cancer for males worldwide, with 
more than 1.1 million new cases diagnosed in 2012.1,2 The prevalence of prostate 
cancer is higher in developed countries (68%), while the highest incident rates 
have been reported for Australia and New Zealand.2,3 Whereas the 5-year survival 
rate of men diagnosed with a localised (confined to prostate) or regional (nearby 
areas) stage is nearly 100%, it dramatically declines for patients suffering from 
advanced cancer that has spread to distant lymph nodes or organs such as bones.4 
Therefore, prostate cancer is a major health concern and research has been 
undertaken to understand the progression of this disease, as well as to improve 
medical treatment. In 2014, $254 million was spent on prostate cancer research 
projects in the United States by the National Institute of Health (NIH) which 
brings prostate cancer to the top 5 of NIH-funded cancer research.5 
Traditionally, cancer research has been focussed on the tumour itself, i.e. the 
epithelium of the tumour microenvironment (TME). However, a growing number 
of studies suggest a pivotal role of the surrounding stroma in tumour growth, 
progression and metastasis. The tumour stroma mainly consists of fibroblasts, also 
termed as reactive or cancer-associated fibroblasts (CAFs). Endothelial cells (ECs), 
pericytes, leukocytes and the specific composition of the extracellular matrix 
(ECM) in the TME also contribute to the malignancy and behaviour of cancer 
cells.6 The interaction, i.e. the crosstalk and exchange of signalling molecules 
between CAF progenitor and cancer cells, drives the co-evolution of the tumour 
and the TME during disease progression. It is postulated that the tumour stroma 
thereby promotes ECM-remodelling, inflammation, immune suppression, 
angiogenesis and other so-called hallmarks of cancer progression.7 
In order to understand the complex interplay between different cell types that 
ultimately results in metastasis of the primary tumour, researchers generally 
employ either animal (mouse or rat) models, or conventional two-dimensional 
(2D) cell culture techniques to test treatments on cells grown in an unnatural 
environment such as on tissue culture plastic (TCP). Meanwhile, enormous 
progress has been made in the field of tissue engineering, which was defined in 
the 1980s as ‘the application of the principles and methods of engineering and life 
sciences towards the fundamental understanding of structure-function 
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relationships in normal and pathological mammalian tissues and the development 
of biological substitutes to restore, maintain or improve functions’. In other words, 
researchers aim to mimic and build up the natural occurring environment of 
specific cells or tissues in vitro for potential applications in regenerative medicine, 
which is the fundamental difference between commonly applied 2D cell culture 
and tissue-engineered constructs (TEC) in in vitro studies. The latter offers cancer 
research, among other disciplines in the area of biomedical research, the third 
dimension (3D), and reflects the natural ECM of cells found in vivo more closely.8,9 
On the other hand, animal models have greater clinical relevance than in vitro 
settings, though a whole organism adds complexity to a study. For instance, the 
contribution of the inflammatory response might complicate the interpretation of 
in vivo models. Moreover, translation of (pharmacological) studies to the clinic is 
challenging, most probably due to the undeniable differences in rodent and 
human metabolism.10 Therefore, novel 3D humanised in vitro approaches (the use 
of human-derived primary cells investigated in a well-defined 3D environment) 
are promising to deepen our understanding of cancer biology. 
Natural hydrogel platforms made of ECM components like collagen or laminin 
can be employed as a 3D setting for biomedical research. Matrigel, an ECM 
isolated from Engelbreth-Holm-Swarm mouse sarcoma cells, is the most 
prominent example for 3D matrices and was considered as the material of choice 
for many years.11,12 For instance, by embedding normal and cancer epithelial cells 
within this gold standard material, the importance of 3D cell-ECM interactions in 
influencing cell behaviour has been clearly shown.13–15 This ground-breaking work 
demonstrates that 3D matrices used for in vitro studies, rather than cell 
monolayers, can provide in vivo-like conditions, which in turn might help to get a 
more accurate understanding of the cell biology in diseases like cancer.  
Although naturally-derived matrices like Matrigel allowed fascinating insights in 
the interplay between cells and their microenvironment, the limitations of these 
materials became gradually more evident.16 In particular, batch-to-batch variations 
affect reproducibility of the experimental work,17,18 and it is hard to modify their 
intrinsic biological, chemical and physical characteristics. Additionally, most 
natural hydrogels have poor mechanical stability and durability, factors that are 
critical for long-term cell culture (> 3 days). 
To overcome these obstacles, a new generation of 3D matrices was needed. 
Synthetic hydrogels (covalently crosslinked, commonly polyethylene-glycol 
(PEG)-based19 polymer networks that possess high water contents) represent one 
major part within the group of ´biomaterials´, which were developed and 
established by the tissue engineering community. They are accessible for cell-
1   Introduction 
3 
responsive modifications like incorporation of biological active substances (i.e. 
binding motifs, cleavable peptide sequences, growth factors) or changes in the 
physico-chemical properties (i.e. stiffness). It has been successfully demonstrated 
that synthetic polymer materials show in vivo-like performance, comparable to 
naturally-derived matrices,20 while they are equipped with high design flexibility, 
allowing the detailed investigation of cellular processes.21–23 
One special example of synthetic materials are starPEG-heparin hydrogels, which 
consist of a synthetic (PEG) and a naturally occurring (heparin) part.24 Besides the 
aforementioned advantages of synthetic hydrogels, this platform is also capable to 
interact with several growth factors (GFs) and other signalling molecules, i.e. due 
to the (highly negatively charged) heparin component the hydrogel can bind and 
release these factors which can be exploited in various cellular applications.25–27 In 
particular, its high potential for 3D in vitro angiogenesis models has been 
proven.28–30 Another hydrogel system, gelatine methacrylate hydrogel (GelMA), 
has been recently described to support angiogenesis in vitro.31,32 Therefore, the 
investigation of cellular interactions in the TME by using these versatile 3D in vitro 
platforms allows for gaining valuable new insights in the process of tumour 
development and metastasis. 
1.2 Objectives 
As the uncontrolled growth of the primary tumour and the formation of 
metastasis are reliant on excessive nutrient and oxygen supply, the process of 
vascularisation is of particular interest.33,34 Although the direct impact of CAFs on 
angiogenesis in prostate cancer is not quite clear (an increased expression of 
angiogenic factors by normal stromal cells under hypoxic conditions and 
involvement of normal stromal cells and CAF-derived factors in the formation of 
capillary-like structures (CLSs) in 2D or 3D cancer models have been reported),35–37 
several studies focussing on different cancer entities indicate an important role of 
the reactive fibroblasts.38–41 By using animal models, these studies provide 
powerful insights in molecular and cellular interactions governing the process of 
tumour vascularisation. However, the need for well-defined and controlled 3D 
humanised models in biological cancer research has been extensively 
discussed.10,42,43 Nevertheless, the specific interplay of CAFs and endothelial cells 
in the human prostatic niche has not been investigated yet in 3D engineered 
constructs. 
The aim of this thesis is to determine the angiogenic capability of CAFs isolated 
from patients diagnosed with high aggressiveness of prostate cancer (Gleason 
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score 7 - 9). For this purpose, CAFs and human umbilical vein endothelial cells 
(HUVECs) were co-cultured by using two hydrogel platforms. This novel 3D 
approach reflects a very early stage of metastasis, in which CAFs are recruited to 
the metastatic site to lay the ground for metastasis-initiating cells,44–46 e.g. 
attracting ECs and promoting vascularisation by the secretion of angiogenic 
factors.47 
 
Thus, the following main goals were addressed within this thesis: 
a) Mechanical characterisation of GelMA and starPEG-heparin hydrogels. 
 
b) Analysis of the diffusion of the potent angiogenic factor vascular 
endothelial growth factor A (VEGF165), its low heparin-affine counterpart 
(VEGF121), heparin-binding epidermal growth factor (hb-EGF, high heparin 
affinity) and EGF (low heparin affinity) in starPEG-heparin hydrogels.  
 
c) Capability of GelMA and starPEG-heparin hydrogels to support 
vasculogenesis in vitro. 
 
d) Influence of CAFs and normal prostate fibroblasts (NPFs) on angiogenic 
response in a humanised co-culture model. As many analysis methods are 
based on 2D images, this includes the development of a robust 3D analysis 
tool. 
 
e) Comparison of semi-synthetic (starPEG-heparin) and natural (Matrigel) 
hydrogels for this purpose. 
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2. Literature review 
2.1 Cancer biology 
2.1.1 Transformed epithelial cells and cancer progression 
Carcinogenesis is defined as a process whereby benign epithelial cells acquire 
malignant characteristics.48 Cancer cells produce their own GFs and acquire 
resistance to apoptotic signals, leading to uncontrolled division and growth.49 
Deregulated oncogenes and/or tumour suppressor genes are thought to confer 
enhanced proliferative capacity to the cancer cell, and every cell in the tumour has 
the same capacity to proliferate extensively.50 However, in the past two decades 
this traditional view has changed. Researchers found evidence that only a small 
subpopulation of the deregulated cell mass is capable of self-renewal and 
differentiation into a tumour. This observation has been confirmed for different 
cancer entities.51–54 The capability of self-renewal and differentiation is a 
fundamental hallmark of totipotent embryonic stem cells (ESCs), the origin of all 
cells and the three germ layers within the body. Accordingly, the aforementioned 
subpopulation of cells in tumours is termed as cancer stem cells (CSCs). As ESCs 
and CSCs share so many mechanisms in regulating self-renewal and 
differentiation, it is believed that mutations convert the normal stem cell self-
renewal pathway into a promotor of neoplastic proliferation.55–57 
During growth, the tumour displaces and impairs benign tissue of the organ it 
resides in. But as long as the malignant cells are confined to the primary tumour, 
survival rate of patients is usually high. The formation of metastasis (the spread of 
the tumour to distant organs where secondary tumours are formed), especially for 
prostate cancer,4 dramatically worsens the clinical outcome, i.e. the prognosis for 
the patient.58,59 A critical step during metastasis (but also for multiple aspects of 
normal embryonic morphogenesis) is the epithelial-mesenchymal transition (EMT) 
of cancer cells, which allows them to escape from the surrounding tissue 
(invasion) and to enter the bloodstream or lymph node system (intravasation).60–62 
During EMT, they lose tight and adherent junctions which usually keep cancer 
cells in close contact to nearby cells and develop into a mesenchymal, migratory 
phenotype. Once cancer cells travel through blood and lymphatic vessels, these 
specific cancer cells are termed circulating tumour cells (CTCs).63 Cells that survive 
turbulence and immune surveillance in the circulatory system attach to the vessel 
walls at distant sites, leave the bloodstream (extravasation) and eventually reach a 
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secondary organ as disseminated tumour cells (DTCs). After dormancy, in which 
the proliferation is ceased in order to wait for suitable environmental 
conditions,64,65 DTCs start to grow aggressively and initiate a secondary tumour in 
the new environment (colonisation).66,67 It is assumed that DTCs need to undergo 
the reverse process of EMT, termed mesenchymal-epithelial transition (MET) for 
effective colonisation of the new host tissue.68,69 CTCs and DTCs are known to 
possess genotypic and phenotypic similarities with CSCs,70,71 which might explain 
relapse of the disease in patients previously believed to have been cured. For 
example, one study suggests circulating prostate cancer cells can occupy the 
hematopoietic stem cell niche in the bone marrow which might support the cancer 
cells to adapt to the local environment and to survive therapeutic stress like 
chemotherapy.72 Moreover, the dormant state of DTCs could make them less 
sensitive to conventional treatment (of the primary tumour).73,74 
 
Figure 2.1: The metastatic cycle of cancer cells, modified after Schilling et al.365 Cells in 
blue represent metastasising cells (cancer stem cells (CSCs), circulating tumour cells (CTCs), 
disseminated tumour cells (DTCs)), green cells are differentiated cancer cells not able to self-
renew and proliferate but are also found in the circulatory system. The different steps 
associated with metastasis (circle) are accompanied by the hallmarks of cancer progression 
(orange highlighted), with angiogenesis being one of the most important process (red 
highlighted). EMT = epithelial-mesenchymal transition; MET = mesenchymal-epithelial 
transition. 
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Throughout the entire journey beginning from the primary tumour to metastasis 
(Figure 2.1), it is now widely accepted that non-malignant cells actively trigger the 
fate of cancer cells.48,75 The specific contribution of the tumour stroma to cancer 
progression, with emphasis on angiogenesis, is described in the following sections. 
2.1.2 The tumour microenvironment (TME) 
It is well-known that a tumour consists of tumour cells and non-malignant host 
cells, such as fibroblasts, endothelial cells, pericytes and immune cells.6 Figure 2.2 
depicts the different cell types of the TME. However, the potential role of these 
non-cancerous cells and ECM components in modulating growth and 
dissemination of the tumour has been underestimated or even neglected for a long 
time.76 The knowledge about the biology of transformed epithelial cells alone was 
believed to be the key to a successful cancer treatment.  
Figure 2.2: The tumour microenvironment (TME), modified after Hanna et al.6 The TME is 
comprised of different cell types, including cancer cells, endothelial cells (ECs), pericytes, 
fibroblasts and immune cells. Cancer cells and the surrounding stromal cells are embedded 
in a tumour-specific extracellular matrix (ECM). 
2   Literature review 
8 
As the efficacy of conventional therapies (killing/removing of neoplastic cells by 
chemotherapy, radiation or surgery) turned out to remain unsatisfactory for many 
patients, cancer researchers started to expand their work into the TME. There is 
now growing awareness that not only cancer cells but also the disordered cell-cell 
and cell-ECM crosstalk in the TME determine the course of tumour development 
and therefore malignant behaviour.48,76–79 Homeostatic disorders between the 
prostatic epithelium and stroma apparently initiate and promote carcinogenesis, 
creating a ‘vicious cycle’ of reciprocal interactions that drives the co-evolution of 
cancer cells and adjacent stroma.7,48,80 These interactions are mediated by soluble 
factors like GFs, insoluble ECMs and direct cell-cell contact. For instance, co-
inoculation of reactive stromal cells and non-tumorigenic epithelial cells 
stimulated progression of tumorigenesis,81–83 whereas embryonic prostate 
fibroblasts weakened the malignant progression of prostate cancer cells in vivo.84 
Additionally, it has been suggested that aging of the stroma influences its ability 
to instruct and maintain epithelial function, as senescent stromal cells might tend 
to create a cancer-promoting microenvironment.85,86 Furthermore, the tumour 
stroma seemingly blocks an effective immune response that would usually 
suppress or eliminate malignant cells.87,88 These studies illustrate the tremendous 
impact of the tumour stroma on the (transformed) epithelium. 
Fibroblasts are the most abundant cell type of the tumour stroma and a more 
detailed overview of their contribution to carcinogenesis is given in the following 
section. 
2.1.3 Cancer-associated fibroblasts (CAFs) 
Myofibroblasts, also termed as activated or reactive fibroblasts, are usually 
involved in wound healing and tissue repair. They regulate the healing response 
and secret pro-angiogenic and pro-inflammatory cytokines,89 thereby creating an 
angiogenesis and epithelial growth stimulating matrix that facilitates tissue 
repair.90,91 Myofibroblasts are usually cleared from the tissue once it is repaired, 
but in fibrotic diseases such as rheumatoid arthritis and arteriosclerosis, they 
persists in an activated state, thereby maintaining the inflammatory process which 
finally leads to dysfunctionality of the tissue and organ.92 CAFs share many 
characteristics with myofibroblats92 and similarities in the tissue remodelling 
processes during wound healing and those occurring in the tumour stroma have 
been described.93,94 
CAFs are considered to originate from different mesenchymal cell types present in 
the TME. In addition to resident fibroblasts,95–97 endothelial cells,98 pericytes,99 
mesenchymal stem cells (MSCs)100 and even cancer cells101 are capable to turn into 
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a reactive fibroblast. The crosstalk and exchange of signalling molecules between 
CAF progenitor and cancerous cells thereby drive the co-evolution of the tumour 
and stroma, which is a requirement for the malignant progression of the disease 
(Figure 2.3A).7,75,102 CAFs isolated from human prostate cancer tissue have even 
been shown to induce tumour formation in benign prostatic hyperplasia (BPH)-1 
prostate epithelial cells which are normally non-tumorigenic. In contrast, 
fibroblasts isolated from benign human prostate specimens (NPFs) were not able 
to do so.82 Interestingly, in vitro propagation of CAFs does not affect their tumour-
promoting phenotype, although they lack interactions with adjacent cancerous 
cells. Like in fibrotic diseases,103 the activated state is established and potentially 
maintained by autocrine signalling loops mediated by stromal cell-derived factor 1 
(SDF-1) and transforming growth factor β (TGF-β; Figure 2.3A).97,104 
Figure 2.3: Development of cancer associated fibroblasts (CAFs) and their impact on 
cancer progression. CAFs originate from different mesenchymal cell types including 
fibroblasts, endothelial cells, pericytes and mesenchymal stem cells (MSCs). The cross-talk 
between CAF progenitor and cancer cells drives the co-evolution of the tumour and 
surrounding stroma (A). Here, CAFs especially promote the malignant progression through 
their contribution to angiogenesis (B). 
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CAFs represent the major part of the non-malignant tumour stroma. They have 
been described to affect almost any of the so-called hallmarks of tumour 
progression (Figure 2.3B).7,105 For instance, it is known the stroma exerts a strong 
influence on EMT, a crucial step for metastasis, and CAFs potentially induce this 
process.106,107 CAFs also support invasiveness108,109 as they, along with 
inflammatory cells and rather than cancer cells themselves, produce matrix 
metalloproteinase (MMPs) which break down the ECM.110–112 Another study 
showed that cancer cells can actually induce MMP production in other cell 
types.113 Besides MMPs, CAFs secret an increased level of tumour and 
angiogenesis-supporting GFs and cytokines, such as SDF-1, TGF-β, VEGF and 
fibroblast growth factors (FGFs).7,79 CAFs also might help to maintain the CSC 
phenotype by the expression of periostin, a component of the ECM.45 An enhanced 
proliferation rate114 and collagenase production,115 which might support cancer 
progression, have also been reported. 
Several studies highlight the impact of CAFs on tumour vascularisation by 
secreting angiogenesis-promoting GFs like SDF-140 and VEGF.38,116 Additionally, 
platelet-derived growth factors (PDGFs), which are mainly secreted by cancerous 
cells,117 and TGF-β stimulate the expression of FGFs,118 and it has been 
demonstrated that inhibition of PDGF signalling pathways in CAFs reduces the 
proliferation and angiogenesis of premalignant cervical lesions in a genetically 
engineered mouse model.39 Besides GFs, CAF-produced ECM components like 
fibronectin and especially type I collagen are also capable to support the formation 
of new blood vessels.119 An overview of CAF-secreted angiogenic factors and their 
function is summarised in Table 2.1. 
Table 2.1: Pro-angiogenic factors secreted by CAFs 
Factor Function 
VEGFs Key player in angiogenesis, modulate proliferation and migration of ECs, 
increase permeability38,79,116,120 
SDF-1 Synergize with VEGF to induce tumour angiogenesis, recruitment of ECs37,79 
FGFs Induce EC proliferation, VEGF expression via paracrine and endocrine 
mechanism79,121–123 
PDGFs Upregulation of FGF-2 and VEGF production, modulating the proliferation 
and recruitment of perivascular cells41,79,124 
TGF-β Induces FGF-2 expression79,118 
Collagen type I Directs EC migration and assembly into new blood vessels125,126 
MMPs Break down ECM, basement membrane. Liberating GFs112,127,128 
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In addition to their tumour-promoting features pointed out above (Figure 2.3B), 
CAFs are known to reduce the efficacy of anti-cancer drugs.41,129 For instance, they 
circumvent anti-VEGF treatment by activating the PDGF-C pathway, which in 
turn can stimulate angiogenesis.41 This is an intriguing example of how the stroma 
impedes an effective cure and expanding the treatment to the stroma has therefore 
become an emerging research field. Stromal cells in the TME directly stimulate 
proliferation and migration of cancer cells as they express high levels of SDF-1. 
Interestingly, inhibitors (e.g. AMD3100) of SDF-1 receptor CXCR4 (C-X-C 
chemokine receptor type 4) have been shown to increase sensitivity of prostate 
cancer cells to chemotherapy in a pre-clinical study.130 As CAFs are thought to be 
comprised of different cell types (s. above), it has been proposed to identify the 
origin of stromal cells in the TME and to target both, cancer cells and the most 
abundant cell type contributing to the CAF population.131 
2.1.4 Immune cells 
The breakdown of natural tissue barriers during invasion and metastasis is often 
accompanied by disruption of the normal tissue architecture. Damaged tissue in 
turn provokes inflammatory responses which directly promote tumorigenesis.132,133 
The inflammatory stroma during wound healing actually resembles that one of the 
TME and thus, tumours can be considered as chronic inflammations or ‘wounds 
that do not heal’.93,94 
Macrophages, the major inflammatory component of the stroma in cancer,62 are 
described to play a dominant role in this context. In fact, they can mediate the anti-
tumour response of the adaptive immune system and have the potential to lyse 
tumour cells,134,135 but malignant cells in turn can convert them into a tumour-
promoting phenotype, the tumour-associated macrophage (TAM).136 TAMs enable 
cancer cells to migrate, invade and metastasise by secretion of a plethora of 
cytokines and MMPs.62,137,138 Consequently, cancer-associated macrophages have 
been found in the area of basement membrane (BM) breakdown in mammary 
tumours139 and also promoted tumorigenesis in a prostate cancer model.140 In 
addition, they are known to enhance angiogenesis (mediated by VEGF and 
PDGF)141,142 and the (hypoxic) TME is thought to support a pro-angiogenic 
phenotype.143  
Like TAMs, mast cells facilitate tumour angiogenesis,144 invasiveness145 and 
enhance immunosuppression146 by secretion of histamine,145 MMPs146 and several 
GFs including EGF, PDGF,147 VEGF148 and TGF-β.149 On the other hand, mast cells 
are also known to carry anti-tumorigenic agents145,150 but the release of these 
molecules (degranulation) might be inhibited by tumour cell-secreted blockers like 
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chondroitin sulphate.151 However, a possible therapeutic strategy could be to 
overcome the tumour cell-mediated inhibition of degranulation or, in a broader 
sense, to harness the intrinsic anti-tumorigenic potential of mast cells and other 
inflammatory cells while simultaneously disabling their tumour-promoting 
phenotype. 
Other inflammatory cells (i.e. lymphocytes, T-regulatory cells, neutrophils, etc.) 
additionally contribute to tumour progression by the secretion of different 
metastasis-supporting cytokines and chemokines.62 However, the debate whether 
tumour-infiltrating lymphocytes mainly exert either pro- or anti-tumorigenic 
activities is still ongoing.133  
2.1.5 Non-cellular components of the TME 
Extracellular matrix (ECM) 
The ECM is mainly composed of glycosaminoglycans (GAGs, e.g. hyaluronic acid, 
heparan sulphate) and fibrous proteins including collagen, laminin and 
fibronectin. This matrix provides biochemical and structural support for the 
surrounding cells and is also made and changed by these cells.152 It serves as a 
reservoir of GFs and cytokines, especially heparin-binding factors interacting with 
heparan sulphate proteoglycans.153 The BM is a thin layer of a specialised ECM 
that is located between epithelial cell sheets or tubes and the underlying or 
surrounding connective tissue.152 ECs and pericytes are separated by the vascular 
BM.154 In tumours, the BM is less crosslinked compared to the normal, extensively 
crosslinked BM, making it more susceptible to proteolysis and turnover.154 While 
collagen type I is generally the most abundant protein in the ECM, collagen type 
IV predominates the BM.152,154 These two types of collagen are also most often 
implicated in cancer progression.155 
The ECM undergoes significant remodelling during tumour progression and it has 
been hypothesized that an altered ECM structure in the TME is the main 
contribution of the stroma on tumorigenesis.78,126 Fibronectin, a well-known ECM 
protein regulates adhesion, migration, proliferation, differentiation and is 
primarily secreted by fibroblasts, epithelial cells and macrophages.156 The 
expression of fibronectin has been shown to be increased in cancer cells.157 It 
mediates the adhesion of ECs to the ECM which allows them to survive, 
proliferate and migrate as the tumour vasculature develops.158–161 Additionally, 
fibronectin not only stimulates growth of cancer cells162 but also recruits fibroblasts 
and macrophages to the tumour site.163 As it has been pointed out above, these 
cells are key players in the progression of cancer. 
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Matrix stiffness has been reported to be implicated in tumour progression, and 
collagens are an important regulator of changes in the cellular mechanical 
microenvironment.164 In the TME, fibroblasts not only deposit more ECM proteins 
like collagen and fibronectin but also increase crosslinking of collagen.165 
However, a rigid matrix has been demonstrated to promote malignant 
transformation of normal epithelial cells.166 Furthermore, cell adhesion to collagen 
regulates cellular functions during tumorigenesis.155 Collagens also play a 
prominent role in tumour angiogenesis.119 One study reports that type I collagen 
directs EC migration and assembly into new blood vessels.125 Besides collagen type 
I, expression of tenascin by stromal cells is increased in the reactive stroma of 
prostate cancer.126 This ECM glycoprotein modulates cell adhesion and migration 
and is usually expressed at sites of tissue remodelling.91 
MMPs 
MMP-2 and MMP-9 secreted by cancer cells and reactive stroma help to break 
down the ECM, thereby releasing factors that are associated with the matrix, for 
example VEGF.127,128 This in turn favours tumour growth, invasion, angiogenesis 
and any other critical step during tumour progression.113,167–171 In some cases, ECM 
components are not fully degraded and these fragments cause a different 
expression pattern than native molecules through so-called ‘cryptic sites’ that 
become accessible for specific cell receptors (like integrins). Fibrin fragments 
increases vascular permeability and collagen, laminin and fibronectin fragments 
enhance migration and proliferation of cells.172 Conversely, MMP-7-mediated 
hydrolysis of collagen type XVIII produces endostatin which is, among other 
collagen fragments, known to inhibit angiogenesis.173 It is hypothesized that MMP 
degradation of the ECM generates a pro-angiogenic environment in the early 
stages of tumour growth and metastasis, whereas MMP-resistant ECM fragments 
show anti-angiogenic characteristics at later cancer stages.154 Although there are 
undeniable tumour-promoting activities, tumour inhibiting effects of some MMPs 
(including generation of anti-angiogenic collagen fragments) became evident.174–176 
This sub-chapter (2.1) briefly explained how cancer is believed to develop (CSCs, 
CTCs, DTCs), but also provides a broad overview of the complex interactions 
between cancer and stromal cells and how they govern the progression of cancer. 
This includes many, if not all processes that contribute to tumorigenesis, such as 
proliferation, migration, invasion and survival. Angiogenesis, one of the most 
important hallmarks of cancer progression, is described in the next sub-chapter in 
further detail. 
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2.2 Molecular mechanisms of angiogenesis and tumour vascularisation 
2.2.1 Physiological process of angiogenesis 
The circulatory system is a prerequisite for the effective functioning of any organ 
in the body. Tissues and organs need to be connected to the host vasculature in 
order to grow normally and to survive.177 The most commonly known function of 
blood vessels is the delivery of oxygen; mammalian cells are located not further 
than 100 - 200 µm away from the vasculature - the diffusion limit for oxygen.34 In 
addition, blood vessels supply nutrients, dispose waste and allow components of 
the immune system to ‘patrol’ the organism.178 
Angiogenesis is defined as the sprouting of capillaries from pre-existing blood 
vessels, which involves the proliferation and migration of ECs, whereas 
differentiation of endothelial progenitor cells (EPCs) into new vascular structures 
is termed as vasculogenesis.179,180 Both processes occur during embryonic 
development in mammals and are usually restricted to wound healing and the 
female reproductive system in adults.181 However, abnormal vessel growth is a 
hallmark of inflammatory disorders and cancer progression (s. below).182  
In mature vessels, quiescent ECs are interconnected by junctional molecules and 
form a monolayer. Gap junctions allow cell-cell communications which is 
fundamental for a synchronised behaviour of ECs in a vessel. VEGF released by 
ECs maintains vascular homeostasis through an autocrine effect.183 ECs are 
covered with pericytes which express inhibitors of EC proliferation and stabilise 
the capillaries by secretion of angiopoietin (ANG)-1 and VEGF. Both cell types 
share and produce a common BM.178 Vascular endothelial (VE)-cadherin, a cell-cell 
adhesion protein, promotes vessel stabilisation whereas N-cadherin supports a 
strong contact between ECs and pericytes.178 
Hypoxia renders ECs responsive to angiogenic signals and sensing of certain 
stimuli (VEGF, ANG-2 and FGF-2) induces the process of angiogenesis that 
involves several temporally coordinated events (Figure 2.4).154,178 First, vasodilation 
occurs181 and nitric oxidase synthase is activated by FGF-2184,185 or VEGF.186,187 In 
response to an increased intracellular level of nitric oxide, guanyl-cyclase 
produces cyclic guanosine monophosphate, which results in relaxation of mural 
cells. Pericytes detach from the vessel wall in response to ANG-2 and vascular 
permeability is increased through the action of VEGF (i.e. formation of 
interconnected vacuoles).188 The intact BM has usually anti-proliferative 
properties, but proteolytic enzymes (MMPs etc.) produced by stromal cells, ECs 
and/or immune cells degrade the BM and convert it into an angiogenesis-
promoting milieu. ECs are released, lose their junctions while the adhesive 
function of VE-cadherin is reduced and migration of the cells is now facilitated.178 
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The action of MMPs further liberates angiogenic factors like VEGF.127 Interestingly, 
soluble VEGF preferentially enlarge vessels whereas MMP-resistant, ECM-bound 
VEGF supports branching.189 Plasma proteins (fibrinogen and plasminogen) 
extravasate from the destabilised vessel and produce a provisional matrix scaffold. 
ECs proliferate and migrate onto this ECM in response to an angiogenic GF 
gradient, MMPs and integrins.178 One EC leads the tip of the sprouting capillary 
and the neighbours of the tip cell (‘stalk cells’) divide to elongate the branch 
(stimulated by FGFs, NOTCH (a transmembrane protein) and placental growth 
factor, PLGF). The tip cell responses to a VEGF gradient by secreting an increased 
amount of delta like ligand (DLL)-4, which activates NOTCH in stalk cells. This in 
turn downregulates the VEGF receptor VEGFR-2, making stalk cells less sensitive 
to VEGF. This cascade ensures that the tip cell takes the lead.190 ANG-1, TGF-β and 
NOTCH stabilise the newly formed structures as they mediate maturation,191 
Figure 2.4: The process of physiological angiogenesis. The quiescent vessel (vascular 
homeostasis) is maintained by EC/pericyte-secreted VEGF and ANG-1 (A). Once an 
angiogenic signal (HIF-1α) is sensed, vasodilation occurs, pericytes detach and the 
basement membrane is broken down through the combined action of VEGF, FGFs, ANG-2 
and MMPs (B). The secretion of DLL-4 ensures the tip cell takes the lead whereas FGFs and 
PLGF stimulate the proliferation of stalk cells (C). ANG-2, TGF-β and TIMPs mediate 
maturation of the nascent vessel while PDGF-B attracts pericytes (D). 
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while PDGF-B chemo-attracts pericytes.192 Mesenchymal cells of the surrounding 
tissue can be recruited to the site of the nascent vessel, where they then 
differentiate into pericytes or into vascular smooth muscle cells, which are located 
abluminal of the BM.193 Tissue inhibitors of metalloproteases (TIMPs) regulate 
MMP activity and allow the deposition of the BM. Finally, the vascular bed is 
remodelled through apoptosis. 
Integrins bind to ECM components and their fragments, but also angiogenic GFs 
(e.g. VEGF, FGFs and ANG-2). The membrane proteins thereby also regulate 
endothelial cell behaviour during angiogenesis and stimulate vessel growth.194 
As it has been outlined above, a myriad of cytokines and signalling cascades are 
involved in angiogenesis and vascular homeostasis. The fine tuned interplay of 
angiogenic factors is deregulated in many pathological conditions, favouring the 
uncontrolled growth of new blood vessels.  
2.2.2 Angiogenesis in cancer 
As it has been pointed out, vessels can be formed by angiogenesis or 
vasculogenesis. Both distinct processes contribute to the development of the 
vasculature that nourishes the tumour, thereby supporting its progression and 
spreading to other parts of the body. Another strategy tumours use to gain access 
to oxygen and nutrients is through co-opting blood vessels. Here, they grow along 
existing vessels and use them for their blood supply. Interestingly, cancer cells can 
also contribute to the tumour vasculature by mimicking ECs (‘vascular mimicry’) 
or even by differentiating into ECs.195 Targeting tumour blood vessels and their 
development became a promising treatment strategy and many pre-clinical 
studies have been conducted to elucidate the specific nature of tumour 
vascularisation.34,196–198 
Specific characteristics of the tumour vasculature 
Tumours, like any other tissue, cannot grow beyond a certain size (several 
millimetres in diameter) without connections to the host vasculature.197 Solid 
tumours usually develop a necrotic, hypoxic core while they grow, which induces 
the stabilisation and upregulation of hypoxia-inducible factor (HIF)-1α by cells 
present in this region of the tumour.199 Additionally, distorted and irregular vessel 
formation lead to insufficient oxygen supply.200 The expression HIF-1α is also 
induced in non-hypoxic cells by oncogenes and GFs, allowing the vascularisation 
of the tumour before it lacks a sufficient oxygen supply.178 
HIF-1α causes an increased expression of proteins regulating angiogenesis 
(especially VEGF),199,201 invasion, survival and glucose metabolism.62,200 TAMs 
preferentially accumulate in hypoxic regions of the tumour and also show an 
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increased expression of the pro-angiogenic factors VEGF and MMP-7.143,202 HIF-1α 
additionally recruits angio-competent bone marrow-derived cells (EPCs etc.) by 
upregulating chemoattractants such as SDF-1.178 
It is known that the paracrine effect of VEGF, released by cells of the TME, 
stimulates branching of the vasculature and causes an abnormal vessel 
growth.203,204 Tumour vessels are immature, leaky and irregular shaped.34 
Additionally, their pattern of interconnections is quite chaotic and an increased 
microvessel density (MVD) has been reported to correlate with poor prognosis in 
many cancer entities including prostate cancer.205 ANG-2, an antagonist of ANG-1, 
is also strongly expressed by hypoxic tumour cells and endothelial cells in tumour 
blood vessels.206,207 This protein is known to promote mural cell detachment, 
vascular permeability and endothelial cell sprouting.208 Consequently, blockage of 
ANG-2 signalling results in vessel regression and normalisation.209 On the other 
hand, ANG-1 supports tumorigenesis by promoting vessel maturation and EC cell 
survival but also prevents extravasation of cancer cells and maintains the integrity 
of healthy blood vessels.208 Abnormal FGF-2 signalling in tumours promotes 
angiogenesis and helps to circumvent anti-VEGF treatment.123,210 Interleukin 8 (IL-
8), a mitogen for ECs and expressed by prostate cancer cells, also increases 
angiogenesis through induction of MMP-9 expression211 while expression of 
thrombospontin-1, an inhibitor of angiogenesis, is downregulated in prostate 
cancer.212 
EPCs 
EPCs potentially contribute to the growth of the tumour-associated vasculature by 
merging with the wall of a growing vessel, where they then differentiate into 
mature ECs.213,214 EPCs can even help the tumour to re-grow after cytotoxic 
therapy by homing to the tumour site and incorporating into or around the 
tumour blood vessels.215,216 The ‘angiogenic switch’ during metastasis (transition 
from an avascular to a vascularised tumour) is at least partly mediated by EPCs.217 
It is assumed they therefore represent an alternative source of ECs.218 However, 
the role and contribution of EPCs in tumour angiogenesis has been questioned as 
a growing number of studies shows contradicting results.219,220 It has been 
proposed that in addition to tumour grade and type, the genetic background of 
the host determines EPC involvement.218 
Pericytes 
The physical and chemical interaction between ECs and pericytes is a prerequisite 
for a functional endothelium.221,222 Pericytes, also termed as ‘mural cells’, stabilise 
blood vessels in the microvasculature by depositing matrix or releasing factors 
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that promote EC differentiation or quiescence.223,224 In a healthy condition, they are 
closely associated with ECs whereas pericytes of the tumour vasculature have an 
abnormal morphology and are just loosely attached.225 Additionally, 30-50% of the 
endothelium in the TME is not covered by pericytes.226 Interestingly, pericyte-
covered tumour vessels are also embedded within a thick fibronectin-containing 
ECM layer, whereas vasculature not expressing fibronectins only have a single 
layer of pericytes or no pericytes.227,228 It can be speculated that fibronectin 
therefore is essential for pericyte homing to tumour vessels, and this process is 
involved in the development of pericyte-mediated resistance to anti-angiogenic 
treatments (s. below). 
Resistance to anti-angiogenic treatment 
Tumour angiogenesis is critical for the malignant progression of cancer229 and 
VEGF is known to be the most potent regulator of angiogenic processes.178 
Therefore, targeting VEGF signalling was considered to be effective in prostate 
cancer therapies.230 Generally, VEGF inhibitors prolong survival of responsive 
patients.178 However, during cancer treatment, many patients with advanced 
cancer eventually become refractory to anti-angiogenic agents.231 Despite the initial 
success, questions have been raised whether anti-angiogenic treatment elicits a 
malignant progression of tumours.232,233 Tumours might develop into a more 
invasive, aggressive and metastasising phenotype upon vessel depletion due to 
hypoxic regions in the tumour.200 VEGF-independent angiogenic pathways 
(upregulated by CAFs and TAMs), vascular mimicry and/or the recruitment of 
EPCs are believed to abolish anti-VEGF treatment (Figure 2.5). 
Figure 2.5: Potential mechanisms of resistance to anti-VEGF treatment in cancer. 
Upregulated angiogenic signalling by stromal or immune cells, homing of endothelial 
progenitor cells (EPCs; yellow) to the site of vessel regeneration, mimicry of ECs or 
differentiating into ECs by CSCs as well as selective targeting of non pericyte-covered 
vessels during therapy can contribute to a refractory tumour vasculature. As they are leaky, 
irregular shaped and grow chaotically, normalisation of the vessels has been proposed as a 
novel, more effective strategy. 
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Pericytes are also thought to play an important role in mediating resistance to anti-
angiogenic therapies (Figure 2.5).210,231 Anti-VEGF treatment might selectively 
target non-covered vessels, and production of VEGF by local pericytes is believed 
to support survival of the remaining vessels.210,225,234 Another study confirmed that 
anti-angiogenic treatment can in fact decrease overall vessel density, but the 
amount of pericyte-covered vessels increased after such therapy.235 Therefore, 
targeting both endothelial cells and pericytes is supposed to be more effective.236 
The PDGF-B signalling is crucial for pericyte homeostasis, and inhibitors of this 
pathway can potentially improve conventional anti-angiogenic strategies.237 
Combination of PDGF-B/PDGF receptor (PDGFR)-β inhibitors with anti-VEGF or 
cytotoxic agents showed promising results in studies with various tumour models, 
whereas monotherapies with these inhibitors are not effective and can even foster 
tumour growth as the vasculature becomes more immature.234,238–240 
Due to the irregular and chaotic growth of tumour vessels and covering pericytes, 
the blood flow is heterogeneous. As a consequence, oxygen, nutrients, immune 
cells and drugs are unevenly distributed to the tumour which potentially selects 
for more malignant cancer cells. The leakiness of abnormal vessels can 
additionally facilitate intravasation of these cells. Therefore, instead of depletion, 
normalisation of tumour vessels has been proposed as a novel, more effective 
treatment strategy.228 In fact, it has been demonstrated that vessel normalisation 
does not affect tumour growth, but reduce tumour cell invasiveness, intravasation 
and metastasis.241 A normally functioning vasculature is also likely to improve 
drug administration and efficacy. Specifically in prostate cancer, the expression of 
prostate-specific membrane antigen (PSMA) is necessary for angiogenesis and EC 
invasion. As the occurrence of this protein is restricted to the vasculature in 
malignant tissue, PSMA is probably an ideal target in cancer therapies.242,243 
During the past two decades our knowledge about the tumour vasculature has 
expanded enormously. We now know how the deregulated process of 
angiogenesis, along with other strategies of malignant cells that improve nutrients 
and oxygen supply, fosters the progression of cancer. However, the investigation 
of the interplay between stromal and endothelial cells residing in the TME within 
a well defined in vitro setup remains challenging. Vascularised TECs are 
promising to deepen our understanding of the stromal contribution to tumour 
vascularisation. 
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2.3 Tissue engineering concepts in cancer research 
TECs are designed to mimic a variety of human tissues in order to restore, 
maintain or improve functions of the defective host tissue. The development of 
biomaterials such as solid scaffolds and viscoelastic matrices are inspired by ECM 
properties found in vivo. These materials are able to provide support and structure 
for cells growing in a 3D environment. Besides their potential in regenerative 
medicine, TECs have been proven to improve certain aspects of in vitro cancer 
research such as cell-ECM interactions and cell growth in three dimensions. The 
advantages of TECs over conventional 2D systems in cancer research are described 
in the first section of this sub-chapter.  
2.3.1 Biological relevance of TECs for cancer research 
Conventional 2D techniques used for in vitro cancer models (Petri dishes, multi-
well plates or glass slides coated with various ECM proteins) helped to gain 
fascinating insights in tumour biology and development. However, due to their 
intrinsic nature, they lack in reproduction of physiological patterns of cell 
adherence, cytoskeletal organization, migration, signal transduction, 
morphogenesis, proliferation, differentiation and response to therapeutic stimuli.8 
By using a 2D setup, the cellular genotype and phenotype is dramatically altered 
compared to the tissue the cells usually reside in and this can cause misleading 
observations and interpretations of experimental results. Moreover, there is now 
growing awareness that microenvironmental (i.e. geometrical, mechanical and 
biological) cues found in the ECM are of the same importance as the cancer cell 
itself.14,244 TECs can reflect the in vivo microenvironment and physiological 
condition more closely than 2D methods and these constructs are therefore 
thought to improve our understanding of cancer biology (Figure 2.6).8,9 
In line with the abovementioned considerations, remarkable differences have been 
reported between 2D and 3D systems in in vitro studies. The growth of cancer cells 
in 3D resembles the morphology of avascular tumours as they form spheroid 
aggregates with a quiescent, necrotic core.245–247 These studies found that the 
proliferation rate was decreased compared to monolayers. Further examples 
illustrate the biological significance of 3D models for tumour growth. One study 
reports that certain MMPs were able to dissolve the BM during cell migration and 
permit growth in a 3D collagen gel, whereas they did not confer increased growth 
capability on cells imbedded on a 2D substrate.248 In another study, cancer cells co-
transfected with kallikrein-related peptidases (enzymes that are known to break 
down ECM proteins) proliferated faster compared to non-transfected controls in 
3D. Conversely, monolayers of cancer cells with increased peptidase expression 
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grew slower than controls. Both studies underpin the contribution of ECM-
degrading enzymes to tumour growth and the shortfall of 2D models to 
recapitulate this in vivo process. Other examples describing important differences 
between 2D and 3D cultures are described in literature. One such study shows 
that expression of the angiogenic factor IL-8 by cancer cells was enhanced when 
cultured in three dimensions.249 Not surprisingly, the expression of other 
chemokines (including angiogenic factors) is also affected by 3D culture.247,250,251 
Another important observation is that tumour cells display greater drug or 
irradiation resistance when grown as multicellular spheroids in a 3D matrix 
compared to a cell monolayer.246,252,253 These studies underscore the physiological 
relevance of novel and sophisticated 3D in vitro settings as they resemble the in 
vivo conditions more closely than 2D cultures. 
2.3.2 In vitro vascularisation 
TECs need sufficient oxygen and nutrient supply and the formation of functional 
blood vessels within the construct is therefore inevitable. This can be achieved by 
either ingrowth of the host vasculature or pre-vascularisation of the construct in 
vitro which then needs to be connected to the circulatory system of the host in 
vivo.177,254 Capillaries and vessels in in vitro culture systems are formed de novo 
rather than from existing vasculature. Thus, to study tumour-endothelium 
interactions and therapeutic strategies, vasculogenesis-supporting TECs are 
considered as a promising new setting.255 
Figure 2.6: Major differences between 3D and 2D culture. Compared to 3D culture, 
adaption to tissue culture plastic (petri dishes etc.) requires more adjustment for cells due to 
environmental changes. Nutrients absorption and interaction with growth factors (GFs), 
ECM molecules and neighbouring cells are restricted to only some parts of the membrane 
which leads to unnatural polarisation of 2D-cultured cells. Migration of cells is confined to a 
2D plane, with little or no resistance from the surrounding ECM and cannot be directed by 
molecular gradients. All together, these alterations affect morphology, proliferation rate, 
differentiation and gene expression patterns of the cells. 
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General requirements 
Particularly, hydrogels are considered to create an appropriate environment for 
both, cells and signalling molecules in order to allow the formation of functional 
vascular networks with lumen in vitro. The complete immersion of cells in a 3D 
matrix (rather than attachment to a porous mesh) allows self-assembling and 
organisation into functional capillary networks. Indeed, ECs form a cord-like 
structure when cultured on top of a cell-instructive 2D surface, but they are not 
able to develop a functional lumen which is critical for an effective perfusion. 
Although this is a well-known drawback, plating ECs on Matrigel is still widely 
used and accepted for the assessment of angiogenic and anti-angiogenic agents.256 
Another important fact that should be kept in mind when using Matrigel is that it 
is rich in angiogenic GFs and contains undefined constituents. An excess supply of 
angiogenic factors potentially complicates the interpretation of the EC response 
and can compromise the general outcome of the experiment. 
The 3D environment is a prerequisite for the development of lumen-containing 
capillaries, but additional features of the native ECM are required for hydrogel 
platforms aiming to enable the formation of vascular structures (Figure 2.7). Here, 
the stiffness of the material plays a critical role. The optimum range varies 
between materials but in all cases increased tube formation ability was associated 
with softer matrices.29,257–259 In contrast, stiff substrates rather support EC adhesion 
and proliferation.260 Besides their mechanical and structural support, the ECM 
triggers cell behaviour via biologically active molecules. At first, ECs need to 
Figure 2.7: ECM features that need to be translated into hydrogels 
in order to support vasculogenesis and other biological processes. 
Stiffness and elasticity need to be adjusted for specific cell types. 
Furthermore, integrin binding sites and the possibility to modify 
their surrounding is highly important for cells in order to grow and 
respond to environmental stimuli like GFs. 
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attach to the matrix via integrins and their binding motifs. In order to move and 
assemble into a network, ECs also have to modify their surroundings (i.e. 
degradation of the matrix). Naturally-derived materials like collagen or fibrin 
hydrogels are intrinsically equipped with binding and cleavable sites, whereas 
synthetic hydrogels require incorporation of additional peptide sequences, such as 
RGD (Arg-Gly-Asp) binding and MMP-degradable sites.21,29 Availability and 
binding capacity of angiogenic GFs is another important aspect in designing 
materials supporting the formation of endothelial networks. This issue is 
discussed in more detail in sections 2.3.4 and 2.3.5. 
Cell source 
The inner layer of blood and lymphatic vessels (i.e. the endothelium) is made of 
ECs and these cells are therefore a key component for vascularised TECs. 
Numerous studies have shown that the addition of ECs to TECs increases 
vascularisation and perfusion in both in vitro and in vivo settings.261 For long-
lasting vessels and maturation of vascular networks in in vitro constructs, 
supporting cells are added. They can have both a direct and indirect impact on the 
formation and maintenance of the capillaries. Indirect supporting cells have a 
profound effect on cell morphology, behaviour and gene expression through 
secretion of pro-angiogenic GFs and cytokines. In mono-culture, endothelial cells 
will not form into tubes and will remain rounded unless the culture media is 
supplemented with angiogenic factors. However, ECs co-cultured with other cell 
types, such as fibroblasts, are able to form CLSs without the need for exogenous 
stimulus.262,263 Direct support is mediated by the addition of mural cells (e.g. MSCs 
that can differentiate into pericyte-like phenotype). These cells are tightly attached 
to ECs, provide mechanical strength and therefore prevent regression and 
collapsing of the newly established capillary network.29,31,264,265 
Alternatives to cell-driven tubulogenesis 
Four main steps can be observed during the formation of capillaries in in vitro 
settings: (1) elongation, migration and cell-cell contact of ECs, (2) development of 
nascent endothelial networks, (3) lumen formation and (4) stabilisation and 
maturation.266 This cell-driven tubulogenesis produces networks that often regress 
after a few days of culture and direction of the growing branches cannot be easily 
controlled. In order to produce a network with tubes that are orientated in a 
desired way, microchannels can be introduced in the hydrogel before they are 
colonised with ECs.267,268 Another benefit of these microfabricated templates for 
cell seeding is that the initial stages of capillary formation can be skipped and 
different cell types can be compartmentalised. However, depending on the 
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technique used for microchannel production, the resolution is either quite low or 
the channels can be leaky due to imprecise fusion of different layers that create the 
construct.261 
A non-biomaterial based approach is the cell-sheet technology. Cells are cultured 
to confluency on temperature-responsive surfaces which allows the deposition of 
several cell layers. One group was able to pre-vascularise a cell sheet construct in 
vitro by incorporating layers of ECs.269 The major limitation here is that the 
constructs are fragile and rather small, which makes it difficult to handle them.270  
2.3.3 Tumour angiogenesis models 
Numerous experimental approaches have been developed to investigate the 
process of angiogenesis and for the assessment of pro- and anti-angiogenic agents 
(examples are migration and proliferation assays, tubule formation assays, the 
chick chorioallantoic membrane assay or the aortic ring assay).256,271 Most of these 
methods are applied in a conventional 2D environment or represent non-
humanised setups with their inherent drawbacks as described above. For instance, 
to demonstrate the influence of CAF-derived SDF-1 on the formation of 
endothelial networks, human microvascular ECs were incubated on top of 
Matrigel with CAF-conditioned medium.37 The effect of conditioned medium from 
cancer cells on 2D EC mono-cultures has also been investigated.272 Another in vitro 
study confirmed the influence of the stromal component on ECs. In this setup, 
myofibroblasts were required for the invasion of ECs into 3D-grown tumour cell 
clusters.273 Other studies looking into the contribution of CAFs to tumour 
vascularisation were performed by using animal models.38–41 However, due to the 
complexity and heterogeneity of in vivo studies, interpretation and translation of 
the results to the human organism remain challenging. 
The development of 3D in vitro cultures of human ECs enabled further research on 
EC morphogenesis under physiological more relevant conditions.274–278 These 
platforms in conjunction with 3D cancer models could potentially open new 
avenues to understand the complex mechanisms regulating tumour angiogenesis 
and for the development of advanced drug screening applications. There are only 
a few approaches described in literature that include both 3D tumour growth and 
3D angiogenesis in the same setup. An early attempt to combine the two strategies 
revealed that fibroblasts might play an important role in tumour vascularisation.36 
In this setup, prostate cancer cells and/or foreskin fibroblasts were cultured in 
collagen matrices and these gels were sandwiched together with ECs containing 
fibrin gels. The presence of fibroblasts had a profound effect on the formation of 
CLSs and this was even more pronounced when cancer cells were added to the 
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culture. Another group used a heterogeneous spheroid model to demonstrate the 
stromal impact on ECs. Here, the pre-grown spheroids containing cancer cells, 
fibroblasts and ECs were fully immersed in a 3D collagen matrix and the 
outgrowth of endothelial sprouts was quantified under different conditions.279 In a 
different experiment, which was also a sandwich design-based tumour 
angiogenesis model, cancer cells were cultured in collagen type I hydrogels. This 
layer was covered with another acellular collagen hydrogel and ECs were then 
seeded on top of the whole construct. The authors recognised that ECs proliferated 
and invaded the top layer in response to cancer cells, resulting in the formation of 
a complex capillary-like tubular network.280 One striking 3D model has recently 
been developed by Seano and others.281 They co-embedded prostate cancer cells 
and arterial explants from human umbilical cords in Matrigel and observed that 
microvessel outgrowth was stimulated by tumour clusters as exogenous GFs were 
not added to the culture. 
Although these models are able to reflect the in vivo conditions more closely than 
other approaches, they still lack some important features that need to be 
considered in order to accurately reproduce either tumour-endothelium 
interactions, or to gain physiologically more relevant information. Studies 
focusing on the stromal contribution to EC response deployed cells which were 
derived from different tissues. Because dermal fibroblasts are easily available, they 
are often co-cultured with cancer cells in various models. However, the 
heterogeneity in the origin of cells raises questions about the biological 
significance. 
Another aspect is that many models aiming to describe an angiogenic response 
within a 3D environment lack a detailed quantification or characterisation of the 
endothelial network.255 While in some studies the presentation of the results is 
only based on image description, a few groups established computer-assisted 
analysis techniques to extract basic parameters such as amount of sprouts or 
capillary length. Interestingly, these tools are often based on 2D image analysis 
methods and thus, even 3D stacks obtained by confocal or multiphoton 
microscopy have to be reduced to a planar plane (e.g. by maximum projection), 
which might result in loss of information of the sample. 
2.3.4 Hydrogel platforms 
The ideal design of a suitable TEC for the investigation of tumour-endothelium 
interactions should follow two premises, (1) mimicry of the TME and (2) support 
for the multiple step process of angiogenesis. Thus far, the only known 
biomaterial that allows formation of lumen-containing capillaries in vitro is a 
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hydrogel. In literature, a plethora of different hydrogel platforms is described that 
support the formation of endothelial networks; others are able to mimic certain 
characteristics of the TME (s. above). Besides the material, the polymerisation 
method of hydrogel precursors can also affect the intended application, which 
must be taken into account when choosing an appropriate setup (Figure 2.8). 
Crosslinking chemistries 
Gelation of hydrogel precursors can be achieved by non-permanent molecular 
entanglements or physical crosslinking (e.g. hydrophobic, electrostatic, specific or 
unspecific protein interactions).282 These physical hydrogels are either formed 
upon change of temperature/pH or by combining components of opposing charge. 
Another polymerisation strategy is to chemically crosslink end-functionalised 
monomers. Although the strong covalent linkage improves stability of the 
product, chemical crosslinking might be disadvantageous in context of cell 
viability and biological functionality. Photo polymerisation (i.e. radical 
polymerisation) and addition reactions are commonly applied in tissue 
engineering application to generate stable chemical junctions.282,283 However, these 
polymerisation reactions are often accompanied by toxic byproducts, or require 
utilisation of crosslinking agents that are potentially harmful to biological material 
or specific cellular processes. If possible, toxic compounds have to be removed 
before the hydrogel is used for in vitro and in vivo applications. As a consequence, 
encapsulation of cells during the polymerisation process is virtually impossible. In 
contrast, physical hydrogels do not require (toxic) crosslinking agents and 
polymerisation occurs without any byproducts. On the one hand, this allows 
encapsulation of cells in hydrogels but on the other hand, physical crosslinking 
can affect long-term stability of the construct. Enzymatically crosslinked hydrogels 
could be used to overcome the limitations of both methods as the mild conditions 
are ideal for cell viability during the gelation process.284 
Naturally-derived matrices 
Hydrogels aim to mimic important structural and biological functions of the 
native ECM and the easiest way to fulfil the requirements for cell-instructive 
materials is to use naturally-derived building blocks. Non-ECM proteins like 
albumin or silk fibroin285 and polysaccharides such as alginate, chitosan or 
agarose286 are well-known to create biofunctional systems. However, these 
materials do not share certain important characteristics with the native ECM that 
affect cell behaviour and thus, the vast majority of commonly used hydrogels is 
rather based on ECM proteins (collagen and fibrinogen/fibrin) and 
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polysaccharides (heparin/heparin sulphate, hyaluronic acid or chondroitin 
sulphate).285 
Components directly isolated from the ECM usually do not need further 
modifications as they already have bio-responsive properties such as attachment 
and degradation sites. Moreover, numerous functional residues of these 
biopolymers are known to interact with cytokines. This feature allows, at least 
partly, the reconstruction of the ECM as a GF-binding and releasing reservoir. 
Overall, due to their intrinsic characteristics, naturally-derived matrices are able to 
reflect the ECM found in vivo quite closely.21 However, there are some drawbacks 
that need to be considered. The adjustment of a desired stiffness is impossible, and 
biopolymers are not easily accessible for tuning and processing (e.g. incorporation 
of functional groups). Reproducibility of experimental results is challenging due to 
batch-to-batch variations. Moreover, naturally-derived components are often 
physically crosslinked and the amount of cleavable sites cannot be controlled, 
which might affect stability and durability of the construct. 
Synthetic matrices 
Synthetic materials have several advantages over naturally-derived components 
that help to overcome these problems. PEG is one of the most common synthetic 
bulk polymers and binds large amounts of water due to the uncharged 
hydrophilic nature. It shows excellent biocompatibility as immunogenic reactions, 
inflammation or infections of PEG-based hydrogels, which can occur with 
naturally-derived matrices, have not been reported. Further examples for synthetic 
materials used in hydrogels include polyvinyl alcohol, polyacrylic acid, and 
polyacrylamide.287 
Huge amounts of these polymers with well-defined properties (molecular weight, 
molecular architecture and microscopic morphology) can be synthesised and 
chemically crosslinked. Compared to physical interactions, the permanent 
covalent bond enhances stability of hydrogels, which is important for long-term 
cell-cultures. Incorporation of bioactive molecules at desired sites of the polymer is 
also easy to achieve.283,288 Furthermore, mechanical properties can be tailored to a 
cell or tissue specific stiffness. Here, the stiffness is adjusted by changing the chain 
length, density and crosslinking degree. These properties make PEG and other 
synthetic polymers an ideal substitute for naturally-derived hydrogel precursors. 
Besides the above mentioned properties, PEG is also known to be protein 
repellent. However, the storage, presentation and administration of chemokines 
such as GFs can be critical for certain cellular applications. The adaption of 
synthetic hydrogels with this feature is difficult and thus, the combination of both, 
a synthetic and natural part has been proposed. These so-called biohybrid 
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hydrogels still have high design flexibility while they can also interact with several 
GFs. For instance, the conjugation of collagen, fibrinogen or heparin with PEG has 
been described.24,289,290 Biohybrid hydrogels based on the highly sulphated, anionic 
GAG heparin and the synthetic polymer PEG have recently gained increased 
attention. Heparin protects, binds and releases cytokines similar to the ECM 
component heparan sulphate, but is also cheap and easily available. Therefore, 
heparin became the GAG of choice in several biomaterial design strategies.285 
2.3.5 StarPEG-heparin hydrogels as cell-instructive matrices 
As it has been described above, PEG-heparin hydrogels combine the advantages 
of a synthetic polymer (PEG) and a natural occurring substance (heparin; Figure 
2.9). A four-arm star-shaped (star)PEG provides flexibility to the system and can 
be crosslinked with heparin by carbodiimide active ester chemistry,24 by Michael-
type addition,26,291 or non-covalently by heparin affine peptide sequences attached 
to the polymer292 to form a biohybrid hydrogel. Maleimide-thiol Michael-type 
additions are highly specific for thiols over other nucleophiles, have fast reaction 
kinetics and create a covalent linkage between the two components without any 
by-products. Therefore, this reaction allows the formation of stable starPEG-
heparin hydrogels in situ without affecting the viability of encapsulated cells. 
Heparin-containing hydrogels are regarded to (at least partly) mimic the GF 
Figure 2.8: Important advantageous and disadvantageous of naturally-derived (collagen, 
fibrin, etc.) and synthetic (mostly PEG) hydrogel precursors and their crosslinking 
mechanisms. 
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reservoir of the ECM as they can reversibly immobilise several proteins, including 
the angiogenic factors VEGF-A, FGF-2, and SDF-1, by electrostatic 
interactions.25,28,293 Another big advantage is that these biohybrid hydrogels allow 
the decoupling of biomolecular functionalisations from variations in viscoelastic 
matrix characteristics. By changing the crosslinking degree, the stiffness can be 
varied while the content of the GF binding heparin component stays constant.24  
These unique features can be exploited for a wide range of cellular applications. 
For example, to dissect the influence of pro-angiogenic stimuli, different 
parameters (GF presentation, adhesion characteristics and matrix elasticity) can be 
tested independently from each other.28 Furthermore, these hydrogels have been 
shown to bind and release large amounts of two important angiogenic GFs (VEGF, 
FGF-2) in parallel and independently. Additionally, bioactive peptide sequences 
(adhesion ligands and MMP-cleavable sites) can be added to the system. Taken 
together, hydrogel characteristics allow the fine-tuning and optimisation of 
different parameters in order to create an angiogenic-stimulating environment. 
Consequently, it has been demonstrated that starPEG-heparin hydrogels support 
pro-angiogenic behaviour of ECs such as adhesion, proliferation, migration, and 
differentiation into an elongated phenotype and finally assembly into lumen-
containing endothelial networks in vitro and in vivo.28,29,293 Moreover, it has been 
shown that this biohybrid hydrogel enables the development of both, mature 
tumour spheroids and lumen-containing endothelial capillaries and can therefore 
be used to model 3D tumour angiogenesis in vitro.29,30 
Figure 2.9: The starPEG-heparin hydrogel platform. The stiff, maleimide-functionalised 
heparin is crosslinked with the flexible thiol-terminated starPEG via Michael-type addition 
reactions for in situ hydrogels. MMP-cleavable sequences can be added to starPEG 
molecules and cyclic (c)RGD-integrin binding motifs can be covalently attached to heparin 
which also serves as a GF reservoir. The stiffness can be tuned independently from the 
heparin content. 
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Having the requirements for a versatile and in vivo-like 3D environment in mind, 
the aforementioned properties of a starPEG-heparin hydrogel make it an ideal 
platform to investigate the impact of the tumour stroma on endothelial networks. 
Another example of a hydrogel that provides both, cell-responsive characteristics 
(adhesion and degradable sites) as well as tuneable mechanical and chemical 
properties is GelMA. It is synthesised by adding methacrylate groups to the 
amine-containing side-groups of gelatine, which becomes a photo-crosslinkable 
hydrogel. This platform has also been proven to stimulate vascular morphogenesis 
in vitro.31 Therefore, both hydrogel types, starPEG-heparin and GelMA, will be 
tested concerning their potential for the investigation of tumour stroma-
endothelium interactions within a well-defined 3D in vitro setting. Finally, the 
usage of primary cells and development of a robust 3D analysis technique are 
believed to allow new insights into the contribution of prostatic fibroblasts on 
formation of endothelial networks. 
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3. Material and methods 
3.1 Preparation of starPEG-heparin hydrogel networks 
3.1.1 Gel channels in diffusion chamber 
Diffusion chamber preparation: Silicone Elastomer (Nusil; Carpinteria, CA, USA) was 
prepared according to the manufacturer’s protocol and injected into the custom-
made master device. After curing (60-80°C, 2 - 3 h), the polydimethylsiloxane 
(PDMS) mould was removed and irreversibly attached to a glass slide via oxygen 
plasma treatment (2 - 3 min). Beforehand, the mould and glass slide were rinsed 
with 70% Ethanol followed by a washing step with deionized, decarbonized water 
(MilliQ-water). 
Hydrogel crosslinking: StarPEG-heparin hydrogels were formed by crosslinking 
amino end-functionalised four-arm starPEG with activated carboxylic acid groups 
of heparin as described elsewhere.24 The molar ratio (𝛾) of starPEG to heparin for 
diffusion experiments was set to 1, 1.5, 2 and 3, respectively. Heparin (Molecular 
weight (MW) 14,000; Calbiochem (Merck), Darmstadt, Germany) and a mixture of 
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC; Sigma-Aldrich, Munich, 
Germany) and N-hydroxysulphosuccinimide (sNHS; Sigma-Aldrich) were 
dissolved in ice-cold MilliQ-water by ultrasonication and kept on ice (approx. 2 - 4 
°C) for 10 (𝛾 = 2 & 3), 15 (𝛾 = 1.5) and 20 (𝛾 = 1) min to activate the heparin 
carboxylic acid groups. Amine end-functionalised 4-arm starPEG (MW 10,000; 
Polymer Source, Inc., Dorval, Canada) was dissolved in MilliQ-water on ice and 
subsequently added to the activated heparin. A total polymer content of 5% and a 
2:1:0.83 ratio of EDC:sNHS:NH2-groups of starPEG [mol/mol] were used. The gels 
were labelled by mixing the heparin with 2% of Alexa-Fluor 488-labeled heparin 
(Invitrogen GmbH, Karlsruhe, Germany). 
Hydrogel channels production: For bulk diffusion measurements, hydrogel channels 
were fabricated by injecting 23 µl into the PDMS mould. The length (~ 4 mm) and 
height (~ 3.5 mm) of the channel was adjusted with the help of a Teflon block 
(Figure 3.3A). After polymerization overnight (ON) at room temperature (RT), 
gels were washed and allowed to swell in phosphate buffered saline (PBS; Sigma-
Aldrich) to remove excessive EDC/s-NHS and unbound starPEG/heparin. The PBS 
was changed 3 - 4 times every hour and once again after storage ON. 
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3.1.2 Gel discs in FCS reservoir 
Hydrogels for fluorescence correlation spectroscopy (FCS) measurements were 
produced according to hydrogels designed for bulk diffusion as described in 3.1.1 
with a few modifications. The polymer content was adjusted from 5% to 13.3% 
and a 2:1:1 ratio of EDC:sNHS:NH2-groups was used. 21 µl of the 
starPEG/heparin mixture was placed between two hydrophobic glass cover slips 
that have been treated with chlorinated organopolysiloxane (Sigmacote; Sigma-
Aldrich) to produce gel discs with an initial diameter of 5 mm. After gelation ON, 
cover slips were removed and gel discs were washed and incubated in PBS (ON). 
3.1.3 Gel discs for mechanical characterisation 
For every condition (diffusion studies in diffusion chamber or FCS reservoirs and 
cell culture), slightly different hydrogels were prepared (s. above). To determine 
the stiffness and volumetric swelling characteristics of starPEG-heparin hydrogels, 
67 µl of the starPEG/heparin mixture was placed between two hydrophobic glass 
cover slips. After gelation of the mixture ON, cover slips were removed and the 
free-floating gel discs (initial diameter of 9 mm) were incubated in PBS or 2% FBS 
EGM-2 cell culture media (s. below) for 24 h and 7 d. 
3.1.4 Gel discs for cell embedding 
In situ hydrogels for cell culture were prepared as described by Tsurkan and 
others.26 Peptides containing the MMP-cleavable sequence 
GCGGPQGIWGQGGCG-NH2 were synthesised and conjugated to starPEG 
molecules (MW 15,920). Heparin was modified with an average of 6 maleimide 
groups per molecule (HM6, MW 15,000). HM6 was dissolved in ice cold, serum-
free endothelial growth medium 2 (EGM-2; Lonza, Walkersville, MD, USA). For 
cell attachment, cyclic RGDYC (cRGD, MW 594; Peptides International, Louisville, 
KY, USA) was dissolved in serum-free EGM-2, added to HM6 solution incubated 
on ice for 30 min. In order to stimulate the formation of endothelial networks, 
human recombinant VEGF165 (Prospec, Rehovot, Israel) was reconstituted in PBS 
and added to the HM6-cRGD mixture. Subsequently, cells were harvested in 
serum-free EGM-2 and 11 µl of HM6-cRGD-VEGF165 solution were resuspended in 
11 µl cell solution. StarPEG-MMP conjugate was dissolved in serum-free EGM-2 
and 22 µl of this solution were gently mixed with the modified HM6-cell solution 
and 40 µl were placed in a custom built mould (diameter = 5 mm, height = 2 mm; 
Figure 3.1). Hydrogel formation occurred within several seconds. The final 
concentration of starPEG, HM6 and cRGD was 0.84, 1.5 and 3 mM, respectively (𝛾 
= 0.56). Final VEGF165 concentration was adjusted to 5 µg/ml. Upon 
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polymerisation, gels were immediately immersed in low-serum (2% foetal bovine 
serum, FBS; Biochrom, Berlin, Germany) EGM-2 with 1% penicillin/streptomycin 
(Sigma-Aldrich) and cultured as floating disks.  
3.2 Preparation of other hydrogel types 
In order to compare the performance of starPEG-heparin hydrogels to other gel 
types and to test their potential for the investigation of tumour stroma-
endothelium interactions in general, the hydrogel platforms GelMA and Matrigel 
were included in this work. 
3.2.1 Photopolymerisable gelatine methacrylate (GelMA) 
The photo-crosslinkable GelMA hydrogel was produced as described by 
Schuurman et al. (Figure 3.1).294 Type A gelatine reaction with methacrylic 
anhydride (Sigma-Aldrich) at 50°C for 1h yielded GelMA building blocks. 0.6 g of 
methacrylic anhydride was added dropwise to 10 ml of a 10% solution (w/v) of 
gelatine in PBS. The functionalised polymer was dialysed against distilled water 
for 3 d at 40°C to remove methacrylic acid and anhydride, neutralised with 10% 
sodium bicarbonate (Merck, Darmstadt, Germany), freeze dried and stored at -
20°C before use. 
Hydrogel precursor solutions were prepared in PBS with a final concentration of 
the photo initiator Irgacure 2959 (BASF, Ludwigshafen, Germany) of 0.05% (w/v) 
and photo-crosslinked in a custom built Teflon mould (50 x 4 x 2 mm) using 365 
nm light at an intensity of 1.9 mW x cm-2 for 10 min. in a UVP CL-1000L 
crosslinker (UVP, Upland, California, USA). Final GelMa concentration was 5% 
and 3% (w/v), respectively. Hydrogel stripes were cut in 10 pieces (5 x 4 x 2 mm) 
and incubated in 2% FBS EGM-2 for 24 h or 7 d. Subsequently, hydrogels were 
used for mechanical characterisation (s. below). For cell culture, cells were added 
to the precursor solution before crosslinking (s. below) and hydrogels were 
immersed in 2% FBS EGM-2 after gelation. 
3.2.2 Matrigel for cell culture 
Aliquots of Matrigel (BD Biosciences, Heidelberg, Germany) were stored at -20°C 
before use. For experiments, one aliquot was thawed at 4°C ON and kept on ice 
during preparations. 10 µl Matrigel per well were placed in a special angiogenesis 
chamber (µ-Slide; ibidi, Munich, Germany) according to the manufacturer’s 
protocol. Matrigel samples polymerised at 37°C for 45 min. Subsequently, cells 
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resuspended in 2% FBS EGM-2 were seeded on top of the gel. For co-culture 
experiments, cells were also embedded in Matrigel (s. below). 
To produce free floating discs for long-term cell culture (> 24 h), 40 µl per well of 
cell-containing Matrigel were placed in the same mould as starPEG-heparin 
hydrogels for cell culture (Figure 3.1). After polymerisation, Matrigel discs were 
immersed in 2% FBS EGM-2. 
3.3 Characterisation of starPEG-heparin and GelMA hydrogels 
3.3.1 Volumetric swelling degree 
Either empty or cell-laden (2.5 x 106 MSCs/ml) starPEG-heparin or GelMA 
hydrogels were incubated in 2% FBS EGM-2 for 24 h or 7 d. 6 repeats per 
condition were produced and weighed before swelling. 3 of the 6 hydrogels were 
also weighed after 24 h and 7 d, respectively. 70% of the medium was exchanged 
every second or third day for long-term culture. The difference in wet weights was 
expressed as a percentage, and referred to hereafter as effective swelling. The 
same hydrogels (24 h and 7 d) were further used for compression tests to 
determine the stiffness. 
3.3.2 Compression test 
Compression tests were performed on hydrogels that are produced for cell culture 
applications to determine the stiffness. Unloaded starPEG-heparin and GelMA 
Figure 3.1: Hydrogel preparation of starPEG-heparin and GelMA hydrogels for cell 
culture. For starPEG-heparin gels, all components were dissolved in EGM-2 and cRGD, GFs 
and cells were added to the heparin solution before crosslinking with starPEG. The 
precursors polymerised in custom-built circular moulds (left). GelMA polymers were 
dissolved in PBS and mixed with a photo initiator. This precursor solution was transferred 
to a custom-built Teflon mould and crosslinked by UV radiation (right). 
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hydrogels (N = 3 - 4) were incubated in 2% FBS EGM-2 for at least 24h to allow 
complete swelling of the gels. The compressive moduli (E) of unloaded and cell-
laden hydrogels (from volumetric swelling tests) were measured in an unconfined 
arrangement using an Instron 5848 microtester with a 5 N load cell. During 
testing, constructs were submerged in PBS at 37°C. A displacement rate of 0.01 
mm x s−1 was applied using a non-porous indenter, and the modulus was taken 
from the linear region of the stress-strain curve from 10 to 15% strain.294 Values 
obtained by this method were then converted into storage modulus values (G’ = 
E/3). 
3.3.3 Rheology 
Rheological measurements were performed on starPEG-heparin hydrogels that 
are produced for GF diffusion studies as described elsewhere.24 Briefly, the storage 
modulus (G’) as a measure of stiffness of the final networks (N = 3) was 
determined using oscillating measurements on a rotational rheometer with plate-
plate geometry (plate diameter 25 mm, gap width 3 mm). Dynamic frequency 
sweep tests under strain control were carried out at RT in a shear frequency range 
of 1 to 100 rad/s. The strain amplitude was set to 3% and storage modulus was 
measured as a function of the shear frequency. According to the rubber-elasticity 
theory,24 the average pore size (ζ) of the network (distance between two 
entanglement points) can be estimated by using this equation:  
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Here, G’ is the storage modulus, NA is the Avogadro constant, R is the molar gas 
constant, and T is the temperature.  
3.4 Growth factor diffusion studies in starPEG-heparin hydrogels 
StarPEG-heparin hydrogels were further characterised by investigating transport 
processes of GFs through networks of different characteristics. FCS and a bulk 
diffusion approach were employed to elucidate the diffusional behaviour of two 
protein pairs, EGF/hb-EGF and VEGF isoforms 121/165 (VEGF121/VEGF165). Each 
pair consists of a low and high heparin affine component. Proteins of one pair 
share a comparable hydrodynamic radius (Rh), whereas the pairs are varying in 
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size (Figure 3.2 and Table 3.1; molecular properties were obtained from 
literature295–299 or were calculated300,301). Interestingly, low affine forms exhibit an 
isoelectric point (pI) less than 7, whereas high affine forms have a pI > 7 (Table 
3.1). However, all proteins show both, negative and (more important) positive 
surface potentials (Figure 3.2). 
Table 3.1: Physical properties of GFs used in this study, including molecular weight (MW), 
hydrodynamic radius (Rh), radius of gyration (Rg) and isoelectric point (pI). Values in 
brackets represent calculations based on theoretical assumptions (for more information, s. 
text). 
Protein MW [kDa] Rh [nm] Rg [nm] pI 
EGF 6.2 [1.41] 1.85 [1.15] 1.15 4.6 
hb-EGF 9.7 [1.67] [1.3] 10 
VEGF121 28.4 [2.53] 2.8 [1.79] 6.4 
VEGF165 38.2 [2.84] [2.01] 8.5 
 
In detail, the affinity to heparin, size and concentration of the proteins as well as 
the mesh size of the hydrogel network were systematically varied to conclude on 
the parameters affecting the transport processes. Furthermore, different working 
solutions (PBS, cell culture medium and PBS-chitosan (~ 5 kDa; Heppe Medical 
Chitosan GmbH, Halle, Germany) to mask oppositely-charged affinity-centres, i.e. 
sulphate groups of heparin) were applied to deepen the understanding of GF 
diffusion through cytokine-affine networks. 
Figure 3.2: Surface models of proteins used in this study. Negative surface potentials are 
shown in red, positive surface potentials are shown in blue and secondary structures are 
shown in black (background). PDB2PQR366,367 and Adaptive Poisson-Boltzmann Solver 
(APBS)368 software were used to evaluate the electrostatic properties. Models were 
illustrated by PyMol.369 
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3.4.1 Protein labelling 
EGF, hb-EGF, VEGF165 and VEGF121 were purchased from PeproTech GmbH 
(Hamburg, Germany) and labelled with Alexa Fluor 555 according to the Alexa 
Fluor 555 Microscale Protein Labelling Kit manual (Molecular Probes, distributed 
by Invitrogen, Darmstadt, Germany). Subsequently, all protein solutions were 
additionally purified with the help of centrifugal filters (Amicon Ultra-0.5, 
Ultracel-3 Membrane, 3 kDa cut-off size; Millipore, Molsheim, France). The protein 
concentration and degree of labelling was determined with a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) according to 
the manufacturer’s protocol. Protein solutions were immediately used or stored in 
PBS in working aliquots at -20°C. 
3.4.2 Fluorescence correlation spectroscopy (FCS) 
Reservoir preparation (Figure 3.3B): Glass slides were rinsed with 70% Ethanol 
followed by a washing step with MilliQ-water. 2 ml Eppendorf tubes were cut, 
and the upper part (without the lid) was glued to a glass slide (Silicone adhesive 
MED-1511; Nusil). Gel discs (13.3 wt %; N = 4 - 5) were incubated in different 
working solutions for at least 24 h at RT (protein concentration: 10 µg/ml, unless 
noted otherwise) before diffusion of cytokines were measured. 
Setup: Experiments were performed on a commercial FCS unit, based on an LSM 
510 inverted fluorescence microscope (Confocor 3, Zeiss, Wetzlar, Germany). To 
excite the dye Alexa 555, a 543 nm beam from He-Ne laser was coupled into the 
light path of the microscope through an optical fibre and focused by the water 
immersion objective (40 magnification, 1.2 numerical aperture, NA) onto the 
sample. A hardware correlator translates the photon arrival pulses into intensity 
fluctuations and calculates the correlation in real time. The correlation curves were 
acquired and fitted to analytical expressions (see below). For an averaged 
correlation measurement, a minimum of 10 separate correlation measurements 
(each of 10 seconds in duration) were taken at RT, and corresponding standard 
deviations for every point of the experimental curves were calculated from 
multiple experiments. 
FCS measurements:302 The following analytical form of the temporal auto-
correlation G() was used to obtain the diffusion time of a fluorescent molecule 
through the confocal observation volume in the hydrogel system: 
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Here, 

N  is the average number of particles in the observation area, τ the delay 
time, τD the lateral diffusion time of the molecule through the illuminated 
observation volume and r0 and z0 the radius and axial length of the observation 
volume. To extract τD and using the reciprocal standard deviations as weights, the 
average correlation curve for each experiment was fitted to equation 2. 
The effective diffusion coefficient (De) of the cytokines labelled with Alexa 555 is 
determined from the experimentally obtained correlation time (τD) and the known 
lateral with (r0) of the observation volume using the following equation: 
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The lateral width of the observation volume, r0, was determined independently 
from calibration measurements using 50 nM Alexa 555 in 50 mM 
Tris(hydroxymethyl)-aminomethane (TRIS, Sigma-Aldrich) of pH 7 and 
employing the fluorophore’s known diffusion coefficient (4.14 x 10-6 cm2/s) as a 
standard. 
3.4.3 Confocal laser scanning microscopy (cLSM)/fluorescence scanner 
Measurements (Figure 3.3A): For bulk diffusion measurements, a weakly swelling 
hydrogel (5 wt %, 𝛾 = 3; N = 3) was used in order to avoid any defects. Rheology 
and FCS measurements revealed no differences in stiffness (and therefore gel 
mesh size) and diffusive properties, respectively, to the standard condition (13.3 
wt %, 𝛾 = 1; Figure 4.2C). After removing of PBS, protein solution (35-40 µl, 10 
µg/ml) was filled into the reservoir of the channel and the whole chamber was 
sealed using parafilm. Samples were protected from light and incubated at RT for 
24 h, allowing the protein to diffuse into the gel. Thereafter, protein solution was 
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removed and a Teflon block was placed next to the open gel end. The whole 
channel was covered with silicone oil, preventing the gel from drying out. 
Subsequently, time lapse recording was started (t = 0 h, RT). Fluorescence intensity 
was quantified using a Leica SP5 (Leica, Bensheim, Germany) confocal laser 
scanning microscope with a 10 magnification immersion objective (HCPL APO, 
Leica) and aperture pinhole set at 20 µm. The argon laser (excitation wavelength 
488 nm, laser intensity 30%) was used for exciting Alexa 488-labelled gels whereas 
the DPSS laser (excitation wavelength of 561 nm, intensity 20%) was used for 
excitation of Alexa 555-labelled proteins. Alexa 488 and 555 emissions were 
analysed in the 500-530 nm or 570-610 nm range, respectively. The time dependent 
intensity profiles of the proteins were evaluated within the whole gel channel 
length at t = 0 h, 1 h, 3 h, 6 h, 12 h and 24 h. Fluorescence intensity was additionally 
determined by a fluorescence scanner (FLA-5100, Fujifilm, Düsseldorf, Germany). 
The 473 nm-laser and 532 nm-laser were used for exciting Alexa 488 and Alexa 
555, respectively. 
Analysis of protein distribution within the gel channel: Raw image files were imported 
to ImageJ (developed by W. Rasband, National Institutes of Health, Bethesda, 
USA) and protein intensity profiles were extracted at the gel channel centre with 
supporting points every ~ 50 µm (Figure 4.1B,C). The effective diffusion 
coefficients (De) in the hydrogel were determined on the basis of normalised 
intensity profiles following a procedure developed by Carslaw and Jaeger.303,304 In 
short, the normalised intensity profiles measured at t = 0 were fitted with a 
polynomial function and used as reference for the further data evaluation. The 
diffusion coefficients were determined by simultaneously fitting the spatial 
intensity profiles measured at t = 1 h, 3 h, 6 h, 12 h and 24 h according to the 
method of least squares using MATHCAD 15.0 (Parametric Technology 
Corporation, Needham, MA, USA). For every protein, intensity profiles were 
evaluated and used for the calculation of the average diffusion coefficient and 
standard deviation.  
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3.5 In vitro cell culture experiments 
3.5.1 Isolation and cultivation of human umbilical vein endothelial cells 
(HUVECs) 
HUVECs were isolated according the procedure proposed by Weis and co-
workers.305 The vein of umbilical cords not older than 20 h was rinsed with PBS 
and filled with sterile collagenase (446 U/ml; Sigma-Aldrich) to release the cells. 
After incubation for 20 min at 37°C, the enzymatic reaction was stopped by adding 
Figure 3.3: Preparation procedure of bulk 
diffusion and FCS setup. For bulk diffusion 
experiments, a PDMS mould was affixed to 
an ethanol-cleaned glass slide, and a 
hydrogel-channel was formed within the 
mould. After polymerisation, the GF was 
allowed to diffuse into the gel for 24 h. 
Thereafter, protein solution was removed and 
distribution of the GF was monitored for 
another 24 h at RT. To avoid drying, the 
hydrogel was completely covered with 
silicone oil (A). For FCS measurements, 
hydrogel discs were incubated in protein 
solution for at least 24 h before measurements 
were started (B). 
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PBS supplemented with 10 % FBS. The cell-containing solution was filled into a 
sterile tube and centrifuged (Labofuge 400 R; Heraeus, Berlin, Germany) for 5 min 
at 1500 rpm. Next, cells were resuspended in 2% FBS EGM-2 and seeded into a T75 
flask (Techno Plastic Products AG, Trasadingen, Switzerland) coated with 50 
μg/ml fibronectin (Roche Diagnostics GmbH, Mannheim, Germany). HUVECs 
were grown to confluency at 37°C and 5 % CO2, while the medium was changed 
every second day. 
After reaching confluency, cells were used for experiments (passage 3 - 4) and/or 
split into 3 T175 flasks. To do this, the medium was removed and cells were rinsed 
twice with PBS in order to remove dead cells, cell debris and remnants of old 
medium. To release the cells from the flask, the culture was incubated with 3 ml of 
trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; Sigma-Aldrich) for 2 min 
at 37°C. The proteolytic reaction was stopped by applying 5 ml PBS supplemented 
with 10 % FBS. HUVECs were then transferred into a sterile tube, centrifuged for 5 
min at 1500 rpm and resuspended in the corresponding medium (10% FBS or 
serum-free EGM-2 for further cell culture and gel-embedding, respectively). 
3.5.2 Isolation and cultivation of endothelial colony forming cells (ECFCs) 
ECFCs are highly proliferative, form colonies on type 1 rat tail collagen following 
14 -  21 days of culture and match more closely than other cell types the criteria of 
being a true EPC.306,307 Moreover, these cells are known to form human vessels de 
novo in vivo and incorporate into existing vascular networks created by the co-
culture of mature endothelial and fibroblast cells.308 
ECFCs were isolated from human term placenta as described previously.309 
Cotyledons were washed thoroughly to remove all blood in Hanks’ balanced 
saline solution (HBSS; Invitrogen) and digested in 1 mg/ml collagenase I, 1 mg/ml 
DNase-1, and 75 µg/ml dispase solution for 2 h at 37°C. After digestion, the single 
cell suspension was filtered through a 100-µm sieve and centrifuged at 750 g for 5 
min. The supernatant was discarded, and the cell pellet was resuspended in red-
cell lysis buffer and incubated at RT for 10 min. The suspension was then 
centrifuged at 510 g for 5 min. The supernatant was discarded, and the cell pellet 
was washed in HBSS and centrifuged at 510 g for 5 min. Cells were then 
resuspended in ice-cold MACS buffer (PBS containing 2 mM EDTA and 0.5% 
bovine serum albumin (BSA)) and incubated with CD45 (cluster of differentiation 
45) Dynabeads (Invitrogen) for 15 min at 4°C before being placed into a 
Dynamagnet (Invitrogen) holder to deplete CD45-labelled cells. The remaining 
cells were then centrifuged at 510 g for 5 min before being resuspended in 1 ml of 
ice cold MACS buffer. CD34 MACS beads (Miltenyi Biotec, North Ryde, Australia) 
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were then added and incubated at 4°C for 15 min. Cells were washed with MACS 
buffer and centrifuged at 510 g for 5 min before the cell pellet was resuspended in 
3 ml of MACS buffer and passed through a magnetic column to collect labelled 
CD34+ cells. Isolated ECFCs were a gift from the group of Professor Kiarash 
Khosrotehrani (University of Queensland Centre for Clinical Research, Brisbane, 
Australia) and were cultured according to the HUVEC protocol as described 
above. 
3.5.3 Isolation, discrimination and cultivation of normal prostate fibroblasts 
(NPFs) and cancer-associated fibroblast (CAFs) 
Human prostate tissue was collected from radical prostatectomy specimens as 
previously described310 and analysed by routine histopathology to determine the 
Gleason score (a measure of cell differentiation and a pathological indicator of 
biological behaviour, correlating with the stage of the disease and metastatic 
potential; GS). Tissue specimens were diced into 2 - 3 mm3 pieces, then digested in 
digestion media (10% FBS RPMI, 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 100 U/mL penicillin, 100 mg/mL 
streptomycin, 0.5 mg/mL fungizone, 100 mg/mL gentamicin, 225 U/mL 
collagenase Type I and 125 U/mL Hyaluronidase Type II (Sigma-Aldrich)) for 
approximately 16 h. Cell suspensions were washed with PBS and transferred into 
T75 flasks with RPMI (School of Biomedical Sciences, Media and Prep Services, 
Monash University, Australia) containing heat inactivated 5% FBS (Thermo Fisher 
Scientific), 1 nM testosterone (Sigma-Aldrich), 10 ng/mL FGF (Millipore), 100 
U/mL penicillin and 100 mg/mL streptomycin, which selects for the growth of 
stromal cells. 
Stromal cells derived from malignant prostate tissue are known as CAFs, whereas 
cells derived from benign regions are referred to as NPFs. The expression of 
secreted frizzled-related protein 1 is upregulated in tumour stroma and the 
protein is therefore a convenient marker for distinguishing CAFs from NPFs.311 
Furthremore, only CAFs have the ability to induce tumour formation in tissue 
recombination assays.312 To confirm the CAF and NPF status, isolated fibroblasts 
were therefore recombined with BPH-1 cells after primary culture and grafted 
under the renal capsule of immunodeficient mice. After 6 - 8 weeks, grafts were 
collected in order to analyse tumour growth and survival. 
Isolated fibroblasts with confirmed CAF/NPF status were kindly provided by the 
group of Professor Gail Risbridger (Prostate Cancer Research Centre, Monash 
University, Melbourne, Australia). Before use in co-culture experiments, 
fibroblasts were expanded in specific human prostate fibroblasts cell culture 
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medium (s. above, supplemented with 10% FBS) at 37°C in 5% CO2 atmosphere. 
Un-matched stromal cells from 10 patients (pair I-V) were used for this study 
between passages 4 and 9. For all patients, the original patient ID and pathology 
are recorded in Table 3.2: 
Table 3.2: Primary prostatic stromal cell lines used in study. 
Pair Cell line Patient Pathology (Gleason score) 
I 
NPF 64 Benign 
CAF 35 7 
II 
NPF 69 Benign 
CAF 26 7 
III 
NPF 70 Benign 
CAF 72 7 
IV 
NPF 76 Benign 
CAF 74 7 
V 
NPF 79 Benign 
CAF 67 9 
 
3.5.4 Mono-culture of HUVECs or ECFCs in different hydrogels 
To test the tube formation ability of ECs in different hydrogels, 6 x 106 HUVECs29 
or ECFCs/ml were embedded in starPEG-heparin gel discs and 6 or 1.85 x 106 
cells/ml were embedded in GelMA hydrogels and crosslinked. After 
polymerisation, gels were transferred into a 24 well plate (one gel (40 µl) per well) 
and incubated in 1.5 ml EGM-2 supplemented with 2% FBS and 
penicillin/streptomycin. 70% of the medium was exchanged every second or third 
day. Formation of endothelial networks was monitored every day and bright field 
images were taken at different time points. Alternately, cell viability was tested for 
different conditions. For further image processing of 3D endothelial networks, 
samples were washed twice in PBS and fixed in 4% paraformaldehyde for 15 
minutes at day 7 (s. sub-sections 3.6.3 - 3.6.6). 
3.5.5 Co-culture of HUVECs and NPFs/CAFs in starPEG-heparin hydrogels 
To investigate the impact of CAFs and NPFs on the formation of endothelial 
networks, 6 x 106 HUVECs/ml and 0.6 x 106 (10:1 ratio) or 1.2 x 106 (5:1 ratio) NPFs 
and CAFs/ml, respectively, were co-embedded in starPEG-heparin gel discs (N = 
3 - 4) and cultured as described above. HUVEC mono-cultures with or without 
recombinant VEGF served as positive and negative control, respectively. Instead 
of co-embedding, fibroblasts were also seeded in 24 well plates (2.4 x 104/well) 16 h 
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prior to hydrogel incubation to demonstrate potential paracrine effects of CAFs or 
NPFs on endothelial networks. In both setups, cell culture supernatants were 
collected for protein expression analysis. Figure 3.4 depicts the different settings. 
Samples were processed as described above. 
For CXCR4-inhibitor studies, cell culture medium was supplemented with 1 µg/ml 
AMD3100 (Sigma-Aldrich) or 1ng/ml human recombinant SDF-1 (Miltenyi Biotec, 
Bergisch Gladbach, Germany) were added to the hydrogels.  
3.5.6 Co-culture of HUVECs and NPFs/CAFs in Matrigel 
In order to compare starPEG-heparin hydrogels to a commonly used hydrogel 
system, HUVECs and NPFs/CAFs were also embedded in 40 µl of 100% or 50% 
(diluted in EGM-2) Matrigel discs and treated accordingly (6 or 2.4 x 106 
HUVECs/ml, 10:1 ratio). Besides that, 2 x 104 HUVECs/10 µl Matrigel were seeded 
on top of the gels (N = 3 - 4) and 2 x 103 CAFs or NPFs/10 µl were either embedded 
beforehand (Figure 3.4) or co-seeded with HUVECs. These 2D cultures were 
incubated for 16 h, washed twice in PBS containing Mg2+ and Ca2+ (Sigma-Aldrich) 
and fixed thereafter for image processing. 
3.6 Analysis of in vitro mono and co-cultures 
3.6.1 Live-dead staining after hydrogel-embedding and culture 
Hydrogels of various conditions were collected after 24 h and 7 d of incubation 
and washed with pre-warmed PBS. Next, samples were incubated in 0.1 µg/ml 
fluorescein diacetate (FDA; Sigma-Aldrich) and 5 µg/ml propidium iodide (PI; 
Figure 3.4: Important hydrogel co-cultures used in this work. HUVECs were co-embedded 
with CAFs or normal prostate fibroblasts (NPFs) and HUVEC mono-cultures served as 
positive (VEGF functionalised) and negative (without VEGF in the gel) control (left, middle). 
Cells were also spatially separated (fibroblasts on the well bottom; top right) or HUVECs 
were seeded on top of fibroblasts-containing Matrigel (bottom right). 
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Sigma-Aldrich) in PBS for 2 - 5 min at 37°C. Hydrogels were washed three times in 
PBS and immediately imaged using a Nikon Eclipse-Ti inverted fluorescence 
microscope (Nikon Instruments Inc.). 
3.6.2 Protein detection assay 
Putative angiogenic GFs secreted by NPFs, CAFs and/or HUVECs during co-
culture experiments were measured using multiplex immunoassays based on the 
xMAP technology (Luminex, Austin, TX, USA). Different Bio-Plex Pro magnetic 
cytokine assays were used: Human Cancer Panel I & II, Human MMP and Human 
SDF-1 Alpha Assay (BioRad, Hercules, CA, USA). During cell culture in which 
cells were kept spatially separated (Figure 3.4, top right), 1 ml per well of the 
supernatant was collected at day 5 and stored at -80°C until analysis. Samples 
from three donors were collected. After thawing, 50 µl of the samples were 
transferred into a Bio-Plex Pro 96 flat bottom well plate (BioRad). The assay was 
performed according to the manufacturer´s instruction. Automated washing was 
performed using a Bio-Plex Pro wash station equipped with a magnet (BioRad). 
Finally, samples were analysed via flow cytometric imaging with Bio-Plex 200 and 
Bio-Plex Manager Software (BioRad). 
3.6.3 Immunocytochemistry 
Cell-laden hydrogels (3D) were stained with monoclonal human-specific anti-
CD31 antibody (R&D Systems, Minneapolis, MN, USA). Briefly, hydrogels were 
washed in PBS, permeabilised and blocked with Triton X-100 (0.2%) in a 2% BSA-
PBS-solution (Sigma-Aldrich) for 1 hour. Hydrogels were then incubated ON with 
primary antibody solution (10 µg/ml in 1% BSA-PBS). After extensive washing in 
PBS (three times) the next day, hydrogels were incubated with secondary antibody 
(10 µg/ml goat anti-mouse Alexa 488 conjugate (Life Technologies, Darmstadt, 
Germany) in 1% BSA-PBS) ON. To visualise the actin-network of stromal cells, 
some samples were additionally incubated with rhodamine phalloidin (2 U/ml, 
Invitrogen). Finally, hydrogels were washed again (three times) and stained with 
4′,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich). Samples were kept in PBS 
at 4°C until they were imaged. 
2D endothelial networks grown on top of Matrigel were treated similarly. Samples 
were washed in PBS and blocked with a 2% BSA-PBS-solution for 10 min. 
Hydrogels were then incubated with primary antibody solution for 45 min, 
washed three times in PBS and incubated with secondary antibody for 45 min. 
Finally, hydrogels were washed again three times and kept in PBS at 4°C until 
they were imaged. 
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3.6.4 Confocal microscopy 
Confocal images were taken from 3D samples using a Leica SP5 confocal laser 
scanning microscope with a 10x long distance dry objective (HCPL APO, 0.4 NA). 
The argon-laser (excitation wavelength 488 nm) was used to detect CD31-positive 
signals in the gel and the DPSS laser (excitation wavelength of 561 nm) was used 
for excitation of rhodamine. 450 µm thick Z-Stacks were taken at 2.5 µm intervals 
at three different positions in the gel with a pinhole aperture of 1 airy unit (53 µm). 
Resolution of images was set to 512 x 512 pixels, resulting in a voxel size of 3 x 3 x 
2.5 µm3. The total volume of one imaged spot in the gel was approximately 1 µl. 
As the fluorescence signal weakens with increasing gel depth, laser power and/or 
gain was constantly adjusted during the scanning process. 
3.6.5 Conventional image analysis of endothelial networks 
2D samples were imaged using an inverse fluorescence microscope (Axio 
Observer Z1 equipped with a Colibri light source, Carl Zeiss, Jena, Germany). One 
fluorescence image per sample was taken with a 2.5x magnification objective (NA 
0.075) to visualise CD31-positive cell structures. Next, images were imported in 
AngioTool software (v 0.6a)313 and endothelial networks were quantified by using 
an intensity range from 15 - 255. Vessel diameters with a threshold of 10 and 
above were included whereas small particles with a threshold of 1000 and below 
were removed. Value of ‘Fill holes’ function was set to 1000. 
Images from one confocal scan of 3D samples were overlapped and thereby 
merged into a single image by applying the maximum intensity z-projection (MIP) 
function in ImageJ. Endothelial networks were analysed with AngioTool (intensity 
threshold = 90 and 255, vessel diameter threshold = 3 and particle size threshold = 
100). 
3.6.6 3D image reconstruction and skeletonisation of endothelial networks 
For a true 3D analysis of 3D endothelial networks, the protocol described by 
Krishnan et al. was adapted and optimised.314 Amira software (FEI SAS, Mérignac 
cedex, France) was used to reconstruct and present volumetric scans as well as for 
skeletonisation of endothelial networks in order to extract important parameters 
such as length, branching and diameter of CLSs (Figure 3.5). Intensity artefacts in 
images with slice depth were reduced using an algorithm that fit an exponential 
curve to average intensities. 2D and 3D digital median filters as well as a 3D 
Gaussian smoothing filter were applied to reduce background noise of single 
images and 3D stacks. Stacks were further deconvolved using a point spread 
function generated from the NA (0.4), wavelength of light emitted from the Alexa 
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488 dye (520 nm) and the refractive index of the gel (≈ water = 1.333). An 
automated thresholding algorithm based on a Gaussian distribution was used to 
binarise each stack (ImageJ). A size filter of 600 mm3 was applied to remove debris 
and small cell clusters. Images were then visualised and/or skeletonised. A 
Chamfer distance map was generated as a part of the skeletonisation process, and 
these data were used to determine average diameter and length of each segment. 
Coordinates of points from the skeletonisation were processed by the program 
WinFiber3D (available at http://mrl.sci.utah.edu/software/winfiber3d) to calculate 
morphometric parameters, including amount, length, branch points, diameter and 
volume of CLSs.  
Figure 3.5: Volumetric image reconstruction, manipulation and skeletonisation. 3-4 spots 
per gel were imaged and analysed. For a detailed 3D quantification of network 
characteristics, stacks of raw images (A) were processed, deconvolved (B) and binarised (C). 
3D images of the samples could then be reconstructed (D). Small particles were removed 
(E, F) and images were finally skeletonised (G) to extract important vessel parameters 
(length, diameter, branching, etc.).  
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3.7 Data analysis 
Statistical analysis was performed using student´s t-test, one-way analysis of 
variance (ANOVA) and post-hoc Tukey-Kramer multiple comparison test with the 
software ‘Prism’, version 5.04. Results for analysis with ´P´ value less than 0.05 
were considered to indicate statistically significant differences (* - P < 0.05; ** - P < 
0.01; *** - P < 0.001; **** - P < 0.0001). All data are presented as mean ± standard 
deviation (SD), unless otherwise stated. 
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4. Results and discussion 
4.1 Growth factor transport processes in cytokine affine hydrogels 
The first goal of this work was to describe important physico-chemical 
characteristics of GelMA and starPEG-heparin hydrogels. Besides the commonly 
determined parameters stiffness and effective swelling, the transport processes of 
GFs widely used in cell culture models within the cytokine-affine starPEG-heparin 
network are of special interest. Therefore, four proteins (EGF/hb-EGF and 
VEGF121/VEGF165) were fluorescently labelled and their effective diffusion 
coefficient was measured under different conditions by FCS. In detail, the affinity 
(hb-EGF and VEGF165 are known for strong, specific interactions with heparin), the 
size of the GFs (hydrodynamic radius differences) and the mesh size of the 
hydrogel network were systematically varied to make conclusions on the 
parameters affecting the transport processes in such networks. Furthermore, the 
influence of the protein concentration and the effect of cell culture medium on the 
protein diffusion in the hydrogels were investigated and conditions were tested 
when the affinity-centres (sulphate groups of heparin) were masked by oppositely 
charged macromolecules (chitosan). In order to validate the experimental results 
obtained by FCS, the protein distribution in macroscopic hydrogel channels was 
detected at distinct time points by cLSM and a fluorescence scanner. Examples for 
typical FCS correlation fit and bulk diffusion analysis are shown in Figure 4.1. The 
determination of stiffness for different hydrogel types used in these studies is 
shown in Figure S.1. 
4.1.1 Diffusion in aqueous solutions and starPEG-heparin hydrogels 
In aqueous solutions, the diffusivity mainly depends on temperature, medium 
viscosity and hydrodynamic radius of the molecule, as described by the Stokes-
Einstein equation: 
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Here, D0 is the diffusion coefficient of the solute in a given solution, k is 
Boltzmann’s constant (1.38 x 10-23 J/K), T is temperature and η is the viscosity of 
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the solvent (1.0 x 10-3 Nm/s2 for water at 293 K). If Rg is known, D0 can also be 
estimated by using the equation proposed by He and Niemeyer, which 
additionally includes the MW as a structural parameter of the protein:315  
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Figure 4.1: Typical examples for fluorescence correlation spectroscopy (FCS) correlation 
fit and bulk diffusion analysis. FCS fits show a correlation curve of EGF and VEGF165 in 
starPEG-heparin hydrogels (𝛾 = 1, G´ ≈ 1.5 kPa; A). The time-dependent distribution of these 
GFs within a hydrogel channel was detected by confocal laser scanning microscopy (cLSM; 
left) or a fluorescence scanner (right) and analysed by plotting the normalised fluorescent 
intensity (I0 = Intensity at 0 min.) of proteins at several positions (x; B). Intensities (grey 
values) were only extracted at the centre of the hydrogel (C). 
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As predicted by equations 4 and 5, the diffusion coefficient of proteins in PBS 
solution decreased with higher Rh or higher MW and Rg (Figure 4.2A, light grey 
bars). Values derived from equation 5 can be considered to be more relevant as the 
MW is additionally taken into account. Rh and Rg are not known for most of the 
GFs used in this work and therefore have to be estimated (Table 3.1).300,301 
However, calculations of Rg for bigger proteins (> 100 amino acids) are not reliable 
and therefore, the theoretical values of D0 for VEGF isoforms are based on 
equation 4 and for (hb-)EGF on equation 5. Theoretical and experimental (middle 
bars, determined by FCS) values match quite closely; small differences could be 
explained by the dye which is attached to the proteins. Whereas just one dye 
molecule is attached to one molecule of the smallest protein (EGF), the average 
degree of labelling (mol dye/mol protein) increases with protein size from ≈ 3 (hb-
EGF) over 4 (VEGF121) to almost 6 (VEGF165; data not shown). As expected, EGF 
diffused faster in PBS (D0 = 142±10 µm2/s) than hb-EGF (D0 = 107±8 µm2/s) and D0 
of VEGF-isoforms is only half of that of EGF (69±5 and 65±5 µm2/s). Figure 4.2A 
also shows the tremendous impact of the gel network on protein diffusivity. 
Comparing diffusion in PBS and starPEG-heparin hydrogels (dark grey bars), 
diffusivity was greatly decreased for each tested protein. Specifically, in the case of 
VEGF isoforms (which share a similar Rh and D0 in PBS), diffusivity of VEGF165 
showed a marked decrease when compared with VEGF121, the weak heparin 
interacting isoform (from 65±5 and 69±5 to 4±1 and 20±5 µm2/s, respectively). It can 
therefore be concluded that the diffusion of GFs in cytokine-affine hydrogels is not 
only affected by steric interactions. For a more detailed discussion, see section 
4.1.3 (Effect of protein size, heparin affinity and hydrogel network on diffusivity).     
4.1.2 Comparison of FCS and bulk diffusion methods  
The diffusive properties of GFs were additionally analysed using a bulk diffusion 
approach to validate the FCS data. The fluorescence intensity (and therefore 
protein distribution) within the hydrogel channel was recorded by cLSM or a 
fluorescence scanner for 24 h. Subsequently, the effective diffusion constant (De) 
was calculated and compared to FCS data. Overall, the determined diffusivity did 
not deviate significantly from FCS results (De = 72±15, 39±5, 20±7 and 9±1 µm2/s for 
EGF, hb-EGF, VEGF121 and VEGF165, respectively, as determined by fluorescence 
scanner; Figure 4.2B). 
The diffusion chamber (or PDMS mould) does not allow unhindered swelling of 
the hydrogel channel, which especially occurs in gels with a low crosslinking 
degree. Therefore, a hydrogel with weak swelling properties was filled into the 
mould in order to avoid any potential defects that could arise in strongly swelling 
4   Results and discussion 
52 
hydrogels. As the solid content of this hydrogel was decreased (5 wt%), the molar 
ratio of starPEG to heparin had to be adjusted (𝛾 = 3) to keep the stiffness 
comparable to standard conditions (13.3 wt%, 𝛾 = 1; Figure 4.2C & Figure S.1). The 
standard and weak swelling gels were analysed concerning the diffusivity of all 
GFs, and FCS data revealed no major differences between these two gels (Figure 
4.2C). This underscores the robustness of both the FCS and bulk approach for 
determining the effective diffusion coefficient of GFs in starPEG-heparin 
hydrogels.  
Both techniques (FCS and bulk diffusion measurement) are suitable to investigate 
transport processes through cytokine-affine networks; however, obtaining data 
from bulk diffusion setups is time-consuming. As a consequence, the diffusive 
characteristics of starPEG-heparin hydrogels were further analysed by FCS only 
and the results are described in the following sub-sections.  
Figure 4.2: Diffusivity of all tested growth factors in PBS (supernatant) and in starPEG-
heparin hydrogels. Theoretical predictions for diffusivity of proteins in aqueous solutions 
are in line with experimental data as determined by FCS. Values obtained in hydrogels 
decreased considerably compared to PBS (A). Diffusion constants obtained by FCS (13 wt% 
gel, 𝛾 = 1, G´ ≈ 1.5 kPa) and bulk diffusion setups (cLSM/scanner; 5 wt% gel, 𝛾 = 3, G´ ≈ 2.5 
kPa) did not differ significantly (B). Rheology as well as FCS measurements revealed no 
major differences in stiffness (i.e. gel mesh size) and diffusive properties between the two 
gel types (determined by FCS; C). All data are presented as mean ± SD (N = 4-5 for FCS and 
3-4 for bulk diffusion measurements). 
4   Results and discussion 
53 
4.1.3 Effect of protein size, heparin affinity and hydrogel network on 
diffusivity 
One important goal was to evaluate the impact of protein size and heparin 
binding affinity on diffusivity in the starPEG-heparin hydrogel system. Therefore, 
low- and high-heparin affine forms of two protein pairs of different molecular size 
were compared. In order to obtain a comprehensive overview, De is normalised to 
the diffusion constant of the respective protein in PBS (D0).  
The high affine molecules exhibited a lower De/D0 ratio than their low affine 
counterpart (De/D0 = 0.53±0.03 and 0.34±0.05 for EGF and hb-EGF; 0.3±0.07 and 
0.07±0.01 for VEGF121 and VEGF165; Figure 4.3A & B, left bars). In addition, 
comparing low and high affinity molecules (EGF/VEGF121 and hb-EGF/VEGF165), 
the normalised diffusion constant was decreased when the molecular size was 
increased (Figure 4.3C). These observations indicate that both, a steric and 
electrostatic component influence the diffusion of charged GFs through starPEG-
heparin networks. As a next step, the impact of heparin affinity was therefore 
decoupled from steric interactions by adding chitosan (~ 5 kDa) to the incubation 
Figure 4.3: Effect of protein size, heparin affinity and hydrogel network on diffusivity. 
Normalised diffusion constants (D0 = diffusion constant in PBS) of EGF growth factor pair 
(A) and VEGF isoforms (B) in standard hydrogels (𝛾 = 1, G´ ≈ 1.5 kPa) with or without the 
addition of positively charged chitosan to PBS-growth factor solution, as determined by 
FCS. Comparison of proteins with similar heparin affinity (C). Cartoon depicting the protein 
molecular size to hydrogel mesh size ratio (D). All data are presented as mean ± SD (N = 4-
5). Statistical significance, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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solutions. The positive charge of the polysaccharide was expected to mask the 
electrostatic effects. Based on the average charge density of both heparin and 
chitosan, different ratios of these molecules were applied (Figure 4.4). A weight 
ratio of 0.5:1 (charge ratio of ~ 0.25:1 between chitosan and heparin, assuming an 
average charge density of 0.8 and 3 per chitosan316 and heparin317 disaccharide, 
respectively) did not show major differences compared to incubation solutions 
without any chitosan. In contrast, a weight ratio of 2:1 (charge ratio of 1:1) had a 
significant impact on GF diffusion. Here, the diffusivity of all tested proteins 
increased to a similar level (De/D0 = 0.75±0.09 - 0.85±0.08; Figure 4.3A & B, right 
bars). Regardless of heparin affinity, the diffusivity of each protein changed 
significantly when chitosan was added to the incubation solution. 
It is very likely that electrostatic interactions between heparin and GFs do not 
occur or can be neglected in chitosan solutions with a neutralising charge ratio. 
The contribution of the steric influence of the gel network to a decreased 
diffusivity of all proteins in hydrogels can therefore be estimated to approx. 20%. 
A similar observation has been found in hydrogels exhibiting only weak 
electrostatic interactions with proteins of different size.318 Moreover, diffusivity 
data of all proteins within chitosan loaded hydrogels are in line with theoretically 
expected values for non-specific interacting networks (Table 4.1), as described by 
Lustig and Peppas:319 
 
Figure 4.4: Effect of chitosan concentration on diffusivity. Normalised diffusion constants 
of all growth factors in standard hydrogels (𝛾 = 1, G´ ≈ 1.5 kPa), as determined by FCS. 
Proteins were diluted in PBS with different chitosan concentrations (PBS only, 0.5:1 and 2:1 
weight ratio [g/g] to oppositely charged heparin). The chitosan amount corresponds to 
charge ratios of 0:1, 0.25:1 and 1:1. All data are presented as mean ± SD (N = 4-5). 
4   Results and discussion 
55 
 
 
 















1h
0e  1
Q
Q
Y
e
R
DD

 (6) 
 
 
Here, ζ is the mesh size of the network, Y is the ratio of the critical volume 
required for translational movement of the encapsulated particle to the average 
free volume per molecule of solvent (approximated as 0.1) and Q is the volumetric 
swelling ratio. Taken together, the data from literature and the theoretical 
estimations elaborated by Lustig and Peppas support the assumption that most, if 
not all, electrostatic interactions between heparin and GFs have been abolished, 
which allowed revealing of the steric influence on diffusivity. 
Table 4.1: Theoretically and experimentally derived effective diffusion coefficient of 
different growth factors in polymer networks. Calculations are based on theoretical 
assumptions reported for a non-specific interacting hydrogel network (equation 6).319 By 
the addition of chitosan to starPEG heparin hydrogels, protein specific interactions were 
masked and diffusivity was most likely affected by steric interactions only. 
De [µm2/s] EGF hb-EGF VEGF121 VEGF165 
Lustig/Peppas 107 79 47 43 
+ Chitosan 110 80 55 55 
 
Furthermore, the data from this work and from literature clearly demonstrate that 
another factor has a tremendous impact on GF diffusion through starPEG-heparin 
hydrogels: electrostatic binding affinity to heparin. Although EGF and VEGF121 do 
not contain a specific heparin-binding domain and both cytokines have a negative 
net charge at physiological pH (Table 3.1), their surface is partly positively 
charged (Figure 3.2), and this may contribute to heparin interactions which in turn 
potentially affect diffusion.  
The effect of (electrostatic) interactions on diffusive properties of solutes in 
polymer networks has been analysed in several publications.320–322 However, the 
review of these articles does not allow for clear conclusions. Two studies did not 
detect an influence of charge on diffusivity except on the release of molecules.323,324 
Here, the determination of the diffusion coefficient was based on concentration 
profiles of the supernatant, and the authors argued that only the ‘mobile fraction’ 
accounts for calculations. The immobile fraction was retained in the gel, thus it did 
not contribute to the diffusion constant. The majority of the studies however, 
indicate that network-solute interaction does play a role. The results deviate 
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qualitatively as attraction (repulsion) between these components has been found 
to either accelerate or hinder the diffusion of particles. Hirota and co-workers 
observed an enhanced diffusion of myoglobin in an oppositely charged gel 
network,325 whereas Johansson et al. reported that an attractive electrostatic 
interaction between the diffusant and the fibre decreased the observed diffusion 
coefficient.326,327 A hindered diffusion due to solute/polymer interactions was also 
found by Ende and Peppas.328 These contradictory results could be explained by 
the chosen setup; in this work, as well as by Johansson et al., the self-diffusion 
coefficient was examined whereas Hirota et al. measured the mutual diffusion 
coefficient (which describes the diffusion in a multi-component system, e.g. when 
a gradient is dissipated by diffusion of the solute(s) and the solvent). 
Data from this work show evidence that strong electrostatic bindings of proteins 
to oppositely charged heparin decreases the diffusion dramatically as compared to 
weaker interacting solutes of comparable size. Moreover, although two proteins 
have the same qualitative net charge as heparin at physiological pH, the 
determined diffusion constant of these molecules was still lower than theoretical 
values predicted for non-interacting polymer networks (s. above). In line with 
these results, Ende and Peppas found that opposite charges reduce diffusivity and 
that electrostatic interactions can affect diffusion to a greater extent than a particle 
size/mesh size ratio.328 Interestingly, they also reported a hindered diffusion for 
insulin (pI = 5.3) in an anionic hydrogel at pH = 7. Theoretically, the interactions 
causing the decrease in the observed diffusion constant are repulsive, and it is 
assumed that repulsion reduces the overall mesh size and therefore diffusion.325 
However, it is not unlikely that insulin (like the proteins tested in this work which 
have a pI < 7) temporarily binds to the anionic polymer due to regional positive 
surface potentials. On the other hand, it can also be argued that strong binding as 
well as repulsion between polymers and solutes reduce diffusivity. Further work 
is needed to shed light on this particular discrepancy.  
Remarkably, the De/D0 ratios of VEGF isoforms are even lower than that of EGF 
proteins. However, there is no evidence in literature that VEGF165 binds stronger to 
heparin than hb-EGF (Kd = 165 and 4.7 nM, respectively).329,330 The probability to 
interact with the network/heparin (and therefore to reduce the diffusivity) is 
higher for larger proteins than for smaller ones (Figure 4.3D). Besides that, a 
significant decrease in De in a PEG-based hydrogel system was observed for 
proteins with Rh from ≈ 1.5 to > 2 nm.331 Taken together, these assumptions and 
cited publications may explain the data obtained in this work. Apparently, the 
diffusivity of (positively) charged proteins within an untreated starPEG-heparin 
4   Results and discussion 
57 
hydrogel is decreased synergistically by increasing both, protein size and heparin 
affinity.  
4.1.4 Effect of mesh size on diffusivity 
As a next step, the influence of the network mesh size on diffusivity was 
examined. For this purpose, the molar ratio was varied from 𝛾 = 1 to 1.5 and 2, 
obtaining hydrogels with different storage moduli (G´ ≈ 1.5, 4.0 and 6.5 kPa, 
respectively; Figure S.1) while the heparin content was kept constant. With the 
help of G´, the theoretical network mesh size could be calculated according to 
equation 1 (14, 10 and 8.5 nm, respectively).24 The De/D0 ratio slightly decreased for 
each protein with decreasing mesh size (i.e. increasing storage modulus). 
However, the diffusion did not change significantly between all mesh sizes 
(Figure 4.5). For example, diffusivity of EGF decreased from 0.53±0.03 (G´ ≈ 1.5 
kPa) over 0.46±0.03 (G´ ≈ 4.0 kPa) to 0.44±0.04 (G´ ≈ 6.5 kPa), but differences were 
only significant for gels with G´ ≈ 1.5 and 6.5 kPa. In the case of VEGF121, it 
dropped down from 0.3±0.07 over 0.24±0.07 to 0.22±0.06, but statistical analysis 
revealed no significant differences at all. However, this effect would be expected 
from theory for non-cytokine affine networks332 and the observed trend of 
decreased diffusivity is in line with previously reported data.302 
Previous studies focussing on heparin-bound VEGF165 and FGF-2 did not detect 
any difference in the release profiles of these GFs from starPEG-heparin hydrogels 
with different mesh sizes. Among other techniques, the authors used an enzyme-
linked immunosorbent assay (ELISA) to detect the proteins in the supernatant of 
the gel and observed a rapid increase of the concentration within the first 24 h. 
They explained this burst release with a ‘mobile’ fraction of GFs entrapped within 
the meshwork but not specifically bound to heparin. Moreover, this characteristic 
Figure 4.5: Effect of mesh size on diffusivity. Normalised diffusion constants of EGF 
growth factor pair (A) and VEGF isoforms (B) in hydrogels with different mesh sizes (G´ ≈ 
1.5 kPa → 14 nm, 𝛾 = 1; G´ ≈ 4.0 kPa → 10 nm, 𝛾 = 1.5; G´ ≈ 6.5 kPa → 8.5 nm, 𝛾 = 2), as 
determined by FCS. All data are presented as mean ± SD (N = 4-5). Statistical significance, 
*P < 0.05. 
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can be attributed to surface effects.28 The burst release was followed by a 
continuous and slow release rate of the GFs, which was also independent from the 
mesh size. 
As discussed above, the specific setup and different observations (release profile 
versus diffusion time) may explain the (slight) differences in the outcome of these 
studies and results of this work. Furthermore, only one additional data point (96 
h) was taken after the burst release had occurred and the cumulative protein 
amount in the supernatant did not change much compared to 24 h with the given 
loading concentration (1 µg/ml, VEGF165). On the other hand, the additional 
amount of protein being released after 96 h was much higher when the loading 
concentration had been increased to 10 µg/ml, which is the same concentration 
that has been used in this work. Unfortunately, the authors did not compare 
release profiles with this specific loading concentration from hydrogels with 
different mesh sizes, and this may also explain why they did not observe any 
differences in the release rates. 
4.1.5 Effect of growth factor concentration on diffusivity 
Besides the mesh size, the impact of different GF concentrations on diffusive 
properties was analysed. For this, the protein concentration of the incubation 
solution was decreased from 10 over 5 to 2 µg/ml. As depicted in Figure 4.6, the 
De/D0 ratio of high heparin affine forms increased slightly with decreasing 
concentrations (0.34±0.05, 0.37±0.03, 0.39±0.02 and 0.07±0.02, 0.09±0.02, 0.12±0.02 
for hb-EGF and VEGF165, respectively), while De of the low heparin affine forms 
remained unchanged (De/D0 ≈ 0.53 and 0.31 for EGF and VEGF121, respectively). 
Differences were only significant for VEGF165, 2 and 10 µg/ml. 
Figure 4.6: Effect of growth factor concentration on diffusivity. Normalised diffusion 
constants of EGF growth factor pair (A) and VEGF isoforms (B) in standard hydrogels (𝛾 = 1, 
G´ ≈ 1.5 kPa), as determined by FCS. Proteins were diluted in PBS to different 
concentrations. All data are presented as mean ± SD (N = 4-5). Statistical significance, 
**P < 0.01. 
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A possible explanation for the observed diffusion constants is that more GFs bind 
to heparin at the same time when the protein concentration is increased. These 
immobilised GFs temporarily decreased the local mesh size of the network, which 
in turn affects the diffusion of proteins through the hydrogel (sub-section 4.1.4: 
Effect of mesh size on diffusivity). Although all of the tested GFs probably interact 
with heparin (sub-section 4.1.3: Effect of protein size, heparin affinity and 
hydrogel network on diffusivity), this effect was only observed for proteins 
containing a specific heparin-binding domain (hb-EGF and VEGF165) within the 
given concentration range. These proteins bind strongly to heparin whereas the 
interaction of EGF and VEGF121 with the polysaccharide is weak and does not last 
long enough to affect the average mesh size. In this sense, a more pronounced 
difference would be expected for both concentrations and pore sizes of different 
magnitudes (e.g. 0.1, 1, and 10 µg/ml and 6, 18 and 36 nm, respectively). 
4.1.6 Effect of cell culture medium on diffusivity 
All of the results presented above (sub-sections 4.1.1 - 4.1.5) were derived from 
hydrogels incubated in protein-PBS solutions. Besides that, as starPEG-heparin 
hydrogels have been developed to serve as cell-supportive matrices, a potential 
influence of cell culture media (or its ingredients/supplements) on GF diffusion 
was investigated. Particularly, EC growth medium (EGM-2) and FBS with its 
(usually) unknown composition and concentration of proteins were of special 
interest.  
For FCS measurements, hydrogels were incubated in EGM-2, which contained 
GFs and varying FBS concentrations (0, 0.5, 2, 5, 10 and 20%). Protein diffusivity in 
EGM-2 was then compared to PBS solutions. The results clearly indicate that cell 
culture medium does not affect diffusion of any GF used in this work (Figure 4.7). 
Additionally, De of all tested proteins remained almost constant with different 
serum concentrations in the cell culture medium (≈ 70, 30, 20 and 6 μm2/s for EGF, 
hb-EGF, VEGF121 and VEGF165, respectively). 
4.1.7 General discussion/summary protein diffusion 
GFs trigger important cell responses such as migration, proliferation and 
differentiation, and therefore they are usually added to in vitro cultures as a single 
dose at the time of media change. However, their availability depends on the 
diffusion rate into cell-instructive matrices and the bio-activity will decrease with 
time depending on the initial concentration, stability of the supplement and 
relative up-take by the cells. Incorporation of covalently attached cytokines into 
cell-instructive matrices could help to overcome these drawbacks. However, the 
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activity of chemically immobilised GFs could be compromised and a sustained 
release of soluble, physically immobilised cytokines from hydrogels is therefore 
regarded to be beneficial in order to elicit or maintain a distinct cellular behaviour, 
such as the formation and growing of CLSs by ECs.28,29,293 
Although several cytokines are routinely used in 3D cell culture models, a 
comprehensive understanding of the molecular transport in hydrogels is missing. 
Bulk diffusion-based methods such as blind well chambers (in which a protein 
donor cell is separated from an acceptor cell by a thin hydrogel layer) have been 
reported to determine diffusion constants of several molecules.333 The monitoring 
of the cumulative uptake and release of solutes can also be used to describe 
diffusivity;334 however, as the immobile fraction of particles is retained in the gel 
and due to potential surface effects, this technique does not allow the 
measurement of ‘real’ effective diffusion inside the gel within a reasonable time 
course. To address this issue, several techniques including FCS302,318 and Nuclear 
Magnetic Resonance Spectroscopy335 were adapted to evaluate diffusivities of 
proteins and macromolecules in hydrogels. 
Common to nearly all studies focussing on diffusion through different types of 
hydrogels is that only model molecules such as BSA, immunoglobulins or dextran, 
differing in size and charge (isoelectric points), were chosen. In contrast, the data 
Figure 4.7: Effect of cell culture medium on diffusivity. Diffusion constant of all growth 
factors in standard hydrogels (𝛾 = 1, G´ ≈ 1.5 kPa), as determined by FCS. Proteins were 
diluted in endothelial cell culture medium, supplemented with different concentrations of 
fetal bovine serum (FBS). All data are presented as mean ± SD (N = 4-5). 
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from this work provided a comprehensive understanding about the transport 
phenomena of relevant cell culture GFs within a cytokine affine hydrogel system. 
By the addition of chitosan, the steric part was unravelled from the electrostatic 
influence on diffusivity within starPEG heparin hydrogels. Moreover, a slight 
impact of network mesh size on solute movement through the hydrogel was 
observed as predicted by theory and confirmed by previously published data. A 
potential synergistic action (i.e. reduction) of diffusivity by increasing particle size 
and heparin affinity has also been described. 
Taken together, the presented data are the basis for a fundamental understanding 
of cytokine diffusion in starPEG-heparin hydrogels, supporting the development 
of promising novel 3D cell culture models. 
4.2 GelMA and starPEG-heparin hydrogel characteristics 
Besides starPEG-heparin hydrogels,29 another hydrogel platform, GelMA, has 
recently been described to enable the formation of functional vascular tubes.31 Both 
hydrogels contain adhesion and proteolytically degradable sites and were 
therefore considered to support investigations into CAF-EC interactions in a 3D in 
vitro environment. However, only starPEG-heparin hydrogels can non-covalently 
bind and release GFs, like VEGF165 (hereafter denoted as VEGF). 
At first, the two different gel types were tested to determine whether they allow 
the formation of endothelial networks using mono-cultures of two different EC 
types, ECFCs (an EPC type) and HUVECs. Whereas this has already been 
confirmed for HUVECs in VEGF/cRGD-modified in situ starPEG-heparin gels, 
formation of vascular tubes in GelMA hydrogels has only been shown when ECs 
were co-cultured with MSCs. In both hydrogel platforms, the co-culture of ECs 
with MSCs has been proven to be beneficial for the formation of endothelial 
networks, most probably due to direct cell-cell-interaction/differentiation of MSCs 
into a pericyte phenotype but also because of soluble factors secreted by 
(differentiated) MSCs. In order to gain an unambiguous insight into the role CAFs 
could play in endothelial network formation, any impact of MSCs had to be 
excluded. Therefore, mono-cultures of ECs were needed. 
An EC concentration of 6 x 106 HUVECs/ml starPEG-heparin hydrogel was found 
to be optimum for both, mono- and co-cultures.29 As their mechanical 
characteristics and swelling behaviour can differ, the physical properties of both 
gel types had to be determined, in order to allow for comparisons between the two 
gel types with similar cell densities and stiffness. For this, hydrogels of different 𝛾 
(in situ starPEG-heparin) and solid content (GelMA) with or without MSCs were 
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incubated for 24 h and 7 d in EGM-2 and analysed subsequently. The results are 
shown in Figure 4.8. 
The stiffness of cell-free and cell-laden hydrogel constructs were similar after 
crosslinking and incubation in EGM-2 for 24 h (Figure 4.8B). As reported by 
Freudenberg et al.,24 the storage modulus (G’) of unmodified starPEG-heparin 
hydrogels correlated with the molar ratio of starPEG to heparin, 𝛾, i.e. the stiffness 
increased with higher values of 𝛾 (0.12±0.03 kPa, 𝛾 = 0.56; 0.35±0.2 kPa, 𝛾 = 0.63; 
0.77±0.19 kPa, 𝛾 = 0.75) while the uptake of additional water decreased (effective 
swelling of 139±32, 97±18 and 61±20%, respectively; Figure 4.8A and C, light blue 
bars). Increasing the crosslinking degree (by increasing 𝛾) created a denser 
network that was more rigid (higher storage modulus) and exhibited restricted 
water uptake due to larger retraction forces caused by the higher number of 
covalent bridges within the gel (lower swelling). The same trend was observed 
when cRGD was added to the gel. However, the stiffness and swelling changed 
only slightly with different crosslinking degrees and were of the same magnitude 
as from an unmodified gel with the lowest 𝛾 (0.13±0.07 - 0.21±0.05 kPa and 144±29 
- 162±26%, respectively; Figure 4.8A and C, dotted light blue bars). Theoretically, 
two maleimide groups of HM6 have reacted with cRGD (a 2:1 ratio of cRGD to 
heparin was applied), and the reduced amount of four maleimide groups per 
heparin available for network formation could explain these results. 
Figure 4.8: Mechanical properties and 
effective swelling of (cell-laden) starPEG-
heparin and GelMA hydrogels. The 
stiffness (G’) depended on the molar ratio of 
starPEG to heparin (𝛾) or solid content 
(GelMA; A) and was not affected by 
embedded cells after 24 h of incubation in 
cell culture medium (B). Whereas 
unmodified starPEG-heparin hydrogels 
increased their mass by ~ 60-140%, GelMA 
gels shrank by ~ 20% after 24 h (C). All data 
are presented as mean ± SD (N = 3-4).  
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In the case of GelMA, the stiffness can be adjusted by changing the macromere 
concentration prior to crosslinking.294 Accordingly, G’ increased from 0.23±0.08 
(3%) to 1.13±0.15 kPa (5%) when the solid content was increased. In contrast to 
starPEG-heparin hydrogels, GelMA gels did not swell but shrank after 24 h of 
Figure 4.9: Cell morphology of MSCs in hydrogels of different stiffness at day 3 and 7. 
The stiffness was varied by adjusting the solid content (3 and 5%) for GelMA hydrogels 
(green background) or the crosslinking degree (𝛾 = 0.56, 0.63 and 0.75) for starPEG heparin 
hydrogels (blue background), which were unmodified or cRGD-modified. Only a few 
elongated cells were observed in GelMA gels (highest number after 7 days in 3%), whereas 
changes in morphology depended on the stiffness and cRGD-modification in starPEG-
heparin gels. Scale bar = 100 µm. 
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incubation by 22±5 - 26±5% (Figure 4.8A and C, light green bars). The loss of water 
has also previously been observed for GelMA gels with a macromere 
concentration of ≤ 15%.294 
In order to investigate any impact that supporting cells such as fibroblasts or 
MSCs can have on the stiffness or swelling, cell-laden gels were additionally 
incubated for 7 d. In GelMA gels, no major differences in mechanical properties 
were observed compared to 24 h (Figure 4.8A and C, dark green bars). In contrast, 
the stiffness of unmodified starPEG-heparin hydrogels with higher crosslinking 
degrees (0.75 and 0.63) decreased from 0.77±0.19 and 0.35±0.2 kPa to 0.46±0.24 and 
0.32±0.12 kPa, respectively. For the lowest tested 𝛾 (0.56) it increased slightly from 
0.12±0.03 to 0.16±0.03 kPa. However, the trend for different crosslinking degrees 
was the same as for 24 h. The effective swelling increased from 61±20 to 86±34% 
for the highest crosslinking degree (0.75), whereas it dropped down dramatically 
from 97±18 and 139±32% to 8±21 and 38±7% for hydrogels with 𝛾 = 0.63 and 0.56, 
respectively (Figure 4.8A and C, dark blue bars). Here, a clear trend (such as for 
gels after 24 h of incubation) was not observed. As for the unmodified hydrogels 
with 𝛾 = 0.56 (which were of similar stiffness), all cRGD-modified gels became 
stiffer (from 0.13±0.07 - 0.21±0.05 kPa to 0.26±0.02 - 0.38±0.12 kPa) and lost a 
similar amount of water (effective swelling decreased from 144±29 - 162±26% to 
51±14 - 71±2%) after 7 d compared to 24 h of incubation (Figure 4.8A and C, dotted 
dark blue bars). 
These differences in starPEG-heparin hydrogels between the two time points (24 h 
and 7 d), i.e. increasing or decreasing in stiffness/swelling, could be explained by 
changes in the cell morphology which were observed in different hydrogels 
(Figure 4.9). After 24 h, cells in all gels were round (data not shown), and a few 
cells were elongated in GelMA gels after 3 d. The amount of elongated cells in 
starPEG-heparin hydrogels after 3 d was affected by the initial (t = 24 h) stiffness 
(or crosslinking degree), but not by cRGD modification, and was higher in soft 
gels. These differences were even more pronounced after 7 d of incubation. At this 
time point, a few more elongated cells were observed in softer (3%) compared to 
stiffer (5%) GelMA gels, which was similar to the amount in the stiffest, 
unmodified starPEG-heparin hydrogel. 
An elongated MSC phenotype interacts with the matrix of the gel and is more 
likely to apply pulling forces on the network. These forces cause the gel to shrink29 
and to become stiffer (as observed at hydrogels with an initial stiffness < 0.3 kPa). 
The cells can modify their surrounding matrix by cleaving the network, which also 
affects the stiffness (i.e. makes the gel softer). For example, the starPEG-heparin 
hydrogel with the highest crosslinking degree (0.75, unmodified) prevented 
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elongation in most of the cells up to day 3. MMPs secreted by the cells most likely 
reduced the stiffness over the course of 7 d, which eventually resulted in more 
elongated cells compared to day 3. The hydrogel with the lowest crosslinking 
degree (0.56, unmodified) was soft enough for the cells in order to elongate, and 
an interconnected network was already observed at day 3. This dense cellular 
network pulled on the gel matrix, which caused a stiffer gel at day 7. This effect 
was even more pronounced when cRGD was incorporated, which provided 
additional adhesion sites for the cells. An increased stiffness of the gel was usually 
accompanied by a loss of water at day 7 compared to 24 h, which can be explained 
by the shrinkage of the gels. As most of the cells in GelMA gels did not elongate, 
stiffness and swelling were almost unchanged between gels after 24 h and 7 d of 
incubation. Even in the softest gel (3%), the initial stiffness (and/or UV radiation) 
might have been too high for the cells. A solid content below 3% however, did not 
allow for the production of stable hydrogels (data not shown).  
In summary, the mechanical properties of both types of hydrogels were not 
affected by embedded cells within the first 24 h. During this time, the stiffness was 
adjusted by the solid content (GelMA) or crosslinking degree (starPEG-heparin) of 
the hydrogels. Interestingly, GelMA gels shrank after 24 h of incubation whereas 
starPEG-heparin swelled strongly, and the amount of water taken up depends on 
the initial stiffness. In starPEG-heparin gels, changes in cell morphology affected 
the mechanical properties after 7 d of incubation as gels became stiffer and 
simultaneously lost water compared to gels after 24 h of incubation. As ECs were 
not found to increase or decrease the stiffness and are not known to do so, the data 
collected from this study could now be used to adjust the initial EC density in 
GelMA hydrogels to a concentration similar to that in starPEG-heparin hydrogels 
(1.85 x 106/ml gel). The final cell concentration after swelling (+ 150%)/shrinkage 
(- 20%) in both gels after 24 h was approx. 2.4 x 106/ml. This density was used to 
test and compare the tube formation ability of ECs in GelMA and starPEG-heparin 
hydrogels (section 4.3). 
4.3  Tube formation ability of endothelial cells in different hydrogels 
As HUVECs are already known to form vascular tubes in starPEG-heparin 
hydrogels, these ECs were taken to compare three different types of hydrogels 
concerning their capability to support the formation of 3D endothelial networks: 
starPEG-heparin (𝛾 = 0.56, cRGD- and VEGF-functionalised), GelMA (3%) and 
Matrigel (50 and 100%). All hydrogels contained either an initial HUVEC 
concentration of 6 x 106/ml or a cell density which was normalised according to 
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their swelling behaviour (starPEG-heparin 6, GelMA 1.85 and Matrigel 2.4 x 
106/ml). 
After 24 h, the cell viability was evaluated for cells embedded in GelMA and 
starPEG-heparin gels. Figure 4.10A shows representative pictures of HUVECs 
after live/dead staining (left panel). Almost all HUVECs were found to be alive. 
However, cell elongation and 3D network formation was exclusively observed in 
starPEG-heparin hydrogels under the given conditions (Figure 4.10A, right panel). 
Interestingly, in Matrigel samples, the cells kept a round shape inside the gel, but 
also occasionally started to build up a 2D endothelial network on the surface of the 
gel disc (Figure 4.10B, top row). This is a common and well-known EC response 
and is described in numerous publications, as the 2D Matrigel angiogenesis assay 
is widely used for the assessment of (anti-)angiogenic agents. Although one 
publication reports the formation of 3D CLSs by bovine retinal microvascular 
ECs,336 HUVECs used in this study were not able to develop a 3D network when 
embedded in 100% or 50% Matrigel. There is also no additional evidence in 
literature supporting the hypothesis that HUVECs are capable of forming 3D 
structures in this gel type in vitro. 
Similarly, cells in GelMA gels did not elongate either. It is likely that even the gels 
with a 3% solid content were a bit too stiff for the cells. Additionally, GelMA 
cannot be functionalised with VEGF, which is a prerequisite for EC elongation in 
starPEG-heparin hydrogels (HUVECs without additional VEGF did not elongate; 
data not shown). In contrast, two studies demonstrated the formation of 3D 
endothelial networks in GelMA hydrogels.31,32 GelMA was described to be 
crosslinked by either enzymatic reactions or UV radiation. The overall amount of 
energy applied was 0.134 J/cm2, whereas the GelMA precursor solution was 
irradiated with 1.14 J/cm2 in this work. This relatively high amount of energy was 
necessary in order to obtain fully crosslinked hydrogels, as the volume and 
thickness of these gels were rather high compared to the gels that are described in 
literature. As a consequence, the duration of UV radiation was much higher than 
the amount reported by Chen and co-workers.31 Although the ten-fold increase in 
energy apparently did not affect cell viability, it might have prevented cells from 
differentiation into an elongated phenotype. 
Another difference between this study and previous publications discussed so far 
is that ECFCs (instead of HUVECs) were embedded in GelMA gels. Accordingly, 
these cells were also incubated in two different hydrogels. However, they did not 
form CLSs, neither in GelMA (data not shown) nor in starPEG-heparin gels after 7 
days of incubation (Figure 4.10A, right panel). In GelMA gels, ECFCs needed to be 
exposed to the same amount of energy, which might explain that the cells did not 
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show any sign of differentiation. As HUVECs were able to form an endothelial 
network within starPEG-heparin gels after 7 days, it is not quite clear why ECFCs 
were not able to do so. ECFCs used in the studies mentioned above were always 
co-embedded with MSCs, which indicates that these endothelial progenitor cells 
need the interaction with supportive cells in order to differentiate into an 
elongated shape. 
Figure 4.10: Endothelial cell response in different hydrogels. Most of the embedded ECs 
were alive after 24 h of incubation (A; left panel), formation of 3D networks was only 
observed in starPEG-heparin hydrogels by HUVECs (A; right panel). HUVECs in Matrigel 
samples did not elongate inside the gel, but occasionally formed a 2D network on the 
surface (B; top row), which is a well-known response when ECs are seeded on top of 
Matrigel samples (B; bottom row). Scale bar = 200 (A) and 500 µm (B), respectively. 
Dimensions of the box = 1.5 x 1.5 x 0.45 mm (B, top row). 
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As explained above, HUVECs are capable of forming 2D (but not 3D) networks 
when cultured on top of Matrigel, and this setup was adjusted and improved to 
compare it with the 3D network formation in starPEG-heparin hydrogels. Here, 
different concentrations of HUVECs were seeded on Matrigel discs, and network 
formation was monitored up to 24 h to determine the optimal incubation time. A 
cell density of 1,600 HUVECs/mm2 was found to be suitable for further 
experiments. Networks made of this initial amount of cells were usually fully 
developed after 8 h and degraded thereafter (Figure 4.10B, bottom row). 
Consequently, this setting was used for HUVEC-fibroblast co-cultures within and 
on top of Matrigel discs (see sub-section 4.4.2). 
The results obtained from these experiments clearly show that starPEG-heparin 
hydrogels represent the most promising platform for subsequent 3D co-culture 
experiments. While the stiffness can be adjusted to meet distinct cellular 
requirements, these gels can be also modified with non-permanently immobilised 
angiogenic agents such as VEGF. In contrast, the stiffness of GelMA gels could not 
be lowered to the same extent as starPEG-heparin gels, and GF modification was 
not possible. These factors, alone or in concert with the crosslinking technique, 
potentially affected/inhibited the formation of 3D CLSs. Although the formation of 
3D networks in Matrigel samples could not be achieved either, this platform was 
still chosen for further experiments, as the Matrigel-based 2D angiogenesis assay 
is still widely used to determine the EC response to certain stimuli or inhibitory 
effectors.  
4.4 HUVEC response to fibroblast co-culture 
As described in chapter 2, it is known from literature that expression of many 
angiogenic GFs are upregulated in CAFs. However, these data are derived from 
studies with fibroblasts that were associated with different cancer entities, and the 
first goal therefore was to analyse the relative abundance of factors specifically 
released by CAFs and NPFs that were isolated from patients suffering from 
advanced prostate cancer (GS 7 - 9). Cells from the same (and other) donors were 
subsequently used for 2D (Matrigel) and 3D (starPEG-heparin) co-culture 
experiments. Here, the goal was to check for any differences NPFs and CAFs 
might elicit on endothelial network formation. Additionally, potential differences 
between conventional 2D and more sophisticated 3D analysing tools were of 
interest, as although an increasing number of groups have recognised the high 
potential of 3D in vitro cultures for their work, the analysis of images in these 
studies is usually restricted to 2D methods. Finally, it was tested if soluble factors 
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secreted by the fibroblasts are solely responsible for changes in the structure of 
endothelial networks. 
4.4.1 Angiogenic factors secreted by fibroblasts 
The supernatants of fibroblast-HUVEC co-cultures in starPEG-heparin hydrogels 
were analysed regarding the concentration of important angiogenic regulators. 
The group of molecules of interest comprised ANG-2, FGF-2, PDGF-BB, SDF-1, 
VEGF-A, -C and -D, as well as MMPs-2, -7 and -9. All these proteins are putative 
angiogenic regulators in prostate cancer angiogenesis and/or have been described 
to be produced by CAFs (sub-sections 2.1.3 & 2.2.2). Additionally, insulin-like 
growth factor binding protein (IGFBP; it is known that RNA expression is 
increased in CAFs compared to NPFs; data obtained from the group of Professor 
Risbridger) and IL-8 (specifically plays a role in angiogenesis in prostate cancer; 
sub-section 2.2.2) were included. 
At first, the supernatant of co-cultures inside the gel (fibroblasts and ECs co-
embedded) were analysed regarding SDF-1 concentrations by ELISA (data not 
shown). Here, fibroblasts grown on TCP served as a control. SDF-1 was found to 
be secreted by control CAFs (> 1 ng per ml and 0.3 x 106 cells), but not control 
NPFs. However, analysis of the co-cultures did not show detectable protein 
concentrations in the supernatant of CAF samples. As the total amount of cells per 
volume should be sufficient and SDF-1 is known to strongly bind to heparin,25 it is 
very likely that the protein is retained in the gel body and can therefore not be 
detected in the supernatant. A complete release of the protein from the hydrogel 
for subsequent detection measurements is challenging. Because of this, the 
supernatants derived from co-cultures of cells that were gel-embedded (HUVECs) 
and seeded on TCP (fibroblasts), respectively, were analysed. HUVECs-only 
samples served as a control. 
Figure 4.11 shows the concentration of all proteins in the supernatants of HUVEC 
mono- (control) and HUVEC-fibroblast co-cultures at day 5. The concentration of 
ANG-2, IGFBP-1, PDGF-BB, VEGF-A and -D was similar in mono- and co-
cultures, with a few exceptions. Values between 4788±415 - 7229±500 pg/ml were 
found for ANG-2 in any supernatant but for CAFs of patient 26 (9364±1454 pg/ml; 
Figure 4.11A). The amount of IGFBP-1 was even higher in control samples (102±5 
pg/ml) compared to co-cultures (58±6 - 76±14 pg/ml; Figure 4.11B). PDGF-BB was 
higher concentrated in the supernatant of NPF-HUVEC co-cultures for donor pair 
I (49±9 pg/ml for patient 64 and 20±2 pg/ml for patient 35) but also in the 
supernatant of CAF-HUVEC co-cultures for donor pairs II and III (36±4 and 56±8 
pg/ml for patients 69 and 26, respectively, 25±4 and 41±14 pg/ml for patients 70 
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and 72, respectively). However, the protein amount in HUVEC mono-cultures was 
in a similar range (37±12 pg/ml; Figure 4.11C). The concentration of VEGF-A 
(2257±492 - 2947±1475 pg/ml) and VEGF-D (67±7 - 77±5 pg/ml) was also in a 
similar range for mono- and co-cultures (Figure 4.11D,E). Only CAFs of patient 26 
secreted a higher amount of VEGF-A (3839±991 pg/ml). In contrast, the amount of 
VEGF-C, SDF-1, IL-8 and MMP-2 was significantly higher in HUVEC-fibroblast 
co-cultures compared to HUVEC mono-cultures. It is therefore very likely that 
these factors were primarily secreted by fibroblasts. However, a clear difference in 
expression patterns between NPFs and CAFs could not be observed. In detail, 
between 131±26 - 164±12 pg/ml VEGF-C were detected in co-cultures, whereas 
only 62±15 pg/ml were found in HUVEC mono-cultures (Figure 4.11F). Only NPF-
HUVEC co-culture from patient 64 (donor pair I) secreted a higher amount 
(209±17 pg/ml). HUVEC mono-cultures did not secrete SDF-1 (Figure 4.11G), 
while the concentration of this GF was higher in CAF-HUVEC co-cultures 
(730±149 - 753±195 pg/ml) compared to NPF-HUVEC co-cultures for donor pair II 
(245±35 pg/ml) and donor pair III (523±41 pg/ml). However, for donor pair I, the 
concentration was slightly increased in NPF-HUVEC co-cultures (360±75 and 
312±31 pg/ml, respectively). Between 2306±312 - 3090±524 pg/ml IL-8 were 
detected in the supernatant of all co-cultures, whereas HUVECs secreted almost 
no protein (Figure 4.11H). For donor pair I, a higher amount of IL-8 protein was 
secreted in CAF-HUVEC co-cultures compared to NPF-HUVEC mono-cultures. 
The concentration of MMP-2 was also increased in co-cultures (23,838±2082 - 
29,945±4815 pg/ml) compared to HUVEC mono-cultures (13,110±2986 pg/ml; 
Figure 4.11I). MMP-7 and MMP-9 were not detected in any supernatant; the 
amount of recombinant FGF-2 in original EGM-2 was too high and did therefore 
not allow drawing conclusions about fibroblast-secreted proteins. 
From the data obtained in this experiment, it is not clear whether the expression of 
angiogenic factors by fibroblasts and/or HUVECs in co-cultures might be 
influenced by direct (close cell-cell contact) and/or indirect (paracrine effects) 
interactions. For instance, IGFBP-1 had a higher concentration in HUVEC mono-
cultures when compared to HUVEC-fibroblast co-cultures (Figure 4.11B). It is 
possible that inhibitory regulators of IGFBP-1 expression were secreted by 
fibroblasts and caused the observed drop of free protein concentration. A direct 
impact (co-embedded cells) could not be investigated at all, as secreted factors 
potentially bind to the matrix and are therefore not available for detection assays 
(as discussed above for SDF-1);. Moreover, in this experiment fibroblasts grew on 
TCP (i.e. on a 2D surface), and a 3D environment as provided by the hydrogel 
might have an effect on the expression pattern (see sub-section 2.3.1). 
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Figure 4.11: Protein expression profiles of angiogenic factors. The amount of ANG-2, 
FGF-2, IGFBP-1, PDGF-BB, VEGF-A & -D was found to be similar in all supernatants, i.e. 
these proteins were probably mainly secreted by HUVECs. Fibroblasts primarily secreted 
VEGF-C, IL-8, MMP-2 and SDSF-1. However, a significant difference in the expression 
pattern between NPFs and CAFs was not observed for the given proteins. Patients are 
sorted according to donor pairs defined in chapter 3.5.3 (e.g. patient 64 and 35 represent 
donor pair I). All data are presented as mean ± SD (N = 4). CTRL = HUVEC mono-cultures. 
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In conclusion, prostatic fibroblasts are a major source of the angiogenic factors 
SDF-1, VEGF-C, IL-8 and MMP-2. They therefore potentially affect the formation 
and maintenance of endothelial networks by the secretion of these proteins. 
However, significant differences concerning protein expression between NPFs and 
CAFs could not be confirmed for HUVEC-fibroblast co-cultures in which cells 
were kept spatially separated. Interestingly, in fibroblast mono-cultures which 
were kept in either EGM-2 (commonly used for co-cultures) or RPMI 
(conventional medium for prostatic fibroblasts), the expression of IGFBP-1, IL-8 
and SDF-1 was increased for CAFs compared to NPFs (Supplemental Figure S.2). 
In the case of IGFBP-1, no protein (except patient 70) was detected for NPF 
samples, and the amount secreted by CAFs (6 - 21 pg/ml) was too low to exert an 
effect on the overall concentration in co-cultures, as the protein amount in HUVEC 
mono-cultures was much higher (102±5 pg/ml). A possible paracrine effect by 
angiogenic factors secreted by fibroblasts and/or cellular effect (cell-cell contact) 
was investigated with help of several setups and is described in the following sub-
sections.  
4.4.2 HUVEC-NPF/CAF co-culture in Matrigel 
From sub-section 4.4.1 it is now known which angiogenic factors are secreted by 
prostate fibroblasts. It is very likely that some factors, if not all, affect the 
formation of endothelial networks. In order to verify this hypothesis, co-cultures 
of HUVECs with NPFs or CAFs, embedded in Matrigel discs were tested. As 
described for control samples (HUVECs only) in section 4.3, a formation of 3D 
networks could not be observed after incubation for 7 d in EGM-2 (Figure 4.12, top 
row).  
As HUVECs were not able to form 3D CLSs in Matrigel samples, 2D structures 
were analysed. At first, both cell types were co-seeded (Figure 4.12, middle row). 
However, after incubation for several hours, the cells developed into an irregular-
shaped cell mass. Although these samples were stained for the endothelial-specific 
surface marker CD31, HUVECs could not be distinguished from fibroblasts by 
fluorescence photography. As those structures were not analysable, fibroblasts 
were spatially separated from HUVECs by embedding them in the gel, while 
HUVECs were still seeded on top of the sample (Figure 4.12, bottom row). For the 
sake of incubating the cells for the longest time period possible (to detect any 
potential differences between endothelial networks co-cultured with NPFs or 
CAFs), the cellular structures were fixed after 16 h and analysed (determination of 
vessel length, branching points and area covered by the network). 
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Although some of the samples differ from each other (CAFs from patient 26 vs. 
CAFs from patient 35 and NPFs from patients 69 and 70; Figure 4.13A,C,E), no 
sample showed significant differences to the control level. The average of total 
vessel length (total length of the network) per sample was between 42±4 and 50±4 
mm, total amount of branching points was between 141±16 and 182±23, and the 
area that is covered by the network was between 24±1 and 29±2%. Moreover, 
when data points from all patients were merged into one big group (i.e. when the 
sample size was increased), significant differences were abolished (Figure 
4.13B,D,F). In that case, the average of total length, total amount of branching 
points and area ratio for all conditions was between 44±4 - 47±2 mm, 148±16 - 
164±22 and 25±2 - 27±3%, respectively. A second, independent experiment with 
fibroblasts from the same donors confirmed these observations (Supplemental 
Figure S.3). 
Although the prostatic fibroblasts secrete several proangiogenic factors and CAFs 
have been shown to boost angiogenesis in tumours of different entities in vivo,38–41 
the cells did not affect the formation of 2D endothelial networks compared to 
control samples in the present study. One possible reason could be that the 
incubation time (16 h) was too short for the detection of any significant changes. 
However, the endothelial network on Matrigel was not stable and almost 
Figure 4.12: Co-cultures of HUVECs and NPFs or CAFs in/on top of Matrigel. Both cell 
types were either co-embedded (3D, top row) or co-seeded (2D, middle row). Fibroblasts 
were also embedded in Matrigel while HUVECs were seeded on top (2D, bottom row). 
Comparable to control samples (HUVECs only), formation of 3D capillary-like structures 
was not observed when HUVECs were embedded. When both cell types were co-seeded, 
they developed into an irregular-shaped structure. Only when HUVECs were spatially 
separated from fibroblasts, network structures could be analysed. Scale bar = 500 µm. 
Dimensions of the box = 1.5 x 1.5 x 0.45 mm. 
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completely collapsed when samples were incubated longer than 16 h (Figure 
4.10B, bottom row).256 Furthermore, although the exact composition of Matrigel is 
not known, this hydrogel contains a plethora of (angiogenic) GFs which might 
have annihilated any potential paracrine effect between fibroblasts and ECs. Data 
published by Donovan and co-workers support this hypothesis.337 Here, HUVECs 
were seeded on Matrigel samples and incubated in EGM-2 with or without the 
addition of human recombinant VEGF. The authors did not observe any 
differences between the two conditions. Thus, to overcome these intrinsic 
obstacles of the Matrigel platform, a GF-free hydrogel of well-defined composition 
was needed. 
Figure 4.13: Network parameters of 2D HUVEC cultures on Matrigel, with or without 
embedded fibroblasts. Some samples differed in the total length of the network (A), total 
amount of branching points (C) and area ratio (E; area that is covered by the network/total 
area imaged). However, merging samples of all patients into one group (i.e. increasing the 
sample size) abolished any significant differences in vessel parameters (B, D and F). One 
data point represents the analysis of one sample (N = 5-8), black line represents the average 
of all data points from the same group. Statistical significance, *P < 0.05, **P < 0.01. CTRL = 
HUVEC mono-cultures. 
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4.4.3 HUVEC-NPF/CAF co-culture in starPEG-heparin hydrogels 
It is already known that VEGF-modified starPEG-heparin hydrogels support the 
formation of 3D capillaries in vitro, and these endothelial structures last longer 
than 24 h. Moreover, the addition of other proangiogenic GFs (FGF-2, SDF-1) to 
the system caused an increase in vessel parameters such as length, branching and 
density.29 These properties make starPEG-heparin gels an ideal system to 
investigate a potential impact on the network formation by prostatic fibroblasts. 
Cell viability 
At first, the viability of the now co-embedded HUVEC-fibroblast cultures was 
tested after 24 h and 7 d. Additionally, the viability of NPF/CAF mono-cultures 
after 24 h was evaluated. In general, only a few dead cells were observed in all 
conditions 24 h after cells-embedding, and almost no dead cells were present at 
day 7 of incubation. As depicted by Figure 4.14, a dense network of elongated cells 
had been developed during the time period between 24 h and 7 d, whereas just a 
few single, round cells and no cell-clusters were detected in the gels. Although 
ECs could not be distinguished from NPFs or CAFs by live/dead staining, 
fibroblasts apparently developed into an elongated phenotype and interconnected 
to form a network. This was also observed in fibroblasts mono-cultures at day 7. 
As the total amount of cells was just one-tenth, this network was not as dense as in 
the co-culture (data not shown). 
Figure 4.14: Live/dead staining of fibroblast mono- and HUVEC-fibroblast co-cultures in 
starPEG-heparin hydrogels. Only a few dead cells were detected in NPF or CAF mono- and 
co-cultures 24 h after cell-embedding (top and bottom row, left and centre). Viability was 
almost 100% in co-cultures after 7 d of incubation (top and bottom row, right). Cells 
elongated and formed an interconnected network. However, HUVECs could not be 
distinguished from fibroblasts in this assay. Scale bar = 200 µm. 
4   Results and discussion 
76 
2D versus 3D analysis techniques 
As it is not clear from which cell type the network originated from, samples were 
fixed and immunostained for endothelial-specific marker CD31. Due to the 3D 
nature of the samples, confocal microscopy was employed for the imaging of 
CD31-positive cellular structures. The information of one z-stack (450 µm) was 
then projected onto a 2D plane (MIP), thereby converting the data into a format 
that is suitable for an automatic image analysis program as it has been used in 
sub-section 4.4.2 for 2D cultures. The MIP-technique is commonly applied for 
subsequent analysis purposes, even in 3D systems, as it is fast and easy-to-use. For 
instance, the quantitative sprouting of HUVEC spheroids or endothelial network 
characteristics in collagen, fibrinogen and other gel types/setups have been 
described with the help of MIP.29,31,338–340 Besides this 2D approach, CD31-positive 
structures in mono- or co-culture samples were additionally 3D-reconstructed in 
this study, and this allowed for a ‘real’ 3D description of parameters such as vessel 
length and density. Before one of the methods was routinely employed for further 
analysis of all starPEG-heparin samples, the significance of the extracted 
quantitative data of control samples (HUVECs only) was assessed by comparing 
the 2D and 3D technique.  
For this purpose, the parameters total and average vessel length, total amount of 
vessels and branching points as well as the area and volume, respectively, which 
are covered by CD31-positive structures, were determined. Comparing 2D and 3D 
analysis, the total vessel length was found to be similar up to a depth of 200 µm in 
z-direction (27±5 - 30±3 mm). However, when the observation volume was 
increased (450 µm in z-direction), 3D analysis revealed a higher total vessel length 
(63±7 mm) when compared to 2D analysis (52±4 mm; Figure 4.15A). For all of the 
other parameters tested, major differences were also observed in smaller 
observation volumes and were more pronounced in bigger volumes. In detail, the 
total amount of branching points was determined as 257±35 (642±81) by 2D 
analysis and as 56±23 (162±44) by 3D analysis (Figure 4.15C). When the 
observation volume was increased, the values determined by both methods 
increased as well. A similar trend was observed for the parameters average vessel 
length (0.49±0.16 and 3.0±1.1 mm for 2D analysis, 0.19±0.03 and 0.23±0.02 mm for 
3D analysis; Figure 4.15B) and area/volume that is covered by CD31-positive cells 
(19±2 and 31±2% for 2D analysis, 0.47±0.18 and 0.53±0.15% for 3D analysis; Figure 
4.15E). In both cases, values determined by 2D analysis increased with increasing 
observation volume, whereas they almost did not change when determined by 3D 
analysis. Strikingly, the total amount of vessels decreased with increasing 
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observation volume when determined by 2D analysis (65±14 and 19±7), but 
increased when determined by 3D analysis (143±19 and 283±40; Figure 4.15D). 
Taken together, the quantitative data as determined by 2D and 3D analysis 
differed dramatically. This could be due to several reasons (Figure 4.16): for 
instance, a capillary which grew (more or less) in z-direction is projected as a dot 
or short line. When this structure is recognised, it is either excluded from the 
analysis (because it is too small) or the output does not reflect the actual length. In 
both cases, the length of the total network is underestimated as it is shown by 
Figure 4.15A (450 µm). Another example is the detection of branching points and 
total amount of vessels. In a 3D space, two certain points of two lines could share 
the same xy-coordinates, whereas the z-values of these pointes are different. These 
Figure 4.15: Comparison of commonly used 2D (Maximum Intensity Projection; MIP) and 
3D analysis techniques for the characterisation of 3D endothelial structures. Major 
differences in total (A) and average (B) vessel length, total amount of branching points (C) 
and vessels (D), as well as area/volume ratios (E) between both methods were determined, 
which were more pronounced when the observation volume was increased from 200 to 450 
µm. Examples of MIPs of 200 and 450 µm z-stacks of binarised CD31-positive structures are 
given in (F). All data are presented as mean ± SD (N = 6). Statistical significance, **P < 0.01. 
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structures are projected as one capillary with one branching point, although they 
actually do not cross. Consequently, the branching is overestimated (Figure 
4.15C), whereas the total amount of vessels is underestimated (Figure 4.15D). In 
contrast, a ‘real’ 3D analysis method allows a more accurate determination of the 
parameters. 
As a next step, 450 µm z-stacks of two different conditions, NPF- and CAF-
HUVEC co-cultures, were analysed with both methods. Here, qualitative 
differences in the obtained data set were of special interest. As expected, the 
quantitative differences between both methods were usually high for the same 
condition, comparable to the data discussed above. In general, significant 
differences for all parameters were detected by the 3D, but not the 2D analysis 
method (Figure 4.17A-E). In detail, the total vessel length in the NPF sample was 
determined as 54±3 mm by 2D analysis, and it slightly decreased in the CAF 
sample (55±2 mm). In contrast, an increase in the average length was determined 
by 3D analysis (NPF 77±15 mm, CAF 108±10 mm). The 2D analysis method also 
did not detect major differences for average vessel length (NPF 2.98±1.1 mm, CAF 
2.78±1 mm), branching (NPF 708±67, CAF 703±63), total amount of vessels (NPF 
20±7, CAF 21±5) and area ratio (NPF 31±1%, CAF 31±1%). However, significant 
differences were determined by the 3D analysis. Values for average vessel length 
(NPF 0.26±0.07 mm, CAF 0.41±0.07 mm), branching (NPF 280±95, CAF 563±128) 
Figure 4.16: Schematic illustration of quantitative differences between MIP- and 3D-
derived data sets. Two distinct elongated structures (red) are determined as one structure 
(white) with one pseudo branching point by MIP. Additionally, the total length of a 
structure is underestimated when it is not aligned in parallel to the projection plane (grey). 
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and volume ratio (NPF 0.57±0.15%, CAF 1.17±0.28%) were increased in CAF 
samples when compared to NPF samples, while the total amount of vessels was 
decreased (NPF 307±31, CAF 269±26). In summary, only 3D analysis was able to 
detect differences in important network parameters. 
Considering the results obtained by 2D and 3D analysis, two main conclusions can 
be drawn: 3D analysis is more accurate than 2D analysis for 3D culture, and hence 
it provides more relevant data. However, 2D analysis is the method of choice for 
the quantification of cellular dimensions in many publications. Besides MIPs of 
confocal z-stacks, bright field or phase contrast images are used to evaluate a 
cellular response to external stimuli (e.g. counting sprouts).281,336,341–343 Counting 
Figure 4.17: Endothelial network properties of NPF- and CAF-HUVEC co-cultures 
determined by 2D (MIP) and 3D analysis. Only the 3D technique identified significant 
differences for the parameters total (A) and average vessel length (B), total amount of 
branching (C), total amount of vessels (D) and area/volume ratio (E) between NPF and CAF 
samples. Examples of MIPs of 450 µm z-stacks of binarised CD31-positive structures in NPF 
and CAF-HUVEC co-culture samples are given in (F). All data are presented as mean ± SD 
(N = 6). Statistical significance, *P < 0.05, **P < 0.01, ***P < 0.001. 
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branches or sprouts is straightforward and analysis of samples can be completed 
very quickly. On the other hand, other parameters which could be helpful to 
interpret the data are not considered, and the total amount of sprouts can be 
underestimated due to the reasons presented above. In this sense, the analysis of 
conventional 2D fluorescent images of 3D cultures275,276,279,344,345 has the same 
limitations as the analysis of MIPs and bright filed/phase contrast images shows. 
However, 2D analysis methods are easy-to-use, and hence they are an established, 
widespread tool for data quantification.  
Methodical characterisation of endothelial networks in co-cultures  
Due to the advantages of 3D analysis over 2D analysis, this technique was used for 
further analysis only. Five unmatched NPF-CAF pairs (one pair was derived from 
two different patients) were investigated, and results are shown in Figure 4.18. 
From the representative 3D reconstruction of confocal z-stacks, two major 
differences between the co-cultures can be seen: the endothelial network (shown 
in green) in CAF samples (Figure 4.18B) appears to be denser, while the CLSs 
might be thinner compared to NPF samples (Figure 4.18A). Interestingly, the 
phalloidin counterstaining (red) revealed that not only ECs, but also fibroblasts 
formed a network. Isolated blue dots represent nuclei from cells not contributing 
to any network and can originate from ECs or fibroblasts. 
Indeed, quantitative analysis confirmed remarkable differences between 
endothelial networks co-incubated with NPFs or CAFs. First, in all five 
independent experiments with different donors, the total length of CLSs was 
significantly higher in CAF samples compared to NPF samples (Figure 4.18C). For 
donor pairs I - III, the network length was doubled (2.0±0.66 - 2.2±0.28) in CAF 
samples compared to control levels (dotted line). The length was also increased in 
NPF samples for donor pairs II (1.51±0.4-fold) & III (1.68±0.4-fold), but not for 
donor pair I (1.11±0.37-fold). For donor pairs IV & V, the increase in network 
length was 1.4±0.3 and 1.58±0.29 in CAF samples, respectively, whereas it was not 
(1.05±0.29; IV) or only slightly (1.22±0.19; V) increased in NPF samples. Similarly, 
the average branching was also increased in CAF samples compared to NPF 
samples and control levels (Figure 4.18D). However, differences were only 
significant for donor pairs I - III. CAF samples for these donor pairs showed a 
4.37±3.12 - 5.19±1.97-fold higher branching, whereas the branching in NPF samples 
was only 1.34±0.67 - 3.3±1.94-fold increased compared to control samples. The 
network in CAF samples for donor pairs IV & V showed a slight increase in 
branching (1.61±1.08 & 1.72±0.87), while the branching in NPF samples was similar 
to the control group (1.06±0.68 & 1.38±0.37). 
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Network parameters other than total length and branching could then be 
determined (Figure 4.19). In the case of total amount of vessels, no clear trend 
could be recognised (Figure 4.19A). For donor pairs I, IV and V more vessels were 
counted in CAF samples. Equal values between NPF and CAF samples were 
obtained for donor pair III, whereas the amount is increased in NPF samples for 
donor pair II. Compared to control samples, the average amount of total vessels 
increased for all NPF and CAF donors (1.04±0.12 - 1.29±0.05-fold). The analysis of 
the parameter average vessel length showed a similar trend as the results of the 
parameter total length (Figure 4.19B). For all donor pairs, values were increased in 
CAF samples (significant for donor pairs I - III). In detail, the average vessel length 
was 1.23±0.39 & 1.28±0.39 (IV & V), 1.57±0.51 (I) or 1.96±0.41 & 1.86±0.42 times (II 
& III) higher in CAF samples compared to control samples. In contrast, the 
increase in average length in NPF samples was only 1.37±0.4 & 1.41±0.37-fold 
higher for donor pairs II & III, while no differences between NPF and control 
Figure 4.18: Endothelial network characteristics in HUVEC-NPF and -CAF co-cultures in 
starPEG-heparin hydrogels. Representative 3D-reconstruction of confocal z-stacks is 
presented for NPF- (A) and CAF- (B) HUVEC co-cultures. Endothelial structures are shown 
in green; actin staining (red) not overlapping with green structures originates from 
fibroblasts. Cell nuclei are shown in blue. Endothelial cells formed a denser network when 
co-cultured with CAFs, the total vessel length (C) and average branching per vessel (D) 
were increased compared to NPF samples. Values are normalised to control group 
(HUVECs only; dotted line). Dimensions of the box = 1280 x 1280 x 200 µm3. Data derived 
from 5 independent experiments (one per donor pair). Black line represents mean (N = 9-18). 
Statistical significance, *P < 0.05, **P < 0.01, ***P < 0.001. 
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samples could be observed for donor pairs I, IV and V (1.0±0.17). Another 
parameter with no clear trend between NPF and CAF samples was the average 
diameter of the vessels (Figure 4.19C). While vascular structures are thicker in 
CAF samples for donor pairs I - III, thinner vessels were observed in samples of 
donor pairs IV & V. Samples with an increased diameter (NPF donor pair V; CAF 
donor pair II & III) were also generally 1.1±0.09 times thicker than the control 
level, whereas other samples were similar to the control group (NPF donor pair I - 
III; CAF donor pair I & V). For donor pair IV, the diameter in both, NPF (0.93±0.09) 
and CAF (0.86±0.05) samples was even lower than control level.  
All but one of the vessel parameters mentioned above (total and average vessel 
length, total amount of vessels and average vessel diameter) are connected to and 
can explain the outcome of the last factor presented in this study, the volume ratio 
(Figure 4.19D). This value describes the amount of CD31 positive (i.e. endothelial) 
structures that have been detected in the observation volume of the sample. For 
instance, the ratio was significantly increased in CAF samples compared to NPF 
samples for donor pairs I - III (2.13±1.0 - 2.62±0.75 and 1.04±0.04 - 1.78±0.73 times, 
Figure 4.19: Quantitative analysis of further endothelial network characteristics. While no 
clear trend can be seen for the parameters total amount of vessels (A) and average diameter 
(C), the average vessel length (B) and volume ratio (D) were increased (or similar) in CAF 
samples compared to NPF samples. Values are normalised to control group (HUVECs only; 
dotted line). Data derived from 5 independent experiments (one per donor pair). Black line 
represents mean (N = 9-18). Statistical significance, *P < 0.05, **P < 0.01, ***P < 0.001. 
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respectively, higher than control level), although the total amount of vessels was 
either increased (I), decreased (II) or equal (III) compared to NPF samples. This 
can be explained by an increased total and average vessel length, as well as a 
higher average vessel diameter in CAF samples. For donor pairs IV & V, the ratio 
was similar in NPF and CAF samples (and similar (1.0±0.23; IV) or 1.41±0.28 - 
1.54±0.38-fold increased (V) compared to the control group), although the 
parameters total and average vessel length, as well as total number of vessels, 
were increased in CAF samples. However, in that case, the average diameter was 
decreased compared to NPF samples. Taken together, the interplay of all these 
parameters determines the volume of a vascular network, which, in addition to 
the surface area, directly affects the oxygen and nutrient availability in tissues in 
vivo. 
Effect of cell ratio on fibroblast-related response in endothelial networks  
As a next step, the cellular ratio (HUVECs:fibroblasts) was decreased from 10:1 to 
5:1, i.e. the concentration of fibroblasts was doubled while the amount of HUVECs 
was kept constant. By doing this, a possible effect of an increased fibroblast 
amount (and therefore increased concentration of angiogenic factors) on 
endothelial networks could be observed. However, as depicted by Figure 4.20, no 
significant differences were detected between a 10:1 and 5:1 ratio for donor pair 
IV. For instance, the total vessel length (22±4 & 20±6 mm for NPF samples and 
control group, 30±4 mm for CAF samples; Figure 4.20A) and average branching 
per vessel (0.45±0.16 & 0.42±0.19 for NPF samples and control group, 0.6±0.19 for 
CAF samples; Figure 4.20B) did not change with an increased amount of 
fibroblasts. Apparently, a 10:1 ratio is sufficient to see a significant impact of CAFs 
on endothelial cells in starPEG-heparin hydrogels, and an increased amount of 
fibroblasts does not change this effect to a higher (or lower) extent. 
Figure 4.20: Effect of cellular ratios on endothelial network parameters. A 5:1 ratio 
(HUVECs:fibroblasts) did not change the principal effect CAFs exerted on endothelial cells 
in starPEG-heparin hydrogels compared to the commonly used cellular ratio (10:1), as 
shown for the parameters total vessel length (A) and average branching per vessel (B). All 
data are presented as mean ± SD (N = 9). 
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SDF-1 receptor blockage and addition of recombinant SDF-1  
Finally, as it is now known which specific angiogenic regulators are produced and 
secreted by NPFs and CAFs (SDF-1, VEGF-C, IL-8 and MMP-2; sub-section 4.4.1), 
inhibitor studies were performed. CAF-secreted SDF-1 has been identified as a key 
player in promoting angiogenesis40,79 and preliminary expression studies (obtained 
by ELISA, data not shown) detected this protein in CAF-, but not NPF-derived 
supernatants. Because of this, it was considered as a promising candidate being 
responsible for the observed differences between CAF and NPF samples. It was 
therefore expected that the inhibitor of SDF-1 receptor CXCR4 (AMD3100) reduces 
the CAF-related response to control or NPF levels. In addition, recombinant SDF-1 
was thought to boost endothelial network parameters to an extent similar to CAF 
samples. As shown in Figure 4.21, the inhibitor only had a minor effect on CAF 
samples for donor pair II; the total vessel length decreased from 70±20 to 64±11 
mm (Figure 4.21A), and the average branching was reduced from 1.13±0.43 to 
1.0±0.53 per vessel (Figure 4.21B). However, the differences were not significant. A 
stronger effect could be observed for NPF samples. Here, the total vessel length 
dropped down from 52±14 to 39±7 mm, and the average branching decreased from 
0.57±0.41 to 0.29±0.08 per vessel. Control (i.e. HUVECs only) samples were almost 
unaffected (total vessel length 35±10 mm and average branching 0.22±0.13 per 
vessel). 
In contrast, the addition of recombinant SDF-1 to control (HUVECs only) samples 
only provoked a slight increase in total vessel length (from 30±10 to 39±5 mm; 
Figure 4.21C), while the network length in CAF samples (59±20 mm), but not NPF 
samples (33±11 mm), was increased compared to control samples for donor pair I. 
Instead, the average branching (0.15±0.08 to 0.38±0.21 per vessel) and average 
diameter (8.7±0.7 to 10.9±1.4 µm) were significantly increased when HUVEC-only 
cultures were supplemented with recombinant SDF-1 (Figure 4.21D,E). Here, the 
average branching was much higher than in NPF samples (0.2±0.1 per vessel), 
although not significantly lower compared to CAF samples (0.64±0.46 per vessel). 
Interestingly, the vessels in SDF-1 supplemented samples were also found to be 
much thicker (10.9±1.4) compared to any co-culture condition (8.5±0.5 NPF, 9.1±0.8 
CAF), indicating a more developed, matured nature of the network. This in turn 
explains the dramatic increase in the volume of the network for SDF-1-treated 
samples (0.24±0.1 to 0.49±0.17% volume ratio; Figure 4.21F), which was now 
similar to the volume ratio in CAF samples (0.52±0.24%). The volume ratio in NPF 
samples however, was similar to non-treated control samples (0.26±0.1%). 
A recently published article describes that recombinant SDF-1 indeed has an effect 
on endothelial cells.29 The authors found that network characteristics such as 
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“branch length”, “branch density” and “area ratio” are significantly increased 
when SDF-1 (in addition to VEGF) is added to starPEG-heparin hydrogels. In 
contrast to this work, the concentration was rather high (5 µg/ml compared to 1 
ng/ml; this amount was approximately secreted by CAFs grown on TCP with the 
same cell density as in co-culture experiments), and network parameters were 
quantified by using a conventional 2D approach, which might explain the 
discrepancy regarding the branch length between both studies. 
Although SDF-1 is known to be secreted by CAFs (and NPFs) and is thought to 
enhance the formation and maintenance of endothelial networks in vitro within in 
a period of seven days, the blockage of its receptor only showed a slight effect in 
Figure 4.21: Effect of SDF-1 receptor inhibitor AMD3100 and recombinant SDF-1 on 
endothelial network parameters. The inhibitor showed a slight effect on total vessel length 
(A) and average branching (B), differences were only significant for NPF samples. The total 
vessel length almost did not change when recombinant SDF-1 was added to the HUVEC 
mono-culture (C). The angiogenic factor primarily caused an increased branching (D) and 
thicker vessels (E), which in turn raised the volume ratio to a value similar to CAF samples 
(F). All data are presented as mean ± SD (N = 9). Statistical significance, *P < 0.05, **P < 0.01, 
***P < 0.001. 
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CAF samples. Similarly, the addition of recombinant SDF-1 to HUVEC-only 
cultures did not elicit a comparable increase in total vessel length as CAFs did. As 
a conclusion, other factors than SDF-1, most likely VEGF-C, IL-8 and MMP-2, 
might have additionally contributed to the CAF (and NPF)-related response. 
Furthermore, as not only CAFs but also NPFs from some patients (69, 70 and 79) 
caused a higher network density compared to control levels and both kinds of 
fibroblasts secreted a similar amount of angiogenic regulators when grown on 
TCP, it is questionable whether these soluble factors alone are responsible for the 
observed differences between NPF and CAF samples. This issue will be further 
discussed in sub-section 4.4.4. 
General discussion 
An abundance of publications have found strong evidence that the tumour stroma 
plays a crucial role in cancer progression, and some of these proposed a potential 
impact of the non-epithelial tissue (usually reactive fibroblasts) on endothelial 
network formation. For instance, one study demonstrated that VEGF-A is 
predominantly expressed in the stromal cells of a tumour in a genetically 
engineered gastric cancer mouse model.38 Using histological methods, the authors 
also noticed a higher MVD in the stomach compared to wild type mice, and 
proposed that reactive fibroblasts caused this increase in vascularisation. In order 
to validate their hypothesis, embryonic fibroblasts were turned into an activated, 
alpha smooth muscle actin (α-SMA) expressing phenotype by incubating these 
cells with conditioned medium (CM) derived from malignant cells. A typical 2D 
(Matrigel-based) tube formation assay was then performed. Here, HUVECs were 
seeded on the gel and incubated in CM derived from the reactive embryonic 
fibroblasts. Although the authors observed an increased amount and relative 
length of tubes in samples that were incubated in CM from reactive fibroblasts 
compared to CM from untreated embryonic fibroblasts, a direct impact of stromal 
gastric fibroblasts on vascularisation was not investigated. Furthermore, the 2D 
Matrigel-angiogenesis assay has some important limitations (as outlined above), 
and the incubation time varied between 18 - 24 h, which can dramatically alter the 
network characteristics, as observed in experiments of this work. Another 
genetically engineered mouse model (cervical cancer) was used to test treatments 
targeting the stroma of tumours.39 Here, the authors observed that the expression 
of FGF-2 in CAFs is suppressed by the inhibition of stromal PDGF receptors, 
which in turn reduced angiogenesis in cervical lesions as determined from 
histological samples. A third animal study supporting the hypothesis of an 
angiogenic CAF phenotype is described by Orimo and co-workors.40 CAFs and 
breast carcinoma cells were subcutaneously co-implanted into immunodeficient 
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nude mice. EPCs were attracted into carcinomas by CAF-secreted SDF-1, thereby 
promoting angiogenesis. 
Common to all studies is the in vivo environment, which makes it challenging to 
dissect the direct endothelial-fibroblast interplay. Additionally, the situation in 
prostate carcinomas is rather unknown as just a few studies (at least partly) aimed 
to analyse stromal-endothelial interactions. Berger and co-workers investigated 
the impact of hypoxia on normal stromal prostate cells, and found an increased 
production of angiogenic factors compared to normoxic conditions.35 Janvier et al. 
developed a 3D in vitro tri-culture system to demonstrate the co-impact of 
fibroblasts and prostate tumour cells on endothelial network formation.36 The 
addition of fibroblasts was a prerequisite to induce tube formation, which was 
enhanced when cancer cells were included. However, the physiological relevance 
is questionable as fibroblasts were derived from the foreskin. Yang and colleagues 
published possibly the most remarkable study in this field.37 They noticed that 
CAFs isolated from prostate adenocarcinomas secret high levels SDF-1 when the 
cells were stimulated with bone morphogenetic protein (BMP) 2 and 7. The SDF-1 
containing CM of stimulated cells in turn induced tube formation in a commonly 
used 2D angiogenesis assay. 
Although all the studies mentioned above highlight the important role the stroma 
potentially plays in the vascularisation of the tumour, most of them lack a detailed 
description of how exactly CAFs might remodel the endothelial network in a more 
physiological in vitro setting. This is the first study comparing NPFs and CAFs 
concerning their angiogenic potential, and provides an optimised 3D analysis 
approach that allowed the extraction of important network parameters from 
experimental data. The results underscore the high relevance of both the stromal 
role concerning cancer progression, and the unique in vitro setting of this work 
concerning the capability to (at least partly) recapitulate the pathological situation. 
For instance, it is known that the MVD in the primary tumour is increased in 
patients with aggressive prostate cancer, increased PSA levels and metastatic 
potential.205,346–349 In addition, during progression of the disease, microvessels 
become shorter and smaller in diameter.205,350 Both traits have also been recognised 
in experiments of this work, as the total length (comparable to MVD) in CAF 
samples was increased, while the diameter (in some, but not all experiments) was 
decreased compared to NPF and control samples. 
Taken together, in this sub-section it has been demonstrated that HUVEC-
fibroblast co-cultures show excellent cell viability after short-term (24 h) and, even 
more important, long-term (7 d) culture when embedded in starPEG-heparin 
hydrogels. The relevance of a suitable analysing technique (‘real 3D’) was 
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discussed, while the shortages and pitfalls of conventional, 2D-based techniques 
have been explained. Most importantly, differences in endothelial network 
characteristics between NPF and CAF samples have been described; CAFs 
primarily elicited an increased total length of the network when directly co-
embedded with ECs. For some donor pairs, the network was also even more 
branched or the vessel diameter was decreased, thereby partly reflecting the 
pathological situation found in the clinic. A specific blockage of SDF-1 receptor 
CXCR4 in CAF samples did not normalise the network parameters to control 
levels, indicating the involvement of other soluble factors and/or mechanisms in 
the CAF-related response. This issue is discussed in sub-section 4.4.4. 
4.4.4 Paracrine signalling 
From previous experiments (protein expression studies, direct co-cultures: 
HUVEC and fibroblasts co-embedded in one hydrogel), the mechanism behind the 
response of endothelial cells to co-embedded CAFs (and NPFs) could not be 
resolved. Both kinds of fibroblasts secrete a similar amount of proangiogenic 
factors (SDF-1, VEGF-C, IL-8 and MMP-2) when grown on TCP and in indirect co-
culture with HUVECs (gel-embedded). It is therefore reasonable to assume that 
the endothelial network which is forming in the HUVEC-containing gel disc is 
influenced by these soluble factors. In order to verify this hypothesis, the networks 
in indirect co-cultures was additionally characterised (as described above) for 
three donor pairs used in previous experiments. In this setup, a possible impact of 
direct cell-cell contact/communication can be excluded. 
For indirect co-culture experiments seeding densities were chosen according to the 
cell ratio that has been used for co-embedded cells (10:1 ratio 
HUVECs:fibroblasts). After 5 days of culture (when the supernatant was 
collected), both kind of fibroblasts, NPFs (Figure 4.22A) and CAFs (Figure 4.22B) 
from all patients used in this study, had already formed a confluent monolayer at 
the well bottom. It was therefore assumed that the cell sheets had secreted a 
sufficient amount of potential angiogenic factors into the supernatant, which could 
then easily reach the ECs in the gel body. 
Figure 4.22C,D show the quantitative results of the network analysis at day 7. As 
expected, the total network length (Figure 4.22C) and average branching per 
vessel (Figure 4.22D) was increased in indirect co-cultures compared to HUVEC 
mono-cultures (control level, dotted line), most likely because of angiogenic 
factors released in the medium (SDF-1, VEGF-C, IL-8 and MMP-2). For donor 
pairs II and III, the total vessel length was 1.4±0.28 - 1.55±0.16-fold, for donor pair I 
only 1.21±0.27-fold increased compared to control levels (Figure 4.22C). However, 
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differences between NPF and CAF samples for each donor pair as they have been 
shown for direct co-culture were not observed. Interestingly, the increase in length 
was similar to NPF samples in direct co-culture experiments, suggesting that also 
soluble factors secreted by NPFs mainly mediated the EC response in this setup. 
Additionally, a 1.43±0.45 - 1.53±0.66-fold increase of average branching for donor 
pairs II and III, but not for donor pair I (1.1±0.45, was found (Figure 4.22D). 
In contrast to direct co-cultures, the increase in total vessel length and average 
branching per vessel was less pronounced in indirect co-cultures for CAF samples. 
Possible explanations for the observed differences are: (1) The expression patterns 
of CAFs changed when the cells were in direct contact with HUVECs and/or 
grown in 3D (hydrogels); (2) Direct cell-cell contact affects the endothelial network 
formation; (3) Insoluble ECM components with proangiogenic properties such as 
fibronectin and collagen I, produced by CAFs, additionally stimulated the growth 
of the endothelial network in direct co-cultures. 
One, two or even all processes together that are mentioned above might have 
contributed to the CAF-related response. However, it is very challenging to 
identify a specific mechanism and break it down to a specific mediator, mainly 
Figure 4.22: Paracrine effect of fibroblast-secreted angiogenic factors on endothelial 
networks. NPFs (A) and CAFs (B) formed a confluent mono-layer at the well bottom after 5 
days of incubation. Both cell types secreted various angiogenic regulators which, most 
likely, influenced the forming endothelial network regarding length (C) and branching (D) 
in starPEG-heparin hydrogels. Values are normalised to control group (HUVECs only; 
dotted line). Black line represents mean (N = 12). Scale bar = 200 µm. 
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due to two reasons: (1) It is almost impossible to fully release GFs (e.g. SDF-1) 
from the hydrogel as many of them, weaker or stronger, interact with the matrix. 
Proteins bound to heparin however, cannot be detected with the help of 
conventional techniques (ELISA, etc.); a possible solution could be to analyse the 
expression pattern on the RNA level. (2) It is not unlikely that all possible factors 
together play a crucial role in this context. Moreover, soluble proteins, direct cell-
cell contact, altered gene expression in a 3D environment and ECM components 
produced by CAFs potentially interact with and influence one another. The way 
CAFs regulate an angiogenic response is probably more complex than expected 
and identifying a concrete mechanism therefore goes beyond the scope of this 
work. 
In summary, soluble proteins secreted by CAFs and NPFs do affect endothelial 
network characteristics by enhancing the total length or branching. Other CAF-
derived factors further stimulate the network growth and alter the network 
properties. A complex interplay of these factors might be responsible for the CAF-
related response. 
4.4.5 General discussion/summary HUVEC response to fibroblast co-culture 
A group of four main proangiogenic players that potentially participate in 
stromal-endothelium interactions has been identified. Among these proteins; two 
were not known to be secreted by prostatic fibroblasts, VEGF-C and IL-8. The 
expression of VEGF-C receptor VEGFR-3 is usually restricted to the lymphatic 
endothelium, and its ligand mainly regulates lymphangiogenesis. In addition, 
VEGF-C has been implicated with angiogenesis in an ischemic limb model351 and 
breast cancer352 as well as lymph node metastases in prostate cancer.353,354 It is 
hypothesised that IL-8, a mitogen for ECs, also promotes angiogenesis in prostate 
cancer.355 The interplay between these factors, SDF-1 (which has already been 
known to be secreted by CAFs in breast40 and prostate37 cancer) and further 
angiogenic regulators (e.g. ANG-2, IGFBP-1, PDGF, VEGF-A and -D) might have 
enhanced or complemented the EC-stimulating effects of VEGF-A (that was added 
to the hydrogel), i.e. growth, elongation and interconnection of HUVECs, as well 
as the stabilisation of the forming network. Fibroblast-derived MMP-2 could have 
additionally supported network growth by cleaving of the hydrogel.  
The main outcome of this section is that CAFs indeed support angiogenesis in a 
3D in vitro setting, when compared to the control group (HUVEC mono-cultures). 
This result is in line with previously published articles focussing on CAFs and 
angiogenesis,37–41 which all describe an angiogenesis-promoting phenotype. 
However, no study reported a detailed and comparable analysis of how prostatic 
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CAFs and NPFs remodel a 3D endothelial network in vitro so far. In this work, 
when CAFs were co-embedded with HUVECs, the network length and branching 
were increased (up to two and five times, respectively). Interestingly, these effects 
could also be observed for HUVEC-NPF co-cultures for some patients, but not to 
the same extent as for CAF samples in the same experiment (~ 1.5 and 2.5-fold 
increase compared to control group). It was speculated that SDF-1 is one of the 
key players mediating the CAF-related response. However, receptor blocking in 
co-cultures and addition of recombinant protein to HUVEC mono-cultures 
revealed that other or additional factors need to be considered. Indirect co-cultures 
demonstrated that soluble factors (most likely SDF-1, VEGF-C, IL-8 and MMP-2) 
released by both, CAFs and NPFs, boost the development of endothelial networks, 
but differences between NPFs and CAFs samples were not observed. As a 
conclusion, altered expression in 3D hydrogels, direct cell-cell contact, insoluble 
ECM components or the interplay of all these possible factors might have caused 
the CAF-related response in direct co-cultures. Besides that, the need for more 
relevant and exact analysing tools in 3D in vitro research has been illustrated. For 
example, MIPs of 3D samples can result in misleading interpretations, as 3D 
constructs are projected onto a 2D plane, thereby loosing potentially crucial 
information. 
The findings concerning the usability of different hydrogel platforms are another 
important point of this section. While the GelMA hydrogel system turned out not 
to be suitable for the intended experiments under the given conditions, the 
commonly used Matrigel tube formation assay did not show any significant 
differences between CAF, NPF or control groups. Two main drawbacks of the 
Matrigel assay are (1) the unknown composition regarding angiogenic regulators, 
and (2) the 2D growth of endothelial networks, which does not reflect the 3D in 
vivo situation at all. In contrast, noticeable differences between CAF, NPF and 
control samples were observed in 3D co-cultures in starPEG-heparin hydrogels. 
This system is well-defined, and no additional GFs or other molecules (except 
recombinant VEGF-A) that could interfere with fibroblast-derived angiogenic 
regulators were present. Furthermore, as HUVECs were able to grow into a 3D, 
interconnected network, fibroblasts could be co-embedded, which brought them 
into close contact to ECs. This spatial vicinity is closer to the in vivo situation, and 
it might be one important factor influencing the EC behaviour. As HUVECs did 
not elongate and connect in Matrigel, the different cell types had to be kept 
spatially separated (HUVECs on top, fibroblasts inside the gel). Besides that, 
Matrigel assays did not allow for long-term incubation of the cells, which also 
might be a critical factor in HUVEC-fibroblast interactions. 
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5. Conclusion and Outlook 
Although contemporary literature contains several hints of an angiogenesis 
promoting CAF phenotype, the specific role of these cells in this context, especially 
in prostate cancer, has not yet been clarified. Several studies for different cancer 
entities employed animal experiments to prove that CAFs and CAF-derived 
soluble factors play a big role in angiogenesis and carcinogenesis. However, a 
detailed characterisation of how prostatic stromal cells affect the forming 
endothelial network has not been described yet under well-defined in vitro 
conditions. The ultimate goal of this work therefore was to elucidate the specific 
impact that malignant, prostatic CAFs might exert on ECs (here: HUVECs) and to 
compare it to the activities of benign NPFs. 
The big advantages of in vitro settings over animal studies are that they are usually 
cheap and can be quickly performed under well-defined conditions. The analysis 
of conventional in vitro data however, can result in misleading interpretations, as 
isolated biological material (i.e. cells) acts and responds differently to certain 
stimuli when kept in a rather unnatural, flat environment. In vivo models therefore 
have greater clinical relevance, but interpretation of results might also be 
challenging, mainly due to complexity (for example, contribution of inflammatory 
pathways) and physiological differences to the human body of an animal host. 
Furthermore, they are expensive, time-consuming and often raise ethical concerns. 
Humanised 3D TECs may help to overcome the aforementioned limitations by 
combining the advantages of both, in vitro cell culture and animal models. They 
are considered to recapitulate the real 3D situation more closely than plastic dishes 
and well plates, while providing an environment with well-known and adjustable 
parameters (but without any disturbing side mechanisms and processes). 
Biocompatible (semi-)synthetic hydrogels and/or scaffolds resembling the ECM 
can be seeded with different human primary cells at the same time, thereby 
creating a construct which partly aims to mimic the ‘real’ human tissue. 
For the first time, a 3D TEC has been used and optimised in order to investigate 
the interplay between malignant or benign prostatic stromal cells and ECs. For this 
purpose, the first goal was to find and characterise a suitable hydrogel system. 
StarPEG-heparin and GelMA hydrogels were promising candidates, as they have 
been previously described to enable the creation of 3D, lumen-containing 
endothelial networks. Both systems were compared in this work concerning their 
physicochemical properties, revealing remarkable differences in their swelling 
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behaviour. Because of their unique non-covalent binding capability to various GFs 
(and potentially other, heparin-binding molecules), starPEG-heparin hydrogels 
were further characterised concerning their diffusional properties. 
Observations of single molecule diffusion through starPEG-heparin hydrogels 
revealed a considerable influence of heparin binding affinity on molecule 
transport processes through the matrix. In order to track them, molecules of 
interest were labelled with a fluorescent dye. By doing this, it is important to note 
that their inherent native properties might have been altered. The attached dye 
molecules changed the MW of the GFs, but also potentially weakened the affinity 
to heparin. Nevertheless, all GFs used in this study were labelled the same way, 
and although the ‘actual’ diffusion constant of the native protein could not be 
measured, the applied technique (which is commonly used for diffusion studies) 
still allowed drawing comparable conclusions among the GFs: Basically, the 
diffusion of similar-sized molecules was faster when a specific heparin-binding 
domain had been removed, while increasing size and heparin affinity of proteins 
synergistically slowed down the diffusion. In addition, it was possible to unravel 
the steric from the electrostatic impact on the diffusion of different GFs inside the 
hydrogel. In summary, this is the first study providing a comprehensive 
understanding about transport phenomena of cell culture relevant GFs within a 
GF affine (electrostatic interacting) hydrogel system. 
The data obtained in these experiments for GF-binding starPEG-heparin hydrogels 
open new avenues for the development of more sophisticated TECs. For instance, 
an increased need for arranging a fine-tuned administration of distinct cytokines is 
arising, including the formation and maintenance of gradients in order to 
appropriately mimic in vivo conditions.356 Possible applications are directed 
migration, outgrowth, assembling and alignment of cellular structures. 
A variety of experimental approaches has already been developed and applied to 
establish cytokine gradients in a well-defined and controlled manner. Generally, 
gradients can be formed by immobilised or soluble factors. In the first case, 
cytokines are covalently attached to the pre-polymer constituents of the hydrogel. 
The gradients are then generated by different techniques357,358 and subsequently 
stabilised by crosslinking reactions. However, due to the covalent bond, these 
setups have some limitations. For instance, cellular access to or uptake of proteins 
may be restrained, and micro- or nanofluidic systems are therefore considered as 
promising tools for the localised functionalisation of hydrogels with soluble GFs 
and other effectors.359,360 These systems allow for the delivering of biomolecules to 
cells with unprecedented precision. However, due to source-sink or flow-based 
protocols361,362 their application is sometimes related to a considerable 
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consumption of expensive GFs, and these setups often involve shear stress to the 
material and biological samples. In addition, continuous supply and removal of 
GFs and other biological active substances is not possible when grafts are 
supposed to be transplanted into animals, excluding experimental approaches 
based on microfluidic techniques from in vivo studies. Furthermore, a common 
feature of the different experimental designs cited above is the use of non- or weak 
protein-interacting hydrogel networks. As a wide variety of signalling molecules 
are known to interact with glycosaminoglycans of the ECM,363 the applicability of 
these results for the prediction of the molecular transport in more complex 
scenarios is limited. 
To overcome these limitations, the GF-affine starPEG-heparin hydrogel could be 
used to create gradients of signal molecules. It has already been shown how these 
materials allow the temporal control of GF concentrations.25,28,293 At least for large 
(Rh > 2 nm) and high heparin affine molecules (e.g. VEGF165), the bulk diffusion 
data presented in this work demonstrated that heparin-cytokine interactions could 
be exploited to generate (relatively) stable gradients, while minimising cytokine 
consumption (and therefore costs). In contrast to non- or weak protein-interacting 
hydrogels, gradients of rather large molecules with high heparin affinities would 
degrade very slowly due to the impaired diffusivity. Samples with pre-defined 
concentration patterns could be produced and then grafted into animals. Like the 
natural ECM, starPEG-heparin hydrogels also potentially prevent enzymatic 
degradation and preserve the activity of heparin-affine proteins in in vivo 
experiments through the non-covalent binding. Therefore, as cell culture medium 
does not affect diffusive properties, hydrogels containing a GF interacting 
substance may be of great benefit for many prospective in vitro and in vivo 
settings.  
The results of this work do not only illustrate possible new ways for the 
development of advanced TECs and other cell culture applications, they 
particularly highlight the enormous importance and relevance of such 
technologies for the enhancement of in vitro cancer models. Two different 
hydrogel platforms, GelMA and starPEG-heparin were initially chosen to test their 
potential regarding endothelial-fibroblast co-culture experiments. At first, their 
physicochemical properties (swelling behaviour and stiffness) were used to create 
comparable conditions for ECs in both gel types, as even slight differences in cell 
density and/or stiffness of the material can prevent the formation of 3D 
endothelial structures. With the chosen parameters and available capacities for 
this work, an interconnected network of ECs however, could not be established in 
rather thick GelMA gel samples. Further improvements of the setup are required, 
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for instance minimising the intensity of UV radiation needed for crosslinking 
reactions. In contrast, as reported by Chwalek et al.,29 HUVECs grew, elongated 
and interconnected in starPEG-heparin hydrogels. On the other hand, ECFCs 
could not be stimulated to create 3D networks in starPEG-heparin hydrogels. They 
are considered to be true EPCs,307 and as such they might depend on the help of 
supporting cell types (such as MSCs) for the formation of CLSs in vitro. ECs were 
not capable of forming 3D networks in Matrigel either. As a conclusion, starPEG-
heparin hydrogels were chosen for subsequent co-culture experiments. However, 
2D Matrigel assays are still commonly used to test for putative angiogenic 
stimulants or inhibitors, and this gel system was therefore also included in further 
experiments. 
For co-culture experiments, HUVECs and fibroblasts were either co-embedded in 
starPEG-heparin hydrogels, or indirectly co-cultured (HUVECs inside the gel, 
fibroblasts on the well bottom). The analysis of the protein expression of several 
proangiogenic factors revealed that SDF-1, VEGF-C, IL-8 and MM-2 were secreted 
by both, CAFs and NPFs in an equal amount. ANG-2, IGFBP-1, PDGF-BB, 
VEGFA- and -D were found to be HUVEC-derived. In indirect co-culture 
experiments, CAFs and NPFs indeed influenced the HUVEC network inside the 
gels. As they were not in close contact to HUVECs, the network length and 
branching were only increased by the action of fibroblast-derived soluble factors. 
Differences in endothelial network parameters were not observed between 
samples of the malignant and benign fibroblast type, which was expected as the 
protein concentrations were similar in CAF- and NPF-HUVEC co-cultures. 
In contrast, significant differences were detected when HUVECs and fibroblasts 
were co-embedded. Compared to control levels, the length and branching were 
increased in both, NPF and CAF samples; but in the presence of the malignant 
fibroblasts, HUVECs responded even stronger. The exact mechanism could not be 
resolved. Altered protein expression by the fibroblasts in the gel, close contact 
between the cells, CAF-derived insoluble ECM molecules or a mixture of all could 
be possible explanations. Nevertheless, with the help of the 3D in vitro model, it 
has been demonstrated for the first time how prostatic fibroblast actually affect the 
formation of CLSs (length, branching), and what kind of mediators are most 
probably responsible for the observed differences (soluble angiogenic regulators, 
other factors). In some samples, CLSs showed further similarities to pathological 
characteristics of microvessels in prostate cancer (decreased diameter for tumours 
diagnosed at an advanced stage). Besides that, significant differences could be 
seen for unmatched cell pairs (NPFs and CAFs were derived from different 
patients). In many other in vitro studies, matched pairs are usually compared (for 
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example, one study interrogated the effect of matched NPFs and CAFs on 
epithelial, non-malignant BPH-1 cells).364 Both aspects underscored the 
physiological relevance and robustness of this model, whereas other experimental 
approaches published so far lack some important features. Here, angiogenesis 
assays were either not included at all,35 rudimentarily designed and/or analysed or 
physiologically less relevant.36,37 CAFs and NPFs have not been compared at all in 
a co-culture model in this context. 
The results of this work further underpin the importance to thoroughly choose a 
suitable material for the intended application. Interestingly, in conventional 2D 
Matrigel angiogenesis assays, no significant differences were found between 
control, NPF and CAF samples at all. It is very likely that angiogenic factors 
present in the Matrigel-matrix masked any effect that fibroblast-secreted 
regulators could exert on endothelial cells. Moreover, 3D and direct co-cultures 
could not be established in Matrigel samples, and 2D endothelial networks were 
stable for ~ 12 - 16 h only. All these findings underline the necessity for the usage 
and further development of advanced, (semi-)synthetic biomaterials with well-
defined, adjustable properties. Besides that, the high relevance of 3D analysing 
techniques for 3D cell cultures has been elaborated. The quantification of 3D 
endothelial structures in most publications is either primitive (e.g. counting 
sprouts by eye) or based on 2D methods (e.g. MIP). In both cases, important 
information for careful interpretation of the data can get lost, as it has been 
demonstrated in this work.  
Despite the advantages and suitability of starPEG-heparin hydrogels for HUVEC-
fibroblast co-cultures, a specific mechanism for the EC-stimulating effects of CAFs 
could not be found. One reason for this might be that secreted proteins can bind 
strongly to heparin, which potentially impairs the detection and analysis. Thus, 
differences in protein expression patterns between 2D and 3D cell culture could 
not be explored. An improved protocol for a complete protein extraction from 
starPEG-heparin hydrogels could help to gather more valuable data. 
Alternatively, the expression could be evaluated on the genomic level. However, 
harsh treatments that are necessary for the release of encapsulated cells might 
compromise the actual expression pattern, and it only provides a vague hint for 
the prognosis on protein expressions. Lastly, it is very challenging to identify a 
possible cross-talk of signalling molecules within a cell mixture, which could 
additionally affect expression patterns in both cell types. 
In summary, the 3D in vitro co-culture model and 3D analysis technique presented 
in this work were successfully employed in order to investigate the stromal impact 
on angiogenesis in prostate cancer. The design and validation go beyond 
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traditional 2D in vitro research in this field, and open new avenues for advanced, 
more complex cancer models. For instance, the co-culture can be extended by 
including other components of the TME (ECM molecules, epithelial cancer cells 
and/or immune cells) and/or by inducing hypoxic conditions, which also play a 
critical role during cancer progression and angiogenesis. Moreover, by using 
primary cells, the 3D in vitro co-culture model can potentially be used to 
determine the angiogenic capability or aggressiveness of the stroma, which is 
unique for each patient. This might help to adjust the medical treatment for 
personal parameters. Improvements from the material part (for example, bio-
printing) can further foster the development of highly sophisticated setups. 
Specific in vivo (CSC) niches could be re-created in vitro at a micron scale, with 
hydrogel layers of different properties (stiffness, GF-binding affinities, other 
modifications) that follow the needs of various cell types present in the TME. 
Layers could be seeded with different cell types to mimic different tissues (for 
example, tumour tissue, bone (marrow) and endothelium). All these 
enhancements can help us to improve our knowledge of cancer angiogenesis 
(epithelial-stromal interactions that lead to tissue remodelling, morphological 
changes of the vasculature and attraction of EPCs and/or ECs), how the niche of 
CTCs and CSCs is made up and maintained, or what kind of mechanisms might 
trigger the outgrowth of secondary tumours. As (GF) gradients also play an 
important role in cancerous tissues (EPC homing to the tumour, vascular 
ingrowth, etc.), different cellular mechanisms can be investigated in vitro and in 
vivo with the help of the gradient-‘stabilising’ starPEG-heparin hydrogel platform. 
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Nomenclature 
2D   Two-dimensional 
3D   Three-dimensional 
α-SMA  Alpha smooth muscle actin 
ANGs   Angiopoietins 
BM   Basement membrane 
BMP   Bone morphogenetic protein 
BPH   Benign prostatic hyperplasia 
CAFs   Cancer-associated fibroblasts 
CD   Cluster of differentiation 
CLSs   Capillary-like structures 
cLSM   Confocal laser scanning microscopy 
CM   Conditioned medium 
CSCs   Cancer stem cells 
CTCs   Circulating tumour cells 
DTCs   Disseminated tumour cells 
ECs   Endothelial cells 
ECM   Extracellular matrix 
EDC   1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
EGF   Epidermal growth factor 
EGM-2  Endothelial growth medium 2 
EMT   Epithelial-mesenchymal transition 
ESCs   Embryonic stem cells 
FBS   Fetal bovine serum 
FCS   Fluorescence correlation spectroscopy 
FGFs   Fibroblast growth factors 
GAGs   Glycosaminoglycans 
GFs   Growth factors 
GS   Gleason score 
hb-EGF  Heparin-binding epidermal growth factor 
HM6   Heparin-maleimide-6 
HUVECs  Human umbilical vein endothelial cells 
IGFBP  Insulin-like growth factor binding protein 
IL-8   Interleukin 8 
MET   Mesenchymal-epithelial transition 
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MMPs  Matrix metalloproteinases 
MSCs   Mesenchymal stem cells 
MVD   Microvessel density 
MW   Molecular weight 
NA   Numerical aperture 
sNHS   N-hydroxysulphosuccinimide 
NIH   National institute of health 
NPFs   Normal prostate fibroblasts 
ON   Overnight 
PBS   Phosphate buffered saline 
PDGFs  Platelet-derived growth factors 
PDMS   Polydimethylsiloxane 
PEG   Polyethylene glycol 
pI   Isoeletric point 
PLGF   Placental growth factor 
PSMA   Prostate-specific membrane antigen 
RT   Room temperature 
SD   Standard deviation 
SDF-1   Stromal cell-derived factor 1 
TAMs   Tumour-associated macrophages 
TCP   Tissue culture plastic 
TEC   Tissue engineered construct 
TGF-β   Transforming growth factor β 
TIMPs  Tissue inhibitors of metalloproteases 
TME   Tumour microenvironment 
VE-cadherin  Vascular endothelial cadherin 
VEGF   Vascular endothelial growth factor 
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Appendix 
Supplemental figures 
 
Figure S.1: Mechanical characterisation of starPEG-heparin hydrogels designated for 
diffusion studies. The storage modulus (G’) was determined by rheological measurements 
for different molar ratios (𝛾) of starPEG to heparin (A) and hydrogels with different solid 
contents (B). All data are presented as mean ± SD (N = 3). 
 
Figure S.2: Angiogenic factors primarily secreted by CAFs in 2D monocultures. Except for 
patient 70, small amounts of IGFBP were secreted by CAFs only (A). Except for donor pair I 
in EGM-2 (patients 64 & 35), IL-8 was secreted in higher amounts by CAFs compared to 
NPFs (B). The concentration of SDF-1 was also higher in CAF cultures (C). Interestingly, the 
type of medium in which fibroblasts were cultured apparently affected the overall amount 
of some proteins in the supernatant. 
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Figure S.3: Network parameters of 2D HUVEC cultures on Matrigel, with or without 
embedded fibroblasts. Repeat of the experiment confirmed observations as described for 
Figure 4.13. One data point represents the analysis of one sample (N = 5-7), black line 
represents the average of all data points from the same group. Statistical significance, *P < 
0.05, **P < 0.01. CTRL = HUVEC mono-cultures. 
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